<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis - Dawson, S - 2023 | Cochrane Library</title> <meta content="Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis - Dawson, S - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013766.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis - Dawson, S - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013766.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013766.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis" name="citation_title"/> <meta content="Sophie Dawson" name="citation_author"/> <meta content="Sophie.Dawson@nuh.nhs.uk" name="citation_author_email"/> <meta content="Carla-Jane Girling" name="citation_author"/> <meta content="University of Sheffield, Innovation Centre" name="citation_author_institution"/> <meta content="Lisa Cowap" name="citation_author"/> <meta content="Staffordshire University" name="citation_author_institution"/> <meta content="David Clark-Carter" name="citation_author"/> <meta content="Staffordshire University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD013766.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/03/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013766.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013766.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013766.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anxiety [therapy]; Anxiety Disorders; *Cognitive Behavioral Therapy; *Cystic Fibrosis [complications, drug therapy]; Psychosocial Intervention; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013766.pub2&amp;doi=10.1002/14651858.CD013766.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013766\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013766\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ms","ja","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013766.pub2",title:"Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis",firstPublishedDate:"Mar 29, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013766.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013766.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013766.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013766.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013766.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013766.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013766.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013766.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013766.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013766.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1644 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013766.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-sec-0109"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-sec-0101"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/appendices#CD013766-sec-0114"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/supinfo/CD013766StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/supinfo/CD013766StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/information#CD013766-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Sophie Dawson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/information#CD013766-cr-0005">Carla-Jane Girling</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/information#CD013766-cr-0006">Lisa Cowap</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013766.pub2/information#CD013766-cr-0007">David Clark-Carter</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/information/en#CD013766-sec-0118">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 March 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013766.pub2">https://doi.org/10.1002/14651858.CD013766.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013766-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013766-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013766-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013766-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013766-abs-0010">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013766-abs-0001" lang="en"> <section id="CD013766-sec-0001"> <h3 class="title" id="CD013766-sec-0001">Background</h3> <p>Adherence to treatment, including inhaled therapies, is low in people with cystic fibrosis (CF). Although psychological interventions for improving adherence to inhaled therapies in people with CF have been developed, no previous published systematic review has evaluated the evidence for efficacy of these interventions. </p> </section> <section id="CD013766-sec-0002"> <h3 class="title" id="CD013766-sec-0002">Objectives</h3> <p>The primary objective of the review was to assess the efficacy of psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (CF). The secondary objective was to establish the most effective components, or behaviour change techniques (BCTs), used in these interventions. </p> </section> <section id="CD013766-sec-0003"> <h3 class="title" id="CD013766-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis Trials Register, which is compiled from electronic database searches and handsearching of journals and conference abstract books. </p> <p>We also searched databases (PubMed; PsycINFO; EBSCO; Scopus; OpenGrey), trials registries (World Health Organization International Clinical Trials Registry Platform; US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov), and the reference lists of relevant articles and reviews, with no restrictions on language, year or publication status. </p> <p>Date of search: 7 August 2022.</p> </section> <section id="CD013766-sec-0004"> <h3 class="title" id="CD013766-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing different types of psychological interventions for improving adherence to inhaled therapies in people with CF of any age, or comparing psychological interventions with usual care. We included quasi‐RCTs if we could reasonably assume that the baseline characteristics were similar in both groups. </p> </section> <section id="CD013766-sec-0005"> <h3 class="title" id="CD013766-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial eligibility and completed data extraction, risk of bias assessments, and BCT coding (using the BCT Taxonomy v1) for all included trials. We resolved any discrepancies by discussion, or by consultation with a third review author as necessary. We assessed the certainty of the evidence using GRADE. </p> </section> <section id="CD013766-sec-0006"> <h3 class="title" id="CD013766-sec-0006">Main results</h3> <p>We included 10 trials (1642 participants) in the review (children and adolescents in four trials; adults in five trials; and children and adults in one trial). Nine trials compared a psychological intervention with usual care; we could combine data from some of these in a number of quantitative analyses. One trial compared a psychological intervention with an active comparator (education plus problem‐solving (EPS)). We identified five ongoing trials. </p> <p>Psychological interventions were generally multi‐component and complex, containing an average of 9.6 BCTs (range 1 to 28). The two most commonly used BCTs included 'problem‐solving' and 'instruction on how to perform the behaviour'. Interventions varied in their type, content and mode of delivery. They included a problem‐solving intervention; a paper‐based self‐management workbook; a telehealth intervention; a group training programme; a digital intervention comprising medication reminders and lung function self‐monitoring; a life‐coaching intervention; a motivational interviewing (MI) intervention; a brief MI intervention (behaviour change counselling); and a digital intervention combined with behaviour change sessions. Intervention duration ranged from 10 weeks to 12 months. Assessment time points ranged from six to eight weeks up to 23 months. </p> <p><b>Psychological interventions compared with usual care</b> </p> <p>We report data here for the 'over six months and up to 12 months' time point. We found that psychological interventions probably improve adherence to inhaled therapies (primary outcome) in people with CF compared with usual care (mean difference (MD) 9.5, 95% confidence interval (CI) 8.60 to 10.40; 1 study, 588 participants; moderate‐certainty evidence). There was no evidence of a difference between groups in our second primary outcome, treatment‐related adverse events: anxiety (MD 0.30, 95% CI ‐0.40 to 1.00; 1 study, 535 participants), or depression (MD ‐0.10, 95% CI ‐0.80 to 0.60; 1 study, 534 participants), although this was low‐certainty evidence. For our secondary outcomes, there was no evidence of a difference between groups in terms of lung function (forced expiratory volume in one second (FEV<sub>1</sub>) % predicted MD 1.40, 95% CI ‐0.20 to 3.00; 1 study, 556 participants; moderate‐certainty evidence); number of pulmonary exacerbations (adjusted rate ratio 0.96, 95% CI 0.83 to 1.11; 1 study, 607 participants; moderate‐certainty evidence); or respiratory symptoms (MD 0.70, 95% CI ‐2.40 to 3.80; 1 study, 534 participants; low‐certainty evidence). However, psychological interventions may improve treatment burden (MD 3.90, 95% CI 1.20 to 6.60; 1 study, 539 participants; low‐certainty evidence). The overall certainty of the evidence ranged from low to moderate across these outcomes. Reasons for downgrading included indirectness (current evidence included adults only whereas our review question was broader and focused on people of any age) and lack of blinding of outcome assessors. </p> <p><b>Psychological interventions compared with an active comparator</b> </p> <p>For this comparison the overall certainty of evidence was very low, based on one trial (n = 128) comparing an MI intervention to EPS for 12 months. We are uncertain whether an MI intervention, compared with EPS, improves adherence to inhaled therapies, lung function, or quality of life in people with CF, or whether there is an effect on pulmonary exacerbations. The included trial for this comparison did not report on treatment‐related adverse events (anxiety and depression). We downgraded all reported outcomes due to small participant numbers, indirectness (trials included only adults), and unclear risk of bias (e.g. selection and attrition bias). </p> </section> <section id="CD013766-sec-0007"> <h3 class="title" id="CD013766-sec-0007">Authors' conclusions</h3> <p>Due to the limited quantity of trials included in this review, as well as the clinical and methodological heterogeneity, it was not possible to identify an overall intervention effect using meta‐analysis. Some moderate‐certainty evidence suggests that psychological interventions (compared with usual care) probably improve adherence to inhaled therapies in people with CF, without increasing treatment‐related adverse events, anxiety and depression (low‐certainty evidence). In future review updates (with ongoing trial results included), we hope to be able to establish the most effective BCTs (or 'active ingredients') of interventions for improving adherence to inhaled therapies in people with CF. </p> <p>Wherever possible, investigators should make use of the most objective measures of adherence available (e.g. data‐logging nebulisers) to accurately determine intervention effects. Outcome reporting needs to be improved to enable combining or separation of measures as appropriate. Likewise, trial reporting needs to include details of intervention content (e.g. BCTs used); duration; intensity; and fidelity. Large trials with a longer follow‐up period (e.g. 12 months) are needed in children with CF. Additionally, more research is needed to determine how to support adherence in 'under‐served' CF populations. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013766-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013766-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013766-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013766-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013766-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013766-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013766-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013766-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013766-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013766-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013766-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013766-abs-0002" lang="en"> <h3>Psychological interventions to help people with cystic fibrosis take their inhaled treatments </h3> <p><b>Key messages</b> </p> <p>Psychological interventions are designed to help people modify their thoughts, feelings and behaviours. </p> <p>We think that psychological interventions are probably better than usual care at helping people with CF to take their inhaled treatments, and may cause little or no harm (e.g. anxiety or depression) when measured six to 12 months after treatment. </p> <p>We are uncertain whether motivational interviewing (MI) was better or worse than education plus problem‐solving (EPS) at helping people with CF to take their inhaled treatments. </p> <p><b>Background</b> </p> <p>CF is a chronic, genetic condition, usually diagnosed at birth through newborn screening. People with CF experience recurrent chest infections due to the build‐up of thick, sticky mucus (or sputum) in their lungs and digestive systems. Inhaled treatments are usually prescribed to either thin sputum (making it easier to clear or cough up), or to treat and control bacteria in the lungs (to reduce infections). </p> <p>People living with any long‐term health condition often struggle to take the number of treatments they are prescribed, and this is no different in CF. </p> <p><b>What did we want to find out?</b> </p> <p>Can psychological interventions help people with CF to take their inhaled treatments, and are there any harmful or unwanted effects of these interventions (e.g. anxiety or depression)? </p> <p>Which techniques (e.g. goal‐setting, problem‐solving) work best at helping people with CF to take their inhaled treatments? </p> <p><b>What did we do?</b> </p> <p>We searched for studies comparing different types of psychological interventions, or comparing the interventions with usual care, for helping people with CF of any age to take their inhaled treatments. </p> <p>We compared and summarised the results of the trials and rated our confidence in the evidence, based on factors such as the trial methods. </p> <p><b>What did we find?</b> </p> <p>We included 10 trials with 1642 people with CF (approximately 54.3% female). Four trials included children and adolescents; five trials included adults; and one trial included both. Nine trials compared a psychological intervention with usual care, and one study compared two psychological interventions (MI versus EPS). People (or in one trial, CF centres) were randomly selected for one group or the other. People were followed up for between six to eight weeks and 23 months. </p> <p>Psychological interventions were wide‐ranging. They included an intervention that combined digital technology (website or app) with support from trained healthcare professionals. Interventions used a range of techniques, with problem‐solving and providing instructions on how to take treatments being the most commonly used. </p> <p><b>Main results</b> </p> <p>Psychological interventions are probably better than usual care at helping people with CF to take their inhaled treatments, and may cause little or no harm (e.g. anxiety or depression) when measured six to 12 months after treatment. Psychological interventions may also improve perceived treatment burden (as measured using a quality of life (QoL) questionnaire). There was no evidence of a difference between groups in terms of lung function (a measure of how well someone's lungs are working), the number of chest infections, or perceived chest symptoms (again measured using a QoL questionnaire). </p> <p>We are uncertain whether MI was better or worse than EPS at helping people with CF to take their inhaled treatments, improving lung function or QoL, or reducing chest infections in people with CF. The included trial did not look at whether MI or EPS caused harm (e.g. anxiety or depression). </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence for psychological interventions being better or worse than usual care ranges from low to moderate. The biggest included trial of psychological interventions (which had results from between six and 12 months after treatment started) focused on adults with CF (aged 16 years and over), whereas the question we wanted to answer was broader (i.e. we cannot be sure if the results would be the same in children). Large trials with a longer follow‐up period (e.g. 12 months) are needed in children with CF. It is possible that because people completing the outcome assessments knew which group they were in, this might affect the results for QoL, anxiety and depression. </p> <p>We are not confident in the evidence comparing MI with EPS. The only trial examining this included a small number of adults, so we cannot be sure if the results would be the same in children or in a larger group of people. We are unsure whether participants were put into the different treatment groups truly at random, so differences between the groups might be due to differences between people rather than the treatments. We are also unsure about people leaving the trial early and how this might affect the results. We also think that because the people completing the outcome assessments knew which group they were in, this might affect the QoL results. </p> <p>Current evidence on which techniques (e.g. goal‐setting, problem‐solving) work best at helping people with CF to take their inhaled treatments is limited. Future trials should provide more details on the techniques used in interventions. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to 7 August 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013766-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013766-sec-0109"></div> <h3 class="title" id="CD013766-sec-0110">Implications for practice</h3> <section id="CD013766-sec-0110"> <p>Due to the limited quantity of trials included in this review, as well as their clinical and methodological heterogeneity, there is insufficient evidence to clearly recommend or refute the use of psychological interventions for improving adherence to inhaled therapies for people with cystic fibrosis (CF) in clinical practice. There is some moderate‐certainty evidence to suggest that psychological interventions probably improve adherence to inhaled therapies in adults with CF compared with usual care, and may have little or no effect on treatment‐related adverse events such as anxiety and depression (low‐certainty evidence). Psychological interventions may also improve treatment burden (low‐certainty evidence). In addition, based on the very low‐certainty evidence from one relatively small trial, we are uncertain whether a psychological intervention (motivational interviewing (MI)) improves adherence to inhaled therapies, lung function or quality of life (QoL), or reduces pulmonary exacerbations in people with CF when compared with an active comparator intervention (education plus problem‐solving (EPS)). </p> <p>It is promising that one included trial showed that a psychological intervention focused on supporting adults with CF to build habits for treatment‐taking can increase adherence to inhaled therapies whilst reducing perceived treatment burden (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). This is an area of importance amongst the CF community, since “simplifying the treatment burden” and "improving and sustaining adherence to treatment" have been identified as two of the top 10 CF research priorities in the James Lind Alliance Priority Setting Partnership (<a href="./references#CD013766-bbs2-0110" title="DaviesG , RowbothamNJ , SmithS , ElliotZC , GathercoleK , RaynerO , et al. Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials. Journal of Cystic Fibrosis2020;19:499-502. [DOI: 10.1016/j.jcf.2019.10.025]">Davies 2020</a>; <a href="./references#CD013766-bbs2-0171" title="RowbothamNJ , SmithS , LeightonPA , RaynerOC , GathercoleK , ElliottZC , et al. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax2018;73(4):388-90. [DOI: 10.1136/thoraxjnl-2017-210473]">Rowbotham 2018</a>). While it is often assumed that simplifying treatment regimens reduces perceived burden and thereby increases adherence (<a href="./references#CD013766-bbs2-0177" title="SchultzA . Adherence to CF treatment can be improved with the right approach!Thorax2022;77(5):428. [DOI: 10.1136/thoraxjnl-2021-218134]">Schultz 2022</a>), the results of the included trial suggest that there are other ways of reducing perceived treatment burden other than withdrawing treatments or replacing treatments with those perceived to be less burdensome (<a href="./references#CD013766-bbs2-0172" title="RowbothamNJ , DanielsTE . Airway clearance and exercise for people with cystic fibrosis: balancing longevity with life [2022]. Pediatric Pulmonology2022;57 Suppl 1:S50-9. [DOI: 10.1002/ppul.25734]">Rowbotham 2022</a>). This may be consistent with previous research highlighting the role of habit on adherence to inhaled therapies in people with CF (<a href="./references#CD013766-bbs2-0086" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: an investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357-80. [DOI: 10.1111/bjhp.12357]">Arden 2019</a>; <a href="./references#CD013766-bbs2-0087" title="BallR , SouthernKW , McCormackP , DuffAJA , BrownleeKG , McNamaraPS . Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time. Journal of Cystic Fibrosis2013;12(5):440-4. [DOI: 10.1016/j.jcf.2012.12.012]">Ball 2013</a>; <a href="./references#CD013766-bbs2-0131" title="HooZH , BooteJ , WildmanMJ , CampbellMJ , GardnerB . Determinants of objective adherence to nebulised medications among adults with cystic fibrosis: an exploratory mixed methods study comparing low and high adherers. Health Psychology and Behavioral Medicine2017;5:299-316. [DOI: 10.1080/21642850.2017.1338958]">Hoo 2017</a>; <a href="./references#CD013766-bbs2-0133" title="HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [DOI: 10.1136/thoraxjnl-2017-211453]">Hoo 2019a</a>), and the suggestion that habit (i.e. "automatically experiencing an urge to use a nebuliser" (<a href="./references#CD013766-bbs2-0133" title="HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [DOI: 10.1136/thoraxjnl-2017-211453]">Hoo 2019a</a>)) may attenuate the relationship between treatment complexity and perceived treatment burden (<a href="./references#CD013766-bbs2-0131" title="HooZH , BooteJ , WildmanMJ , CampbellMJ , GardnerB . Determinants of objective adherence to nebulised medications among adults with cystic fibrosis: an exploratory mixed methods study comparing low and high adherers. Health Psychology and Behavioral Medicine2017;5:299-316. [DOI: 10.1080/21642850.2017.1338958]">Hoo 2017</a>). However, adherence seems to be particularly challenging during adolescence and the transition to adult care (<a href="./references#CD013766-bbs2-0176" title="SawickiGS , OstrengaJ , PetrenK , FinkAK , D'AgostinoE , StrassleC , et al. Risk factors for gaps in care during transfer from pediatric to adult cystic fibrosis programs in the United States. Annals of the American Thoracic Society2018;15(2):234-40. [DOI: 10.1513/AnnalsATS.201705-357OC]">Sawicki 2018</a>). This is the age group with the greatest risk of lung function decline (<a href="./references#CD013766-bbs2-0187" title="VandenbrandenSL , McMullenA , SchechterMS , PastaDJ , MichaelisRL , KonstanMW , et al. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatric Pulmonology2012;47(2):135-43. [DOI: 10.1002/ppul.21526]">VandenBranden 2012</a>). It is therefore likely that an intervention will work in slightly different ways for children and adolescents (who may have high parent/caregiver involvement), compared with adults with CF. </p> <p>Despite previous research highlighting the discrepancy between objective and subjective methods of measuring adherence to inhaled therapies in people with CF (<a href="./references#CD013766-bbs2-0109" title="DanielsT , GoodacreL , SuttonC , PollardK , ConwayS , PeckhamD . Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest2011;140(2):425-32. [DOI: 10.1378/chest.09-3074]">Daniels 2011</a>; <a href="./references#CD013766-bbs2-0184" title="ThortonC , MossN , ChanE . Self-perceived verses electronic monitoring of adherence to nebulised treatment in children with cystic fibrosis - does the use of telehealth system improve nebulisation adherence?European Respiratory Journal2013;42(S57):P2113.">Thorton 2013</a>; <a href="./references#CD013766-bbs2-0188" title="WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. In: Journal of Cystic Fibrosis. Vol. 19S2. 2020:S55-168.">Warnock 2020</a>), objective measures are rarely used in practice (<a href="./references#CD013766-bbs2-0170" title="RobinsonL , MaguireC , HooZH , WildmanMJ . Making the invisible visible: the availability and desirability of adherence data in routine CF care – findings from a national questionnaire survey. F1000Research2020;8:1904. [DOI: 10.12688/f1000research.21033.2]">Robinson 2020</a>). An ongoing observational study ('CFHealthHub Data Observatory') (<a href="https://doi.org/10.1186/ISRCTN14464661" target="_blank">ISRCTN14464661</a>), being conducted in parallel with one of the included trials in this review (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), aims to address this by integrating objective adherence measurement (available from data‐logging nebulisers) into routine CF care, using learning from the randomised controlled trial (RCT) and quality improvement cycles. Over 50% of UK adult CF centres are now involved in the digital learning health system, which also serves as a Trials within Cohorts (TWICs) platform, collecting data from a large number of people with CF as part of routine care with the aim of overcoming some of the challenges associated with conducting trials in rare conditions like CF (e.g. high costs and small sample sizes) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>A previous Cochrane Review highlighted that CF teams need training in mental health in order to integrate manualised psychological interventions, including those aimed at supporting adherence, into CF care (<a href="./references#CD013766-bbs2-0122" title="GoldbeckL , FidikaA , HerleM , QuittnerAL . Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD003148. [DOI: 10.1002/14651858.CD003148.pub3]">Goldbeck 2014</a>). We would argue that non‐adherence should be viewed as "the norm" rather than the exception (<a href="./references#CD013766-bbs2-0160" title="National Institute for Health and Care Excellence (NICE). Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence; 2009. Available from www.nice.org.uk/guidance/cg76.">NICE 2009</a>), and as a "problem of humans" (<a href="./references#CD013766-bbs2-0192" title="WildmanMJ , HooZH . Moving cystic fibrosis care from rescue to prevention by embedding adherence measurement in routine care. Paediatric Respiratory Reviews2014;15(S1):16-8. [DOI: 10.1016/j.prrv.2014.04.007]">Wildman 2014</a>), akin to other health behaviours (e.g. physical inactivity, low fruit and vegetable intake) (<a href="./references#CD013766-bbs2-0191" title="World Health Organization. Good health starts with healthy behaviour; 2021. www.euro.who.int/__data/assets/pdf_file/0005/140666/CorpBrochure_Good_health.pdf.">WHO 2021</a>). Adherence is a skillset that can be developed, and whilst mental health training and expertise within CF teams is undoubtedly important, healthcare professionals also need training and expertise in facilitating 'normal' human behaviour change, which includes supporting adherence. As highlighted in one of the included studies in this review, the competing clinical demands of healthcare professionals can influence the extent to which an intervention can be implemented in practice (e.g. limiting the amount of training and supervision that can be provided) (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). The implementation of psychological interventions for improving adherence to inhaled therapies in practice may therefore require specially trained interventionists (<a href="./references#CD013766-bbs2-0122" title="GoldbeckL , FidikaA , HerleM , QuittnerAL . Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD003148. [DOI: 10.1002/14651858.CD003148.pub3]">Goldbeck 2014</a>), and thus, it may be necessary to develop roles for health psychologists, with expertise in behaviour change, or to increase the behavioural expertise of other healthcare professionals (e.g. physiotherapists, nurses). </p> <p>Finally, despite healthcare professionals being trained to deliver interventions in the included trials, the fidelity of interventions varied (and even across CF centres involved in multicentre trials), and this is likely to be even more of a problem outside the carefully managed and controlled environment of an RCT. It is therefore important to consider how intervention fidelity can be assessed and improved, where necessary, in practice (e.g. through direct observation, audits, coaching and supervision, refresher training (<a href="./references#CD013766-bbs2-0096" title="BreitensteinSM , GrossD , GarveyCA , HillC , FoggL , ResnickB . Implementation fidelity in community-based interventions. Research in Nursing &amp; Health2010;33(2):164-73. [DOI: 10.1002/nur.20373]">Breitenstein 2010</a>)), to ensure that the 'active ingredients' of interventions are delivered. </p> </section> <h3 class="title" id="CD013766-sec-0111">Implications for research</h3> <section id="CD013766-sec-0111"> <p>Protocol deviations such as those seen in the included trials in this review may influence results, and the reasons for them should be taken into account when planning future trials (e.g. they can inform about trial feasibility and acceptability). </p> <p>In future trials, investigators should use the most objective measures of adherence available to accurately determine intervention effects. With the development of data‐logging nebulisers (e.g. Philips I‐neb AAD system and PARI eTrack<sup>®</sup>), which record time‐ and date‐stamped usage data, measuring adherence to inhaled therapies using this method should be the 'gold‐standard', particularly in countries where such devices are available (e.g. the UK). In the absence of objective 'recorded' methods (e.g. data‐logging nebulisers), measuring adherence using pharmacy refill data or medication possession ratio (MPR) (i.e. objective 'count' methods) should be the next best alternative. However, MPR is less granular than electronic data capture and, as an indirect measure, tends to overestimate adherence, with recent research highlighting the gap between the supply of inhaled therapies and actual usage in adults with CF (<a href="./references#CD013766-bbs2-0091" title="BevanA , HooZH , TottonN , GirlingC , DavidsIR , WhelanP . Using a learning health system to understand the mismatch between medicines supply and actual medicines use among adults with cystic fibrosis. Journal of Cystic Fibrosis2022;21(2):323-31. [DOI: 10.1016/j.jcf.2021.09.007]">Bevan 2022a</a>; <a href="./references#CD013766-bbs2-0092" title='BevanA , HooZH , TottonN , GirlingC , DavidsIR , WhelanP , et al. Corrigendum to "Using a learning health system to understand the mismatch between medicines supply and actual medicines use among adults with cystic fibrosis" [J Cyst Fibros (2022), 21/2, 323-331]. Journal of Cystic Fibrosis2022;21(5):893–7. [DOI: 10.1016/j.jcf.2022.07.011]'>Bevan 2022b</a>). Indeed, increases in adherence may not be detected using MPR, as people with CF could be using up their existing supplies of medicines rather than collecting or requesting new supplies. Subjective measures of adherence (e.g. participant diaries and self‐report questionnaires such as the MMAS‐8 (<a href="./references#CD013766-bbs2-0155" title="MoriskyDE , AngA , Krousel-WoodM , WardHJ . Predictive validity of a medication adherence measure in an outpatient setting. Journal of Clinical Hypertension2008;10(5):348-54. [DOI: 10.1111/j.1751-7176.2008.07572.x]">Morisky 2008</a>)) appear to be less widely used in more recent trials. This is promising as it shows that the methodology is advancing alongside evidence that highlights the discrepancy between objective and subjective measures of adherence (<a href="./references#CD013766-bbs2-0109" title="DanielsT , GoodacreL , SuttonC , PollardK , ConwayS , PeckhamD . Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest2011;140(2):425-32. [DOI: 10.1378/chest.09-3074]">Daniels 2011</a>; <a href="./references#CD013766-bbs2-0184" title="ThortonC , MossN , ChanE . Self-perceived verses electronic monitoring of adherence to nebulised treatment in children with cystic fibrosis - does the use of telehealth system improve nebulisation adherence?European Respiratory Journal2013;42(S57):P2113.">Thorton 2013</a>; <a href="./references#CD013766-bbs2-0188" title="WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. In: Journal of Cystic Fibrosis. Vol. 19S2. 2020:S55-168.">Warnock 2020</a>). </p> <p>When adherence is measured, there is often a lack of consistency in the assessment time periods. It is important for investigators to allow time for a 'run‐in' period to overcome issues of increased adherence due to a novelty effect (<a href="./references#CD013766-bbs2-0179" title="ShinG , FengY , JarrahiMH , GafinowitzN . Beyond novelty effect: a mixed-methods exploration into the motivation for long-term activity tracker use. JAMIA Open2018;2(1):62-72. [DOI: 10.1093/jamiaopen/ooy048]">Shin 2018</a>), or 'white coat adherence', which are often short‐lived (<a href="./references#CD013766-bbs2-0085" title="ApterAJ , ReisineST , AffleckG , BarrowsE , ZuwallackRL . Adherence with twice-daily dosing of inhaled steroids: socioeconomic and health-belief differences. American Journal of Respiratory and Critical Care Medicine1998;157:1810-7. [DOI: 10.1164/ajrccm.157.6.9712007]">Apter 1998</a>; <a href="./references#CD013766-bbs2-0154" title="ModiAC , IngerskiLM , RauschJR , GlauserTA , DrotarD . White coat adherence over the first year of therapy in pediatric epilepsy. Journal of Pediatrics2012;161(4):695-9.e1.. [DOI: 10.1016/j.jpeds.2012.03.059]">Modi 2012</a>; <a href="./references#CD013766-bbs2-0164" title="PodsadeckiTJ , VrijensBC , ToussetEP , RodeRA , HannaGH . “White Coat Compliance” limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clinical Trials2008;9(4):238-46. [DOI: 10.1310/hct0904-238]">Podsadecki 2008</a>). Adherence is complex and varies across times and situations, and so measuring adherence over a longer period of time where possible is important in order to gain a more accurate assessment of adherence, although there is no consensus on how long adherence should be monitored for. </p> <p>The reporting of interventions could be improved, for example, when reporting a composite MPR (cMPR), the MPRs for individual treatments should be reported alongside cMPR data where possible to allow the differentiation between MPRs for individual treatments. Investigators should also clearly report the time intervals for the data collection and, where multiple versions of a measure are available, e.g. the CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>), investigators should specify which version has been used (e.g. Teen/Adult or Older child 12 to 13 years or Young child 6 to 11 years or Parent/caregiver 6 to 13 years) and whether different versions have been used with different participants in the trial, to facilitate data analysis where appropriate. </p> <p>Furthermore, details of intervention mode of delivery, duration and intensity (e.g. number and duration of sessions) should be provided in order to better understand how interventions could be implemented in clinical practice (<a href="./references#CD013766-bbs2-0128" title="HoffmannTC , GlasziouPP , BoutronI , MilneR , PereraR , MoherD , et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ2014;348:g1687. [DOI: 10.1136/bmj.g1687]">Hoffmann 2014</a>). It would also be helpful if investigators provided more details on the content of interventions, including the care provided to the control group (whether that is an active comparator or usual care (<a href="./references#CD013766-bbs2-0149" title="MichieS , FixsenD , GrimshawJM , EcclesMP . Specifying and reporting complex behaviour change interventions: the need for a scientific method. Implementation Science2009;4(40). [DOI: 10.1186/1748-5908-4-40]">Michie 2009</a>)), and described the BCTs used. This would help to create a shared language and more easily enable the comparison of interventions (e.g. using meta‐regression to investigate the impact of type and number of BCTs on intervention effectiveness). </p> <p>In this review, outcomes were assessed using a variety of measures, which makes it difficult to compare and combine the results. Depression, for example, was measured using four different scales: eight‐item Patient Health Questionnaire depression scale (PHQ‐8) (<a href="./references#CD013766-bbs2-0143" title="KroenkeK , StrineTW , SpritzerRL , WilliamsJB , BerryJT , MokdadAH . The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders2009;114(1-3):163-73. [DOI: 10.1016/j.jad.2008.06.026]">Kroenke 2009</a>); Major Depression Inventory (MDI) (<a href="./references#CD013766-bbs2-0089" title="BechP , RasmussenNA , OlsenLR , NoerholmV , AbildgaardW . The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. Journal of Affective Disorders2001;66(2-3):159-64. [DOI: 10.1016/S0165-0327(00)00309-8]">Bech 2001</a>); Center for Epidemiologic Studies Depression Scale (CES‐D) (<a href="./references#CD013766-bbs2-0167" title="RadloffLS . The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Applied Psychological Measurement1977;1(3):385-401. [DOI: 10.1177/014662167700100306]">Radloff 1977</a>); and Hospital Anxiety and Depression Scale (HADS) (<a href="./references#CD013766-bbs2-0195" title="ZigmondAS , SnaithRP . The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica1983;67(6):361-70. [DOI: 10.1111/j.1600-0447.1983.tb09716.x]">Zigmond 1983</a>); anxiety using three: HADS (<a href="./references#CD013766-bbs2-0195" title="ZigmondAS , SnaithRP . The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica1983;67(6):361-70. [DOI: 10.1111/j.1600-0447.1983.tb09716.x]">Zigmond 1983</a>), State‐Trait Anxiety Inventory (STAI)‐short form (<a href="./references#CD013766-bbs2-0147" title="MarteauTM , BekkerH . The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). British Journal of Clinical Psychology1992;31:301-6. [DOI: 10.1111/j.2044-8260.1992.tb00997.x]">Marteau 1992</a>), and Generalised Anxiety Disorder (GAD)‐7 (<a href="./references#CD013766-bbs2-0183" title="SpitzerRL , KroenkeK , WilliamsJBW , LöweB . A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine2006;166(10):1092-7. [DOI: 10.1001/archinte.166.10.1092]">Spitzer 2006</a>); and two trials even used multiple measures to assess one outcome. This highlights the need for a 'core' outcome set in CF (<a href="./references#CD013766-bbs2-0116" title="DwanK , KirkhamJJ , WilliamsonPR , GambleC . Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis. BMJ Open2013;3:e002709. [DOI: 10.1136/bmjopen-2013-002709]">Dwan 2013</a>), an agreed, standardised set of outcomes that should be measured to improve the comparability of trials (<a href="./references#CD013766-bbs2-0193" title="WilliamsonPR , AltmanDG , BagleyH , BarnesKL , BlazebyJM , BrookesST , et al. The COMET Handbook: version 1.0. Trials2017;18 Suppl 3:280. [DOI: 10.1186/s13063-017-1978-4]">Williamson 2017</a>). </p> <p>In addition, participants should be recruited to adherence trials because their adherence is low, not just because they are willing to participate. It is not only important to consider attrition and withdrawals, but who is volunteering to take part in adherence trials in the first place (and who is declining). Given the issues with adherence during adolescence and the transition to adult care which are highlighted above (<a href="#CD013766-sec-0110">Implications for practice</a>), more research is needed to assess the possible differences in the BCTs used in different populations (e.g. whether some BCTs are more effective when used in paediatrics compared to adult care). More research is also needed to understand how to support adherence in 'under‐served' or 'harder to reach' CF populations. </p> <p>Lastly, when designing RCTs, it is important that intervention designers, researchers and clinicians consider how interventions will be embedded into practice. Of the trials included in this review, many interventions were delivered by healthcare professionals rather than researchers (e.g. registered nurses, physiotherapists, psychologists etc.), which is promising and suggests that healthcare professionals can be trained to deliver such interventions. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013766-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013766-sec-0008"></div> <div class="table" id="CD013766-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: psychological interventions compared with usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychological interventions compared with usual care for improving adherence to inhaled therapies in people with CF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children, adolescents or adults with CF </p> <p><b>Settings</b>: single or multicentre; UK‐, USA‐ or Denmark‐based; hospital, clinic or community </p> <p><b>Intervention</b>: psychological interventions (self‐management intervention comprising digital platform and behaviour change sessions; life coaching intervention; problem‐solving intervention) </p> <p><b>Comparison</b>: usual care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Usual care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Psychological interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adherence to inhaled therapies: % of prescribed inhaled therapies taken</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The adjusted mean % of prescribed inhaled therapies taken was 9.50% higher in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.50 (8.60 to 10.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>588 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An objective recorded measure (using data‐logging nebulisers) where a higher score indicates higher adherence. </p> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐related adverse events</b> </p> <p><b>Anxiety:</b> </p> <p>GAD‐7 (<a href="./references#CD013766-bbs2-0183" title="SpitzerRL , KroenkeK , WilliamsJBW , LöweB . A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine2006;166(10):1092-7. [DOI: 10.1001/archinte.166.10.1092]">Spitzer 2006</a>) </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The adjusted mean anxiety score was 0.3 higher in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.30 (‐0.40 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>535 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Scale from: 0 to 21 (higher score indicates greater anxiety).</p> <p>No evidence of treatment‐related adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐related adverse events</b> </p> <p><b>Depression</b> </p> <p>PHQ‐8 (<a href="./references#CD013766-bbs2-0143" title="KroenkeK , StrineTW , SpritzerRL , WilliamsJB , BerryJT , MokdadAH . The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders2009;114(1-3):163-73. [DOI: 10.1016/j.jad.2008.06.026]">Kroenke 2009</a>) </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The adjusted mean depression score was 0.10 lower in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.10 (‐0.80 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>534 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Scale from: 0 to 24 (higher score indicates greater depression).</p> <p>No evidence of treatment‐related adverse events.</p> <p>One other study assessed depression using 2 measures at this time point (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). This study also found no difference between groups on any depression measure. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>QoL</b> </p> <p>CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Treatment burden</b> </p> <p>The adjusted mean treatment burden score was 3.90 higher in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.90 (1.20 to 6.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>539 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Scale from: 0 to 100 (higher score indicates better QoL).</p> <p>2 other studies assessed treatment burden at this time point (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). These 2 studies found no difference between groups. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Respiratory symptoms</b> </p> <p>The adjusted mean score for respiratory symptoms was 0.70 higher in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.70 (‐2.40 to 3.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>534 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Scale from: 0 to 100 (higher score indicates better QoL).</p> <p>No difference between groups.</p> <p>2 other studies assessed respiratory symptoms at this time point (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). These 2 studies also found no difference between groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lung function</b> </p> <p>FEV<sub>1</sub> % predicted </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The adjusted mean FEV<sub>1</sub> score was 1.40% predicted higher in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.40 (‐0.20 to 3.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>556 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>A higher score indicates better lung function.</p> <p>No difference between groups.</p> <p>2 other studies assessed FEV<sub>1</sub>% predicted at this time point (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). Post‐intervention data were not available in 1 study, so results have been reported narratively (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>); no intervention effects were found for any of the secondary outcomes compared to usual care (and FEV<sub>1</sub>% predicted was a secondary outcome). The other study also found no difference between groups (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>In one trial, there were 526 exacerbations in the control arm (adjusted rate 1.77/year, n = 303) compared with 482 in the intervention arm (1.63/year, n = 304). There was no difference between groups in exacerbation incidence rates (adjusted<sup>e</sup> RR 0.96, 95% CI 0.83 to 1.11; unadjusted RR 0.92, 95% CI 0.77 to 1.10) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>607 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this study, pulmonary exacerbations were defined as "Number of exacerbations treated with IV antibiotics with at least 1 modified Fuchs’ criteria (e.g. change in sputum, increased cough) (<a href="./references#CD013766-bbs2-0168" title="RatjenF , DurhamT , NavratilT , SchabergA , AccursoFJ , Wainwright C et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis2012;11(6):539-49. [DOI: 10.1016/j.jcf.2012.05.003]">Ratjen 2012</a>)." The authors reported that incidence RRs indicated no between‐group difference in exacerbations (MD 0.96 (95% CI 0.83 to 1.12); P = 0.64) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>One other study assessed pulmonary exacerbations at this time point (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). Post‐intervention data were not available in this study and results have been reported narratively. It was also unclear how this study defined exacerbations. The authors did however report that no intervention effect was found for pulmonary exacerbations (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CF: cystic fibrosis; CFQ‐R: Cystic Fibrosis Questionnaire‐Revised (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>); CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume at 1 second; GAD‐7: Generalized Anxiety Disorder‐7 (<a href="./references#CD013766-bbs2-0183" title="SpitzerRL , KroenkeK , WilliamsJBW , LöweB . A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine2006;166(10):1092-7. [DOI: 10.1001/archinte.166.10.1092]">Spitzer 2006</a>); IV: intravenous; MD: mean difference; PHQ‐8: Patient Health Questionnaire‐8 (<a href="./references#CD013766-bbs2-0143" title="KroenkeK , StrineTW , SpritzerRL , WilliamsJB , BerryJT , MokdadAH . The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders2009;114(1-3):163-73. [DOI: 10.1016/j.jad.2008.06.026]">Kroenke 2009</a>); QoL: quality of life; RR: rate ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Non‐blinding of outcome assessors would not affect the results as it is an objective measure, so no need to downgrade.<br/><sup>b</sup>Downgraded once due to indirectness. The evidence includes only adults with CF aged 16 years and older, and was not designed to answer the specific question posed in this review.<br/><sup>c</sup>The post‐intervention MDs are adjusted for past year IV antibiotic days, CF centre, and outcome measure at baseline.<br/><sup>d</sup>Downgraded once due to unclear risk of detection bias, as outcome assessors were not blinded.<br/><sup>e</sup>The post‐intervention MDs are adjusted for CF centre and past year IV antibiotic days. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013766-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: psychological interventions compared with an active comparator</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychological interventions compared with an active comparator intervention (e.g. education plus problem‐solving; EPS) for improving adherence to inhaled therapies in people with cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults (aged 16 years and over) with CF </p> <p><b>Settings</b>: single CF centre in the USA </p> <p><b>Intervention</b>: psychological intervention (MI) </p> <p><b>Comparison</b>: active comparator (EPS) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Active comparator (EPS)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Psychological intervention (MI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adherence to inhaled therapies cMPR</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Please see comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An objective‐count measure (cMPR), which included inhaled therapies (dornase alfa, hypertonic saline, inhaled tobramycin, and aztreonam), as well as one non‐inhaled treatment (azithromycin). </p> <p>This study reported only medians and IQRs (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). At 12 months, median (IQR) cMPR was 54 (37 to 73) in the MI group, compared with 51 (17 to 71) in the EPS group. The study authors also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that no intervention effects were found for the cMPR (P = 0.763; no effect size reported or calculable) or any of the individual drugs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐related adverse events</b> </p> <p><b>Anxiety</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐related adverse events</b> </p> <p><b>Depression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Please see comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scale from: 0 to 100 (higher score indicates better QoL)</p> <p>This study reported only medians and IQRs for QoL, measured using 3 domains of the CFQ‐R (respiratory, physical functioning, and treatment burden) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). At 12 months, median (IQR) score was 67 (50 to 83) in the MI group and 67 (50 to 72) in the EPS group (respiratory); 79 (60 to 96) in the MI group and 79 (54 to 96) in the EPS group (physical functioning); and 56 (44 to 67) in the MI group and 56 (44 to 78) in the EPS group (treatment burden). The investigators also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that no intervention effects were found for QoL at this time point. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lung function</b> FEV<sub>1</sub> % predicted </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Please see comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A higher score indicates better lung function.</p> <p>This study reported only medians and IQRs (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). At 12 months, median (IQR) FEV<sub>1</sub>% predicted was 66% (48 to 85%) in the MI group and 64% (49 to 84%) in the EPS group. The authors also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that the intervention had no effect on lung function (P = 0.773; no effect size reported or calculable). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Please see comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study reported the percentage of people in each group with at least 1 exacerbation in the past year (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). Method of assessing exacerbations not reported. We calculated the number of participants in each group who had experienced an exacerbation over the 12‐month study period. In the MI group, 12 out of 63 participants (19%) experienced an exacerbation compared with 12 out of 65 (18%) in the EPS group. The study authors also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that the intervention had no effect on pulmonary exacerbations (P = 0.929; no effect size reported or calculable). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CF: cystic fibrosis; CFQ‐R: Cystic Fibrosis Questionnaire‐Revised (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>); cMPR: composite medication possession ratio; EPS: education plus problem‐solving; FEV<sub>1</sub>: forced expiratory volume at 1 second; IQR: interquartile range; MI: motivational interviewing; QoL: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for imprecision; relatively small participant numbers which do not meet the optimal information size.<br/><sup>b</sup>Downgraded once due to indirectness. The evidence includes only adults with CF aged 16 years and older, and was not designed to answer the specific question posed in this review.<br/><sup>c</sup>Downgraded once due to unclear risk of selection bias and attrition bias.<br/><sup>d</sup>Downgraded once due to unclear risk of selection bias (not reported), attrition bias (withdrawals not described), and detection bias (outcome assessors not blinded). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013766-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013766-sec-0009"></div> <section id="CD013766-sec-0010"> <h3 class="title" id="CD013766-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is a chronic, genetic condition affecting over 10,500 people in the UK (<a href="./references#CD013766-bbs2-0186" title="UK Cystic Fibrosis Trust. UK Cystic Fibrosis Registry: annual data report 2019. www.cysticfibrosis.org.uk/~/media/documents/the-work-we-do/uk-cf-registry/registry-report-2019.ashx?la=en.">UK CF Registry 2019</a>), 30,000 people in the USA (<a href="./references#CD013766-bbs2-0099" title="CF Foundation Patient Registry. 2018 Annual Data Report. www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf (accessed 23 August 2020).">CF Foundation Patient Registry 2019</a>), and around 90,000 people worldwide (<a href="./references#CD013766-bbs2-0090" title="BellSC , MallMA , GutierrezH , MacekM , MadgeS , DaviesJC , et al. The future of cystic fibrosis care: a global perspective. Lancet. Respiratory Medicine2020;8:65-124. [DOI: 10.1016/S2213-2600(19)30337-6]">Bell 2020</a>). One in 25 people in the UK carries the faulty gene that causes CF, usually without realising it (<a href="./references#CD013766-bbs2-0108" title="Cystic Fibrosis Trust. What is cystic fibrosis?www.cysticfibrosis.org.uk/what-is-cystic-fibrosis (accessed 24 October 2019).">Cystic Fibrosis Trust 2019</a>). People with CF are prone to recurrent chest infections, or pulmonary exacerbations, due to the build‐up of thick, sticky mucus (or sputum) in their lungs and digestive systems. </p> <p>Although people with CF are living longer, their life expectancy remains well below average, and the median predicted survival age of someone born with CF in 2018 ranges between 47.3 years in the UK (<a href="./references#CD013766-bbs2-0185" title="UK Cystic Fibrosis Trust. UK Cystic Fibrosis Registry: annual data report 2018. www.cysticfibrosis.org.uk/~/media/documents/the-work-we-do/uk-cf-registry/2018-registry-annual-data-report.ashx?la=en.">UK CF Registry 2018</a>), 47.4 years in the USA (<a href="./references#CD013766-bbs2-0099" title="CF Foundation Patient Registry. 2018 Annual Data Report. www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf (accessed 23 August 2020).">CF Foundation Patient Registry 2019</a>), and 52.1 years in Canada (<a href="./references#CD013766-bbs2-0107" title="Cystic Fibrosis Canada. The Canadian Cystic Fibrosis Registry 2018 Annual Data Report; published December 2019. www.cysticfibrosis.ca/uploads/RegistryReport2018/2018RegistryAnnualDataReport.pdf.">Cystic Fibrosis Canada 2019</a>). As lung disease is the primary cause of morbidity and mortality in people with CF, nebulised medications (or inhaled therapies) are usually prescribed (<a href="./references#CD013766-bbs2-0119" title="ZolinA , OrentiA , NaehrlichL , vanRensJ , FoxA , KrasnykM , et al. European Cystic Fibrosis Society Patient Registry Annual Data Report 2017; published July 2019. www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR_Report2017_v1.3.pdf.">ECFS Patient Registry 2017</a>), with multiple trials demonstrating their efficacy (<a href="./references#CD013766-bbs2-0180" title="SmithS , RowbothamNJ , ReganKH . Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 3. Art. No: CD001021. [DOI: 10.1002/14651858.CD001021.pub3]">Smith 2018</a>; <a href="./references#CD013766-bbs2-0194" title="YangC , MontgomeryM . Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 9. Art. No: CD001127. [DOI: 10.1002/14651858.CD001127.pub4]">Yang 2018</a>). These treatments are delivered directly to the lungs, thereby reducing side effects, and may include antibiotics to treat or control infections (e.g. tobramycin), mucolytics to thin sputum making it easier to clear (e.g. dornase alfa), and osmotics to draw water into the sputum making it easier to cough up (e.g. hypertonic saline). </p> <p>Whilst advances in medicine mean that many of the symptoms of CF can be managed effectively, 'effective' management itself requires people living with CF to complete a complex daily treatment regimen, comprising daily chest physiotherapy, pancreatic enzymes, nutritional supplements, and inhaled or nebulised therapies. A minimum of one to three nebulised treatments per day are usually prescribed, depending on an individual's characteristics (<a href="./references#CD013766-bbs2-0130" title="HooZH , CurleyR , CampbellMJ , WaltersSJ , HindD , WildmanMJ . Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate “normative adherence”. Patient Preference and Adherence2016;10:887-900. [DOI: 10.2147/PPA.S105530]">Hoo 2016</a>), with treatments taking an average of 41 minutes per day (<a href="./references#CD013766-bbs2-0174" title="SawickiGS , SellersDE , RobinsonWM . High treatment burden in adults with cystic fibrosis: Challenges to disease self-management. Journal of Cystic Fibrosis2009;8:91-6. [DOI: 10.1016/j.jcf.2008.09.007]">Sawicki 2009</a>). </p> <p>Treatments are only effective if they are taken, yet evidence suggests that in high‐income countries, only 50% of people with a chronic condition adhere to treatment recommendations (<a href="./references#CD013766-bbs2-0189" title="World Health Organization. Adherence to long-term therapies: evidence for action; 2003. apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf.">WHO 2003</a>). As with other chronic conditions, low adherence to treatments for CF, including inhaled therapies, is a global problem, with widespread implications for the individual and their family, for CF teams supporting the individual, and for society as a whole. Low adherence to all treatments is associated with an increased number of pulmonary exacerbations requiring intravenous (IV) antibiotics (<a href="./references#CD013766-bbs2-0118" title="EakinMN , BilderbackA , BoyleMP , MogayzelPJ , RiekertKA . Longitudinal association between medication adherence and lung health in people with cystic fibrosis. Journal of Cystic Fibrosis2011;10(4):258-64. [DOI: 10.1016/j.jcf.2011.03.005]">Eakin 2011</a>) and hospitalisations, which incur higher healthcare costs (<a href="./references#CD013766-bbs2-0166" title="QuittnerAL , ZhangJ , MarynchenkoM , ChopraPA , SignorovitchJ , YushkinaY , et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest2014;146(1):142-51. [DOI: 10.1378/chest.13-1926]">Quittner 2014</a>). Two trials have demonstrated the importance of adherence to inhaled therapies on health outcomes, with higher adherence to dornase alfa being associated with a shorter length of hospital stay (<a href="./references#CD013766-bbs2-0156" title="NasrSZ , ChouW , VillaKF , ChangE , BroderMS . Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis. Journal of Medical Economics2013;16(6):1-8. [DOI: 10.3111/13696998.2013.787427]">Nasr 2013</a>); and individuals collecting four or more courses of nebulised tobramycin per year being 60% less likely to be admitted to hospital than those collecting two or fewer courses (<a href="./references#CD013766-bbs2-0097" title="BriesacherBA , QuittnerAL , SaimanL , SaccoP , FouayziH , QuittellLM . Adherence with tobramycin inhaled solution and health care utilization. BMC Pulmonary Medicine2011;11(5). [DOI: 10.1186/1471-2466-11-5]">Briesacher 2011</a>). </p> <p>'Adherence' refers to "the extent to which the patient’s behaviour matches <i>agreed recommendations</i> from the prescriber" (<a href="./references#CD013766-bbs2-0137" title="HorneR , WeinmanJ , BarberN , ElliottR , MorganM , CribbA , et al. Concordance, adherence and compliance in medicine taking: report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R&amp;D (NCCSDO). www.ahpo.net/assets/NCCSDO%20Compliance%202005.pdf2005.">Horne 2005</a>). This term is more patient‐centred and is therefore preferable to the outdated term of 'compliance', which is "the extent to which the individual’s behaviour matches the prescriber's recommendations" (<a href="./references#CD013766-bbs2-0124" title="HaynesRB , TaylorDW , SackettDL . Compliance in health care. Baltimore: Johns Hopkins University Press, 1979.">Haynes 1979</a>). There are different methods of measuring adherence, each of which has varying degrees of objectivity and validity. Self‐reported measures (e.g. questionnaires and diaries) are inexpensive and easy to administer, but are subject to a range of biases, including social desirability and recall bias (<a href="./references#CD013766-bbs2-0162" title="OsterbergL , BlaschkeT . Adherence to medication. New England Journal of Medicine2005;353(5):487-97. [DOI: 10.1056/NEJMra050100]">Osterberg 2005</a>). Objective count measures (e.g. medication possession ratio (MPR)) address these biases, but they too are prone to overestimation as they do not guarantee the treatment has been taken (<a href="./references#CD013766-bbs2-0162" title="OsterbergL , BlaschkeT . Adherence to medication. New England Journal of Medicine2005;353(5):487-97. [DOI: 10.1056/NEJMra050100]">Osterberg 2005</a>). Objective recorded measures (e.g. electronic monitoring devices) are a more accurate, albeit expensive, method of measuring adherence (<a href="./references#CD013766-bbs2-0162" title="OsterbergL , BlaschkeT . Adherence to medication. New England Journal of Medicine2005;353(5):487-97. [DOI: 10.1056/NEJMra050100]">Osterberg 2005</a>). With the development of data‐logging nebulisers (e.g. I‐neb Adaptive Aerosol Delivery (AAD) System (Philips Respironics, Chichester, UK) and eFlow<sup>®</sup> rapid nebuliser system and eTrack<sup>®</sup> controller (PARI Pharma GmbH, Starnberg, Germany)) which record time‐ and date‐stamped data, it is possible to measure adherence to inhaled therapies using this method. Trials using objective recorded measures suggest that adherence to inhaled therapies in people with CF is around 31% to 36% in adults (<a href="./references#CD013766-bbs2-0109" title="DanielsT , GoodacreL , SuttonC , PollardK , ConwayS , PeckhamD . Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest2011;140(2):425-32. [DOI: 10.1378/chest.09-3074]">Daniels 2011</a>; <a href="./references#CD013766-bbs2-0132" title="HooZH , TottonN , WaterhouseS , HindD , GirlingC , BradburnM , et al. Understanding objective adherence to preventative inhaled therapies at a centre level for quality improvement - a CFHealthHub (CFHH) improvement collaborative study. Journal of Cystic Fibrosis2019;18:S51-2. [DOI: 10.1016/S1569-1993(19)30283-8]">Hoo 2019</a>; <a href="./references#CD013766-bbs2-0134" title="HooZH , CurleyR , WaltersSJ , CampbellMJ , WildmanMJ . Exploring the implications of different approaches to estimate centre-level adherence using objective adherence data in an adult cystic fibrosis centre – a retrospective observational study. Journal of Cystic Fibrosis2020;19(1):162-7. [DOI: 10.1016/j.jcf.2019.10.008]">Hoo 2020</a>; <a href="./references#CD013766-bbs2-0135" title="HooZH , TottonN , WaterhouseS , LewisJ , GirlingC , BradburnM , et al. Real-world adherence among adults with cystic fibrosis is low: a retrospective analysis of the CFHealthHub digital learning health system. Chest2021;160(6):2061-5. [DOI: 10.1016/j.chest.2021.06.039]">Hoo 2021</a>) and 65% to 67% in children or adolescents (<a href="./references#CD013766-bbs2-0087" title="BallR , SouthernKW , McCormackP , DuffAJA , BrownleeKG , McNamaraPS . Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time. Journal of Cystic Fibrosis2013;12(5):440-4. [DOI: 10.1016/j.jcf.2012.12.012]">Ball 2013</a>; <a href="./references#CD013766-bbs2-0148" title="McNamaraPS , McCormackP , McDonaldAJ , HeafL , SouthernKW . Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. Journal of Cystic Fibrosis2009;8(4):258-63. [DOI: 10.1016/j.jcf.2009.04.006]">McNamara 2009</a>). The discrepancy between objective and subjective measurement has also been highlighted (<a href="./references#CD013766-bbs2-0109" title="DanielsT , GoodacreL , SuttonC , PollardK , ConwayS , PeckhamD . Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest2011;140(2):425-32. [DOI: 10.1378/chest.09-3074]">Daniels 2011</a>; <a href="./references#CD013766-bbs2-0153" title="ModiAC , LimCS , YuN , GellerD , WagnerMH , QuittnerAL . A multi-method assessment of treatment adherence for children with cystic fibrosis. Journal of Cystic Fibrosis2006;5(3):177-85. [DOI: 10.1016/j.jcf.2006.03.002]">Modi 2006b</a>; <a href="./references#CD013766-bbs2-0184" title="ThortonC , MossN , ChanE . Self-perceived verses electronic monitoring of adherence to nebulised treatment in children with cystic fibrosis - does the use of telehealth system improve nebulisation adherence?European Respiratory Journal2013;42(S57):P2113.">Thorton 2013</a>; <a href="./references#CD013766-bbs2-0188" title="WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. In: Journal of Cystic Fibrosis. Vol. 19S2. 2020:S55-168.">Warnock 2020</a>). </p> </section> <section id="CD013766-sec-0011"> <h3 class="title" id="CD013766-sec-0011">Description of the intervention</h3> <p>Interventions that specifically aim to improve adherence to prescribed medications vary widely (<a href="./references#CD013766-bbs2-0161" title="NieuwlaatR , WilczynskiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a>). Psychological interventions aimed at improving adherence to inhaled therapies in people with CF can therefore take many forms and may be targeted at: people with CF (e.g. patient education, medication reminders, rewards, psychological therapies); their families (e.g. increasing supervision with medication, family therapy); or the multidisciplinary team (MDT) providing specialist care to the person with CF (e.g. training clinicians to communicate more effectively with people with CF). Interventions may be delivered face‐to‐face, over the phone, or using digital technology (e.g. smartphone applications or 'apps' that include rewards, reminders, or providing feedback on treatment‐taking behaviour). </p> <p>Given the complexity of many adherence interventions tested to date (<a href="./references#CD013766-bbs2-0161" title="NieuwlaatR , WilczynskiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a>), and the way in which complex interventions are reported or described in the literature, it is often difficult to determine the content, or the 'active ingredients', of effective interventions that bring about change (<a href="./references#CD013766-bbs2-0149" title="MichieS , FixsenD , GrimshawJM , EcclesMP . Specifying and reporting complex behaviour change interventions: the need for a scientific method. Implementation Science2009;4(40). [DOI: 10.1186/1748-5908-4-40]">Michie 2009</a>). These 'active ingredients', or behaviour change techniques (BCTs), are defined as the "observable, replicable and irreducible components of an intervention designed to alter or redirect causal processes that regulate behaviour" (<a href="./references#CD013766-bbs2-0151" title="MichieS , RichardsonM , JohnstonM , AbrahamC , FrancisJ , HardemanW , et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Annals of Behavioral Medicine2013;46(1):81-95. [DOI: 10.1007/s12160-013-9486-6]">Michie 2013</a>). Often, few details are provided about the BCTs used in interventions, and the terminology used to describe interventions is inconsistent. This makes it difficult to replicate effective interventions, because the core components, or ‘active ingredients’, are not known, and time and resources are wasted because ineffective techniques continue to be implemented (<a href="./references#CD013766-bbs2-0149" title="MichieS , FixsenD , GrimshawJM , EcclesMP . Specifying and reporting complex behaviour change interventions: the need for a scientific method. Implementation Science2009;4(40). [DOI: 10.1186/1748-5908-4-40]">Michie 2009</a>). This review therefore aims to identify the content, or the ‘active ingredients’, of interventions, in terms of the BCTs used, in order to establish the most effective components of interventions for improving adherence to inhaled therapies in people with CF. This will aid understanding of the causal mechanisms underlying adherence behaviour, which will help inform the design of more effective, consistent and cost‐effective interventions in the future (<a href="./references#CD013766-bbs2-0149" title="MichieS , FixsenD , GrimshawJM , EcclesMP . Specifying and reporting complex behaviour change interventions: the need for a scientific method. Implementation Science2009;4(40). [DOI: 10.1186/1748-5908-4-40]">Michie 2009</a>). A reliable, consensually‐agreed taxonomy (BCT Taxonomy version 1; BCTTv1) contains 93 BCTs and provides a common language to identify and describe intervention content (<a href="./references#CD013766-bbs2-0151" title="MichieS , RichardsonM , JohnstonM , AbrahamC , FrancisJ , HardemanW , et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Annals of Behavioral Medicine2013;46(1):81-95. [DOI: 10.1007/s12160-013-9486-6]">Michie 2013</a>). At least two other reviews have used the BCTTv1 to code the BCTs present in complex interventions (<a href="./references#CD013766-bbs2-0094" title="BlackN , JohnstonM , MichieS , Hartmann-BoyceJ , WestR , ViechtbauerW , et al. Behaviour change techniques associated with smoking cessation in intervention and comparator groups of randomized controlled trials: a systematic review and meta-regression. Addiction2020;115(11):2008-20. [DOI: 10.1111/add.15056]">Black 2020</a>; <a href="./references#CD013766-bbs2-0145" title="LawrensonJG , Graham-RoweE , LorencattoF , PresseauJ , BurrJ , IversN , et al. Interventions to increase attendance for diabetic retinopathy screening. Cochrane Database of Systematic Reviews2016, Issue 1. Art. No: CD012054. [DOI: 10.1002/14651858.CD012054]">Lawrenson 2016</a>). Psychological interventions for improving adherence to inhaled therapies in people with CF may incorporate one or more BCTs (e.g. 'problem‐solving', defined as "analysing, or prompting the person to analyse, factors influencing the behaviour and generating or selecting strategies that include overcoming barriers and/or increasing facilitators" (<a href="./references#CD013766-bbs2-0151" title="MichieS , RichardsonM , JohnstonM , AbrahamC , FrancisJ , HardemanW , et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Annals of Behavioral Medicine2013;46(1):81-95. [DOI: 10.1007/s12160-013-9486-6]">Michie 2013</a>)). </p> <p>In this Cochrane Review, we compare interventions to either an active control group or standard care, which usually consists of an annual review or routine reviews (or combination of both) with a specialist CF MDT. </p> </section> <section id="CD013766-sec-0012"> <h3 class="title" id="CD013766-sec-0012">How the intervention might work</h3> <p>Reasons for non‐adherence are wide‐ranging and varied, and understanding these reasons is crucial in order to assist with the development of effective, evidence‐based interventions. Previous studies have attempted to understand the factors influencing adherence to treatments in people with CF, and commonly reported reasons include being too busy or not having the time to take treatments, forgetting to take a treatment, and the level of treatment burden (<a href="./references#CD013766-bbs2-0095" title="BregnballeV , SchiøtzPO , BoisenKA , PresslerT , ThastumM . Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents. Patient Preference and Adherence2011;5:507-15. [DOI: 10.2147/PPA.S25308]">Bregnballe 2011</a>; <a href="./references#CD013766-bbs2-0117" title="DziubanEJ , Saab-AbazeedL , ChaudhrySR , StreetmanDS , NasrSZ . Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45:450-8. [DOI: 10.1002/ppul.21195]">Dziuban 2010</a>; <a href="./references#CD013766-bbs2-0121" title="GeorgeM , Rand-GiovannettiD , EakinMN , BorrelliB , ZettlerM , RiekertKA . Perceptions of barriers and facilitators: Self-management decisions by older adolescents and adults with CF. Journal of Cystic Fibrosis2010;9:425-32. [DOI: 10.1016/j.jcf.2010.08.016]">George 2010</a>; <a href="./references#CD013766-bbs2-0152" title="ModiAC , QuittnerAL . Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way?Journal of Pediatric Psychology2006;31(8):846-58. [DOI: 10.1093/jpepsy/jsj096]">Modi 2006a</a>; <a href="./references#CD013766-bbs2-0175" title="SawickiGS , HellerKS , DemarsN , RobinsonWM . Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Pediatric Pulmonology2015;50:127-36. [DOI: 10.1002/ppul.23017]">Sawicki 2015</a>). Treatment beliefs (e.g. lack of perceived benefit, feeling embarrassed about taking treatments in public, believing it is acceptable to miss treatments) have also been reported to influence adherence to treatments in people with CF (<a href="./references#CD013766-bbs2-0095" title="BregnballeV , SchiøtzPO , BoisenKA , PresslerT , ThastumM . Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents. Patient Preference and Adherence2011;5:507-15. [DOI: 10.2147/PPA.S25308]">Bregnballe 2011</a>; <a href="./references#CD013766-bbs2-0098" title="BucksRS , HawkinsK , SkinnerTC , HornS , SeddonP , HorneR . Adherence to treatment in adolescents with cystic fibrosis: the role of illness perceptions and treatment beliefs. Journal of Pediatric Psychology2009;34(8):893-902. [DOI: 10.1093/jpepsy/jsn135]">Bucks 2009</a>; <a href="./references#CD013766-bbs2-0117" title="DziubanEJ , Saab-AbazeedL , ChaudhrySR , StreetmanDS , NasrSZ . Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45:450-8. [DOI: 10.1002/ppul.21195]">Dziuban 2010</a>; <a href="./references#CD013766-bbs2-0121" title="GeorgeM , Rand-GiovannettiD , EakinMN , BorrelliB , ZettlerM , RiekertKA . Perceptions of barriers and facilitators: Self-management decisions by older adolescents and adults with CF. Journal of Cystic Fibrosis2010;9:425-32. [DOI: 10.1016/j.jcf.2010.08.016]">George 2010</a>; <a href="./references#CD013766-bbs2-0175" title="SawickiGS , HellerKS , DemarsN , RobinsonWM . Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Pediatric Pulmonology2015;50:127-36. [DOI: 10.1002/ppul.23017]">Sawicki 2015</a>). This is consistent with the Necessity‐Concerns Framework (<a href="./references#CD013766-bbs2-0136" title="HorneR , WeinmanJ . Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. Journal of Psychosomatic Research1999;47(6):555-67. [DOI: 10.1016/S0022-3999(99)00057-4]">Horne 1999</a>), which posits that beliefs about the necessity of treatments, and concerns about potential adverse consequences, can influence adherence and non‐adherence to treatments across a wide range of conditions and medications (<a href="./references#CD013766-bbs2-0138" title="HorneR , ChapmanSC , ParhamR , FreemantleN , ForbesA , CooperV . Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLOS One2013;8(12):e80633. [DOI: 10.1371/journal.pone.0080633]">Horne 2013</a>). </p> <p>Whilst treatment beliefs and concerns (i.e. conscious or reflective motivation) may be an important influence on treatment‐taking, it is also important to consider the role of automatic motivation influences, with recent trials highlighting the role of habit (i.e. "automatically experiencing an urge to use a nebuliser"; <a href="./references#CD013766-bbs2-0133" title="HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [DOI: 10.1136/thoraxjnl-2017-211453]">Hoo 2019a</a>) on adherence to inhaled therapies in adults with CF (<a href="./references#CD013766-bbs2-0086" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: an investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357-80. [DOI: 10.1111/bjhp.12357]">Arden 2019</a>; <a href="./references#CD013766-bbs2-0131" title="HooZH , BooteJ , WildmanMJ , CampbellMJ , GardnerB . Determinants of objective adherence to nebulised medications among adults with cystic fibrosis: an exploratory mixed methods study comparing low and high adherers. Health Psychology and Behavioral Medicine2017;5:299-316. [DOI: 10.1080/21642850.2017.1338958]">Hoo 2017</a>; <a href="./references#CD013766-bbs2-0133" title="HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [DOI: 10.1136/thoraxjnl-2017-211453]">Hoo 2019a</a>). Objective adherence data, collected using date‐ and time‐logging nebulisers, have demonstrated that, amongst adolescents with CF, adherence to inhaled therapies is greater on school days compared to weekends or holidays (<a href="./references#CD013766-bbs2-0087" title="BallR , SouthernKW , McCormackP , DuffAJA , BrownleeKG , McNamaraPS . Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time. Journal of Cystic Fibrosis2013;12(5):440-4. [DOI: 10.1016/j.jcf.2012.12.012]">Ball 2013</a>), despite this being a time when adolescents are likely to be busiest and are therefore more susceptible to miss treatments due to burden (<a href="./references#CD013766-bbs2-0131" title="HooZH , BooteJ , WildmanMJ , CampbellMJ , GardnerB . Determinants of objective adherence to nebulised medications among adults with cystic fibrosis: an exploratory mixed methods study comparing low and high adherers. Health Psychology and Behavioral Medicine2017;5:299-316. [DOI: 10.1080/21642850.2017.1338958]">Hoo 2017</a>). </p> <p>Given the complexity and multifactorial nature of adherence, interventions aimed at improving adherence to inhaled therapies are likely to be complex, or contain several interacting components (<a href="./references#CD013766-bbs2-0105" title="CraigP , DieppeP , MacintyreS , MichieS , NazarethI , PetticrewM . Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ2008;337:a1655. [DOI: 10.1136/bmj.a1655]">Craig 2008</a>). A ‘one size fits all’ intervention is therefore unlikely to be effective, as it will need to address issues of capability, opportunity, and motivation (<a href="./references#CD013766-bbs2-0086" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: an investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357-80. [DOI: 10.1111/bjhp.12357]">Arden 2019</a>), as highlighted in the Capability, Opportunity, Motivation, and Behaviour (COM‐B) model of behaviour (<a href="./references#CD013766-bbs2-0150" title="MichieS , vanStralenMM , WestR . The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implentation Science2011;6(42). [DOI: 10.1186/1748-5908-6-42]">Michie 2011</a>). Interventions may include reminders or alarms to target forgetting, but evidence for the efficacy of reminders on adherence is limited (<a href="./references#CD013766-bbs2-0101" title="ChoudhryNK , KrummeAA , ErcolePM , GirdishC , TongAY , KhanNF , et al. Effect of reminder devices on medication adherence: the REMIND randomized clinical trial. JAMA Internal Medicine2017;177(5):624-31. [DOI: 10.1001/jamainternmed.2016.9627]">Choudhry 2017</a>). Although forgetting is often understood to be ‘unintentional’ non‐adherence, it may be given as a reason to justify ‘intentional’ non‐adherence (<a href="./references#CD013766-bbs2-0086" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: an investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357-80. [DOI: 10.1111/bjhp.12357]">Arden 2019</a>; <a href="./references#CD013766-bbs2-0115" title="DrabbleSJ , O’CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119-31. [DOI: 10.1177/1049732319856580]">Drabble 2019</a>; <a href="./references#CD013766-bbs2-0121" title="GeorgeM , Rand-GiovannettiD , EakinMN , BorrelliB , ZettlerM , RiekertKA . Perceptions of barriers and facilitators: Self-management decisions by older adolescents and adults with CF. Journal of Cystic Fibrosis2010;9:425-32. [DOI: 10.1016/j.jcf.2010.08.016]">George 2010</a>), in a more socially acceptable way (<a href="./references#CD013766-bbs2-0115" title="DrabbleSJ , O’CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119-31. [DOI: 10.1177/1049732319856580]">Drabble 2019</a>). Interventions may target the individual's or family members' (e.g. parent/ caregiver) beliefs about the necessity of treatments, and concerns about potential adverse consequences, through psycho‐education or problem‐solving. They may also focus on supporting people with CF to develop routines and build habits for treatment‐taking, e.g. through the use of action planning. Feedback on treatment‐taking behaviour may be provided (<a href="./references#CD013766-bbs2-0113" title="DemonceauJ , RupparT , KristantoP , HughesDA , FargherE , KardasP , et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs2013;73:545-62. [DOI: 10.1007/s40265-013-0041-3]">Demonceau 2013</a>), and interventions may include people with CF self‐monitoring their adherence to inhaled therapies, e.g. using chipped nebulisers and digital technology applications. Healthcare professionals also have an important role in supporting adherence to inhaled therapies in adults with CF (<a href="./references#CD013766-bbs2-0086" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: an investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357-80. [DOI: 10.1111/bjhp.12357]">Arden 2019</a>). National Institute for Health and Care Excellence guidelines recommend the use of a non‐judgemental approach which involves asking open questions and not making assumptions, to promote open and honest conversations in relation to adherence (<a href="./references#CD013766-bbs2-0160" title="National Institute for Health and Care Excellence (NICE). Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence; 2009. Available from www.nice.org.uk/guidance/cg76.">NICE 2009</a>). Interventions may therefore involve training CF MDT members to communicate more effectively with individuals in relation to adherence, or teaching healthcare professionals how to address necessity beliefs and concerns during consultations (<a href="./references#CD013766-bbs2-0100" title="ChapmanSC , BarnesN , BarnesM , WilkinsonA , HartleyJ , PiddockC , et al. Changing adherence-related beliefs about ICS maintenance treatment for asthma: feasibility study of an intervention delivered by asthma nurse specialists. BMJ Open2015;5:e007354. [DOI: 10.1136/bmjopen-2014-007354]">Chapman 2015</a>). </p> </section> <section id="CD013766-sec-0013"> <h3 class="title" id="CD013766-sec-0013">Why it is important to do this review</h3> <p>A previous Cochrane Review concluded that establishing "effective ways to help people follow medical treatments could have far larger effects on health than any treatment itself" (<a href="./references#CD013766-bbs2-0125" title="HaynesR , McDonaldHP , GargA , MontagueP . Interventions for helping patients to follow prescriptions for medications. Cochrane Database of Systematic Reviews2002, Issue 2. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011]">Haynes 2002</a>). Furthermore, “simplifying the treatment burden” and "improving and sustaining adherence to treatment" have been identified as two of the top 10 CF research priorities in the James Lind Alliance Priority Setting Partnership (<a href="./references#CD013766-bbs2-0110" title="DaviesG , RowbothamNJ , SmithS , ElliotZC , GathercoleK , RaynerO , et al. Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials. Journal of Cystic Fibrosis2020;19:499-502. [DOI: 10.1016/j.jcf.2019.10.025]">Davies 2020</a>; <a href="./references#CD013766-bbs2-0171" title="RowbothamNJ , SmithS , LeightonPA , RaynerOC , GathercoleK , ElliottZC , et al. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax2018;73(4):388-90. [DOI: 10.1136/thoraxjnl-2017-210473]">Rowbotham 2018</a>). Adherence research has also been identified as a high priority by the World Health Organization (<a href="./references#CD013766-bbs2-0190" title="World Health Organization. Global Priorities for Research in Patient Safety (first edition); 2008. www.who.int/publications/i/item/WHO-IER-PSP-2008.13.">WHO 2008</a>). Despite this, there have been no previously published systematic reviews to assess the efficacy of psychological interventions for improving adherence to inhaled therapies in people with CF. A previous Cochrane Review protocol that focused on adherence to all treatments in CF was withdrawn (<a href="./references#CD013766-bbs2-0140" title="JonesS , CurleyR , WildmanM , MortonRW , ElphickHE . Interventions for improving adherence to treatment in cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 7. Art. No: CD011665. [DOI: 10.1002/14651858.CD011665.pub2]">Jones 2015</a>). The current Cochrane Review provides a more detailed focus on CF than general adherence reviews (<a href="./references#CD013766-bbs2-0161" title="NieuwlaatR , WilczynskiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a>), and expands upon other CF reviews focused on self‐management interventions (<a href="./references#CD013766-bbs2-0173" title="SavageE , BeirnePV , Ni ChroininM , DuffA , FitzgeraldT , FarrellD . Self-management education for cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD007641. [DOI: 10.1002/14651858.CD007641.pub3]">Savage 2014</a>), and psychological interventions for improving a range of outcomes (<a href="./references#CD013766-bbs2-0122" title="GoldbeckL , FidikaA , HerleM , QuittnerAL . Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD003148. [DOI: 10.1002/14651858.CD003148.pub3]">Goldbeck 2014</a>). We coded interventions in order to establish which BCTs are most effective at improving adherence to inhaled therapies in people with CF. By identifying the 'active ingredients' of interventions, the results of this review will help researchers, intervention designers and clinicians better support people with CF in adhering to their treatments. By focusing on inhaled therapies, this review complements other reviews planned or produced by the group on the theme of adherence (<a href="./references#CD013766-bbs2-0141" title="JonesM , MoffattF , HarveyA , RyanJM . Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis. Cochrane Database of Systematic Reviews2020, Issue 5. Art. No: CD013610. [DOI: 10.1002/14651858.CD013610]">Jones 2020</a>; <a href="./references#CD013766-bbs2-0181" title="SmithS , CalthorpeR , HerbertS , SmythAR . Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis. Cochrane Database of Systematic Reviews2023, Issue 2. Art. No: CD013733. [DOI: 10.1002/14651858.CD013733.pub2]">Smith 2020</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013766-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013766-sec-0014"></div> <p>The primary objective of the review was to assess the efficacy of psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (CF). The secondary objective was to establish the most effective components, or behaviour change techniques (BCTs), used in these interventions. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013766-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013766-sec-0015"></div> <section id="CD013766-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013766-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) and one quasi‐RCT (as we could reasonably assume that the baseline characteristics were similar in both groups). We included RCTs of parallel design and one cluster‐RCT. If cross‐over RCTs had been identified, we planned to include first‐period data only from these trials due to the likely carry‐over effects of the intervention. We included published and unpublished trials, as well as those published as abstracts only. </p> </section> <section id="CD013766-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included participants of any age, gender, and ethnicity who had a diagnosis of CF and who were prescribed inhaled therapies (as confirmed in the methodology of each included RCT). We included participants based in either a hospital or community setting. If appropriate, we planned to include trials that enroled participants with CF and participants with other chronic conditions only if there was a distinction made between the different participant groups (so that non‐CF participants with other chronic conditions could be excluded from our analyses). We also planned to include MDTs or families of people with CF if they were the target participants of an intervention aimed at improving adherence to inhaled therapies in people with CF. </p> <p>Given the wide variety of intervention targets included (i.e. children, adolescents and adults with CF, families of people with CF, and specialist CF MDTs), we were aware that it may not be appropriate to combine the results from different populations in statistical analysis. </p> <p>A previous Cochrane Review highlighted the inclusion bias likely to be present in adherence trials, with many interventions conducted with convenience samples in which participants have higher than average adherence at baseline (<a href="./references#CD013766-bbs2-0161" title="NieuwlaatR , WilczynskiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a>). This is an important methodological issue to consider as this may reduce the statistical power of an included trial to achieve the primary outcome, as the two groups will be similar (and so more power would be needed to detect a between‐group difference, if a difference exists). </p> </section> <section id="CD013766-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We aimed to assess all potential psychological interventions for improving adherence to inhaled therapies in people with CF as detailed above (<a href="#CD013766-sec-0011">Description of the intervention</a>) and which were specifically aimed at people with CF, the families of people with CF, or specialist CF MDTs. We included trials that reported at least one measure of adherence as an outcome. </p> <p>We used the BCTTv1 to identify the BCTs present in interventions in the included trials (<a href="./references#CD013766-bbs2-0151" title="MichieS , RichardsonM , JohnstonM , AbrahamC , FrancisJ , HardemanW , et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Annals of Behavioral Medicine2013;46(1):81-95. [DOI: 10.1007/s12160-013-9486-6]">Michie 2013</a>), in order to establish which BCTs were most effective at improving adherence to inhaled therapies in people with CF. We also coded the BCTs present in the active control groups, as the content and effectiveness of these interventions may vary considerably (<a href="./references#CD013766-bbs2-0111" title="deBruinM , ViechtbauerW , EismaMC , Hartmann-BoyceJ , WestR , BullE , et al. Identifying effective behavioural components of Intervention and Comparison group support provided in SMOKing CEssation (IC-SMOKE) interventions: a systematic review protocol. Systematic Reviews2016;5(77). [DOI: 10.1186/s13643-016-0253-1]">de Bruin 2016</a>). </p> </section> <section id="CD013766-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We planned to assess the following outcome measures.</p> <section id="CD013766-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013766-list-0001"> <li> <p>Adherence to inhaled therapies (measured using both objective and subjective measures)</p> <ol id="CD013766-list-0002"> <li> <p>objective recorded measures (e.g. electronic monitoring nebuliser devices such as Philips I‐neb AAD system and PARI eFlow® rapid nebuliser system and eTrack<sup>®</sup> controller which record date‐ and time‐stamped data) </p> </li> <li> <p>objective count measures (e.g. MPR)</p> </li> <li> <p>subjective measures (e.g. self‐reported adherence; questionnaires; participant diaries)</p> </li> </ol> </li> <li> <p>Treatment‐related adverse events</p> <ol id="CD013766-list-0003"> <li> <p>anxiety as measured by a validated anxiety scale, e.g. Generalized Anxiety Disorder (GAD‐7; <a href="./references#CD013766-bbs2-0183" title="SpitzerRL , KroenkeK , WilliamsJBW , LöweB . A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine2006;166(10):1092-7. [DOI: 10.1001/archinte.166.10.1092]">Spitzer 2006</a>) </p> </li> <li> <p>depression as measured by a validated depression scale, e.g. Patient Health Questionnaire (PHQ‐8; <a href="./references#CD013766-bbs2-0143" title="KroenkeK , StrineTW , SpritzerRL , WilliamsJB , BerryJT , MokdadAH . The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders2009;114(1-3):163-73. [DOI: 10.1016/j.jad.2008.06.026]">Kroenke 2009</a>) </p> </li> </ol> </li> </ol> </p> <p>We included trials with at least one measure of adherence regardless of whether it was a primary or secondary outcome. If an included trial measured adherence using more than one type of measure, then we reported the most reliable measure (i.e. objective measures preferentially reported over subjective measures, using the hierarchy of validity above). This is consistent with other Cochrane Reviews looking at adherence (<a href="./references#CD013766-bbs2-0106" title="CrossAJ , ElliottRA , PetrieK , KuruvillaL , GeorgeJ . Interventions for improving medication‐taking ability and adherence in older adults prescribed multiple medications. Cochrane Database of Systematic Reviews2020, Issue 5. Art. No: CD012419. [DOI: 10.1002/14651858.CD012419.pub2]">Cross 2020</a>; <a href="./references#CD013766-bbs2-0129" title="HollandsGJ , NaughtonF , FarleyA , LindsonN , AveyardP . Interventions to increase adherence to medications for tobacco dependence. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD009164. [DOI: 10.1002/14651858.CD009164.pub3]">Hollands 2019</a>). We excluded studies that did not measure adherence, even if they measured one or more of the other primary or secondary outcomes. </p> <p>We expected adherence to be typically defined as a continuous measure (e.g. total number of doses taken as a percentage of the target number of doses prescribed over a given time period). Alternatively, it can be defined as a dichotomous outcome, e.g. reporting whether the treatment is being used to a prespecified degree (e.g. adherent or non‐adherent for X number of days; adherence 75% and greater versus less than 75%). However, the often arbitrary cut‐off values for distinguishing 'adherence' from 'non‐adherence' (<a href="./references#CD013766-bbs2-0144" title="LamWY , FrescoP . Medication adherence measures: An overview. BioMed Research International2015;217047. [DOI: 10.1155/2015/217047]">Lam 2015</a>) has led to recommendations that research should use measures that are continuous rather than dichotomous (<a href="./references#CD013766-bbs2-0114" title="DiMatteoMR , GiordaniPJ , LepperHS , CroghanTW . Patient adherence and medical treatment outcomes: A meta-analysis. Medical Care2002;40(9):794-811. [DOI: 10.1097/01.MLR.0000024612.61915.2D]">DiMatteo 2002</a>). </p> <p>Where possible, adherence referred to 'normative adherence', a measure that considers a person's characteristics when defining the minimum required treatment regimen (<a href="./references#CD013766-bbs2-0130" title="HooZH , CurleyR , CampbellMJ , WaltersSJ , HindD , WildmanMJ . Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate “normative adherence”. Patient Preference and Adherence2016;10:887-900. [DOI: 10.2147/PPA.S105530]">Hoo 2016</a>). This is in contrast to 'unadjusted adherence', which is where a treatment regimen may be informed by considerations other than treatment effectiveness (e.g. a regimen based on what people with CF feel they can realistically manage rather than a regimen that has been driven by clinical evidence) (<a href="./references#CD013766-bbs2-0130" title="HooZH , CurleyR , CampbellMJ , WaltersSJ , HindD , WildmanMJ . Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate “normative adherence”. Patient Preference and Adherence2016;10:887-900. [DOI: 10.2147/PPA.S105530]">Hoo 2016</a>). </p> </section> <section id="CD013766-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013766-list-0004"> <li> <p>Quality of life (QoL) as measured by a validated QoL questionnaire, e.g. Cystic Fibrosis Questionnaire‐Revised (CFQ‐R; <a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) </p> </li> <li> <p>Lung function (absolute change or percentage change compared to baseline values, or both), measured in forced expiratory volume at one second (FEV<sub>1</sub>) L or per cent (%) predicted </p> </li> <li> <p>Pulmonary exacerbations (using the measure specified in the methodology of each trial, e.g. modified Fuchs criteria (<a href="./references#CD013766-bbs2-0093" title="BiltonD , CannyG , ConwayS , DumciusS , HjelteL , ProesmansM , et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. Journal of Cystic Fibrosis2011;10(2):S79-81. [DOI: 10.1016/S1569-1993(11)60012-X]">Bilton 2011</a>)) </p> <ol id="CD013766-list-0005"> <li> <p>number of exacerbations</p> </li> <li> <p>time to next exacerbation</p> </li> <li> <p>duration of exacerbations (as measured by the total number of IV antibiotic days)</p> </li> </ol> </li> </ol> </p> <p>If outcomes were reported at multiple time points, we extracted data from all time points. To investigate short‐ and long‐term effects, and to reduce the likelihood of missing an effect in trials that reported outcomes at multiple time points, we grouped outcome data into those measured at: up to three months; over three months and up to six months; over six months and up to 12 months; and over 12 months. If trials recorded outcome data at other time points, then we considered examining these as well. </p> </section> </section> </section> <section id="CD013766-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished trials without restrictions on language, year or publication status. </p> <section id="CD013766-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Cystic Fibrosis and Genetic Disorders Group's Information Specialist conducted a search of the Group's Cystic Fibrosis Trials Register for relevant trials using the following terms: treatment adherence OR mental health in CF OR behaviour. </p> <p>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated with each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ Pediatric Pulmonology and the Journal of Cystic Fibrosis. Unpublished work is identified by searching the abstract books of three major CF conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group's <a href="https://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of most recent Register search: 20 September 2022.</p> <p>In addition, the first review author (SD) searched the following databases:</p> <p> <ul id="CD013766-list-0006"> <li> <p>PubMed (<a href="https://www.ncbi.nlm.nih.gov/pubmed/" target="_blank">www.ncbi.nlm.nih.gov/pubmed/</a>; 1946 to 11 August 2022); </p> </li> <li> <p>PsycINFO EBSCO (<a href="https://search.ebscohost.com/login.asp?profile=ehost&amp;defaultdb=psyh" target="_blank">www.search.ebscohost.com</a>; 1887 to 7 August 2022); </p> </li> <li> <p>Scopus (<a href="https://www.elsevier.com/en-gb/solutions/scopus" target="_blank">www.elsevier.com/en-gb/solutions/scopus</a>; 1823 to 7 August 2022); </p> </li> <li> <p>OpenGrey (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>; searched 14 November 2020). As of 1 December 2020, the OpenGrey Repository was discontinued and preserved as a closed archive in the DANS EASY data archive, so this search was not updated. </p> </li> </ul> </p> <p>They also searched the following trials registries:</p> <p> <ul id="CD013766-list-0007"> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>; searched 14 August 2022); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 7 August 2022). </p> </li> </ul> </p> <p>See <a href="./appendices#CD013766-sec-0115">Appendix 1</a> for details of the search strategies. </p> </section> <section id="CD013766-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of included trials and any relevant systematic reviews identified for further references to relevant trials. We contacted leaders and organisations in the field to obtain additional information on relevant trials. </p> </section> </section> <section id="CD013766-sec-0026"> <h3 class="title" id="CD013766-sec-0026">Data collection and analysis</h3> <section id="CD013766-sec-0027"> <h4 class="title">Selection of studies</h4> <p>One author (SD) imported the search results onto systematic review screening software (<a href="./references#CD013766-bbs2-0104" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 02 January 2022. Available at covidence.org.">Covidence</a>). Three review authors (SD, LC, CG) used <a href="./references#CD013766-bbs2-0104" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 02 January 2022. Available at covidence.org.">Covidence</a> to independently screen all titles and abstracts identified from the search for their relevance for inclusion in the review. This was based on trial design, types of participants and interventions (as detailed above). Two authors independently screened all titles and abstracts (as first author, SD screened all studies; and LC and CG each screened a proportion of all studies). As two of the review authors (SD, CG) had links with two of the included trials (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), two other review authors (LC, DCC) who had no links with these trials and did not work in CF verified the inclusion of these trials. We tried to obtain full‐text publications of those deemed either eligible or potentially eligible, as well as for those where eligibility was unclear. We identified and excluded duplicates and collated multiple reports of the same trial so that each trial, rather than each report, was the unit of interest in the review. After the screening of the titles and abstracts, we independently screened full‐text publications and identified trials for inclusion in the review according to the predetermined eligibility criteria. As first author, SD screened all full‐text publications, and both LC and CG each screened a proportion of all trials. If we identified non‐English trials, we assessed these and, if necessary, planned to translate these with the assistance of a native speaker (e.g. by posting a request on Cochrane TaskExchange). In this review, we obtained one unpublished thesis written in French for full‐text screening, which was translated with the assistance of a non‐native French speaker. We recorded the reasons for exclusion of trials in the '<a href="./references#CD013766-sec-0125" title="">Characteristics of excluded studies</a>' table. Two review authors (SD and LC, or SD and CG) resolved any disagreements regarding the inclusion of a trial by discussion. If necessary, we had planned to consult with a third author (LC or CG) who had not been involved with the screening of that trial. </p> </section> <section id="CD013766-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>SD developed a data extraction form using the Cochrane template, which two review authors (SD, CG) piloted, undertaking any amendments as necessary. We extracted the following main sets of data from each included trial: </p> <p> <ol id="CD013766-list-0008"> <li> <p>trial details (lead author; date);</p> </li> <li> <p>methods (trial design and timetable, randomisation, allocation concealment);</p> </li> <li> <p>participants (participant condition(s) and demographics, age, gender, ethnicity, socioeconomic status, numbers of participants in each trial arm, trial participant inclusion and exclusion criteria); </p> </li> <li> <p>interventions (content and format of interventions, including details of information provided, intervention setting and delivery provider); </p> </li> <li> <p>outcomes (outcome measures, assessment time points, analysis, results);</p> </li> <li> <p>additional comments.</p> </li> </ol> </p> <p>Two review authors (SD, CG) independently extracted data and resolved discrepancies through discussion, or through consultation with a third author if necessary (LC). As two of the review authors (SD, CG) had links with two of the included trials (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), they were not involved in data extraction of those trials. Instead, these trials were extracted by the other two review authors (LC, DCC). The lead review author (SD) entered the data into RevMan, with the second review author (CG) checking the accuracy of the data entry (<a href="./references#CD013766-bbs2-0169" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <p>We coded the extracted intervention descriptions into component BCTs using the BCTTv1, an established taxonomy of 93 BCTs, as a coding framework (<a href="./references#CD013766-bbs2-0151" title="MichieS , RichardsonM , JohnstonM , AbrahamC , FrancisJ , HardemanW , et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Annals of Behavioral Medicine2013;46(1):81-95. [DOI: 10.1007/s12160-013-9486-6]">Michie 2013</a>). We coded BCTs for each intended recipient; we also coded each intervention separately, including control arms, and coded BCTs as 'present' or 'absent' for each intervention description. As originally described (<a href="./references#CD013766-bbs2-0149" title="MichieS , FixsenD , GrimshawJM , EcclesMP . Specifying and reporting complex behaviour change interventions: the need for a scientific method. Implementation Science2009;4(40). [DOI: 10.1186/1748-5908-4-40]">Michie 2009</a>), and highlighted in a Cochrane Review (<a href="./references#CD013766-bbs2-0145" title="LawrensonJG , Graham-RoweE , LorencattoF , PresseauJ , BurrJ , IversN , et al. Interventions to increase attendance for diabetic retinopathy screening. Cochrane Database of Systematic Reviews2016, Issue 1. Art. No: CD012054. [DOI: 10.1002/14651858.CD012054]">Lawrenson 2016</a>), complex behaviour change interventions are often poorly reported, which makes it challenging to identify the intervention content or BCTs used. As such, SD contacted the authors of included trials about the content of their interventions if there was insufficient information available (<a href="./references#CD013766-bbs2-0151" title="MichieS , RichardsonM , JohnstonM , AbrahamC , FrancisJ , HardemanW , et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Annals of Behavioral Medicine2013;46(1):81-95. [DOI: 10.1007/s12160-013-9486-6]">Michie 2013</a>). We requested additional materials or information that would provide further detail on the content of the intervention (e.g. trial protocol, letters sent to participants, participant information sheets, intervention manuals (<a href="./references#CD013766-bbs2-0146" title="LorencattoF , WestR , StavriZ , MichieS . How well is intervention content described in published reports of smoking cessation interventions?Nicotine &amp; Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco2013;15(7):1273–82. [DOI: 10.1093/ntr/nts266]">Lorencatto 2013</a>)). We coded received materials using the taxonomy in the same manner as for the corresponding published reports. Two review authors (SD, CG) who had both undertaken BCT coding training (<a href="./references#CD013766-bbs2-0088" title="BCT Taxonomy online training. BCT Taxonomy, accessed 10 August 2021. Available at bct-taxonomy.com.">BCT Taxonomy 2021</a>) independently conducted BCT coding, resolving discrepancies by discussion or by consultation with a third author (LC) if necessary. Two trials had already been coded by the study authors in the published reports (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), and we made no amendments. </p> <p>We narratively recorded and reported any results that we were not able to formally analyse in RevMan (<a href="./references#CD013766-bbs2-0169" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD013766-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SD, CG) independently assessed the risk of bias (or methodological quality) for each included trial, with any disagreements resolved by discussion. SD contacted the trial authors for additional information about the trial methods if necessary. As two of the review authors are or were involved with a wider programme of work linked to two included studies (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>) (though not the trials themselves), they were not involved in the risk of bias or GRADE assessments for these trials. Instead, the other two review authors (LC, DCC) assessed their risk of bias. We used the Cochrane risk of bias (RoB 1) tool to assess the following domains: sequence generation or randomisation; allocation concealment; blinding of participants, personnel and outcomes assessors; incomplete outcome data; and selective outcome reporting (<a href="./references#CD013766-bbs2-0126" title="Higgins JP AltmanDG , Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). However, blinding of participants and personnel is typically not possible in trials of psychological interventions. As such, the assessment of blinding only included the outcome assessors. We categorised the overall risk of bias of included trials as low, high, or unclear, according to the criteria specified by <a href="./references#CD013766-bbs2-0126" title="Higgins JP AltmanDG , Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>, and presented this (along with a justification for the judgement) in the '<a href="./references#CD013766-sec-0124" title="">Characteristics of included studies</a>' table. </p> </section> <section id="CD013766-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>If appropriate (e.g. when interventions, participants and the underlying clinical questions and outcomes were similar enough for pooling to make sense), we had planned to conduct a meta‐analysis. When single trials reported multiple trial arms, we had planned to only include the relevant arms. For continuous variables, we calculated mean differences (MDs) with 95% confidence intervals (CIs); or standardised mean differences (SMDs) with 95% CIs when the same outcome was measured on different scales. To interpret SMDs, we used Cohen's effect sizes of 0.2 to represent a small effect, 0.5 a moderate effect and 0.8 a large effect (<a href="./references#CD013766-bbs2-0102" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc., 1988.">Cohen 1988</a>). </p> <p>For dichotomous variables, we planned to present risk ratios (RRs) with 95% CIs. For data reported as rates or count data (e.g. number of pulmonary exacerbations), we planned to calculate rate ratios with 95% CIs. As anticipated given the outcome measures listed (e.g. adherence to inhaled therapies; lung function, QoL), most of the data we collected in this review were continuous. </p> <p>Since most trials reported endpoint data or final scores and only two trials reported the adjusted difference in means between groups (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), we entered both of these in separate analyses in the analysis section of the review (to avoid selective reporting and ensure the most robust (adjusted) data were presented where available). Change from baseline was presented in one trial (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), but since this trial also reported adjusted data which takes baseline into account, we favoured use of the adjusted data. </p> <p>We narratively described any skewed data reported as medians and ranges.</p> <p>As detailed in the review protocol (<a href="./references#CD013766-bbs2-0196" title="DawsonS , CowapL , Clark-CarterD , GirlingC . Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD013766. [DOI: 10.1002/14651858.CD013766]">Dawson 2020</a>), if an included trial measured adherence using more than one type of measure, then we reported the most reliable measure (i.e. objective measures preferentially reported over subjective measures, using the hierarchy of validity listed in the '<a href="#CD013766-sec-0020">Types of outcome measures</a>' section). </p> </section> <section id="CD013766-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>For cluster‐RCTs, we planned to only include data in the meta‐analyses if the available data had been adjusted to account for the clustering (or could be adjusted, based on recommendations (<a href="./references#CD013766-bbs2-0127" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022</a>)). We identified a single cluster‐RCT (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>), and the authors reported that they used generalised estimating equations to account for clustering within sites. The results of this study were quite difficult to interpret, and we were unable to access additional data despite repeated attempts to contact the trial authors. Two outcomes (exacerbations and lung function) were reported at baseline only; the only results we could interpret were absolute post‐treatment mean scores for each QoL domain, which we included in the analyses as if they were from a parallel trial where the unit of analysis is the participant. </p> <p>If we had identified any cross‐over RCTs, we planned to include data from the first period only as we cannot exclude a carry‐over effect of the intervention. </p> <p>If trials reported multiple measurements or observations from each participant for the same outcome (e.g. if data from two measures of depression were reported for each participant), to avoid double‐counting of participants or selectively choosing an outcome to report, we presented the data for each measure with no totals or summary statistics for each outcome (added post hoc)<i>.</i> In addition, if trials assessed an outcome using a measure that was completed independently by both children/adolescents with CF and parents/caregivers of people with CF (e.g. a child and parent/caregiver score for the same outcome were reported), we included data from the children and adolescents with CF only, to avoid double‐counting of participants (added post hoc). </p> </section> <section id="CD013766-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>If data (e.g. descriptive statistics) were missing from the included trials, one author (SD) attempted contact with the original trial authors (by email) to obtain these data. In future updates, if data such as standard deviations (SDs) are missing, where appropriate, we will calculate these from standard errors (SEs), CIs, t‐values or P values (if reported) (<a href="./references#CD013766-bbs2-0112" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). </p> </section> <section id="CD013766-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess clinical and methodological heterogeneity by considering the variation in the characteristics of the participants, interventions, outcomes and trial designs. We planned to visually inspect forest plots and use the Chi² test and the I² statistic to measure heterogeneity among the trials included in each analysis (with an I² value greater than 50% considered to represent substantial heterogeneity (<a href="./references#CD013766-bbs2-0126" title="Higgins JP AltmanDG , Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>)). Due to a lack of data, we were only able to combine limited results from different trials in a small number of analyses; therefore, we have not formally assessed heterogeneity in this version of the review. </p> </section> <section id="CD013766-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We used a comprehensive search strategy, which included searching for unpublished trials (grey literature) and searching trials registers (see '<a href="#CD013766-sec-0023">Search methods for identification of studies</a>') to minimise reporting biases. If data were not reported or published in full, the first review author (SD) contacted the trial authors to try to obtain the full data, or the reason for not publishing these data. Although not possible in this review, in future updates, if we are able to pool more than 10 trials in a meta‐analysis, we will use funnel plots to assess the possibility of publication bias (<a href="./references#CD013766-bbs2-0163" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Page 2022</a>). </p> </section> <section id="CD013766-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Although we have entered data into the '<a href="./references#CD013766-sec-0113" title="">Data and analyses</a>' section of the review, it is not currently possible to identify an overall intervention effect using meta‐analysis due to the substantial level of heterogeneity present in the included trials, in terms of participants (age), interventions (content and mode of delivery), and outcomes (measures, number and range of assessment time points). As such, we have presented a narrative synthesis of the 10 included trials and have combined the limited results from nine trials in a small number of quantitative analyses. As specified in the protocol (<a href="./references#CD013766-bbs2-0196" title="DawsonS , CowapL , Clark-CarterD , GirlingC . Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD013766. [DOI: 10.1002/14651858.CD013766]">Dawson 2020</a>), we used a random‐effects model as we assumed that there would be variation between studies (e.g. in terms of participants, interventions and outcomes). For future updates, if trials are sufficiently similar in terms of participants, eligibility criteria, interventions (type and intent) and outcomes (including the timeframe of follow‐up and type of measure used), we will consider meta‐analysis as described above (<a href="#CD013766-sec-0033">Assessment of heterogeneity</a>). If appropriate, we will perform a sensitivity analysis using a fixed‐effect model. </p> </section> <section id="CD013766-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For future updates, if sufficient data are available, we will conduct subgroup analyses with respect to: </p> <p> <ol id="CD013766-list-0009"> <li> <p>the target intervention participants (e.g. children and adolescents with CF; adults with CF; families of people with CF; or MDTs). In trials that include participants with a range of ages (i.e. children and adolescents or adults or unspecified), we will classify adults with CF as 18 years and over, and children and adolescents with CF as under 18 years of age; </p> </li> <li> <p>studies that focus on adherence to multiple CF treatments (i.e. a combination of inhaled and non‐inhaled therapies) compared to those that focus on inhaled therapies only (added post hoc); and </p> </li> <li> <p>the BCTs used.</p> </li> </ol> </p> <p>We planned to investigate the impact of type and number of BCTs on effect size by meta‐regression, but this was not possible due to the limited number of included trials in the review. </p> </section> <section id="CD013766-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We did not undertake any sensitivity analyses in this version of the review. If sufficient data had been available, we would have undertaken sensitivity analyses to assess the robustness of the results by excluding trials with an unclear or high risk of overall bias. This may have involved excluding trials in which adherence was measured using subjective methods (e.g. self‐reported adherence; questionnaires; participant diaries). We will consider this in future updates. </p> </section> <section id="CD013766-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We developed a summary of findings table for each comparison presented in the review (psychological interventions versus usual care: <a href="./full#CD013766-tbl-0001">summary of findings Table 1</a>; and psychological interventions versus active comparator group (e.g. education plus problem‐solving; EPS): <a href="./full#CD013766-tbl-0002">summary of findings Table 2</a>) using the following outcomes at the 'over six months and up to 12 months' time point: </p> <p> <ol id="CD013766-list-0010"> <li> <p>adherence to inhaled therapies (% completed treatments) (we planned to report using SMD for all results combined from six to 12 months, but since only one trial was included for this outcome in <a href="./full#CD013766-tbl-0001">summary of findings Table 1</a>, we instead reported using MD); </p> </li> <li> <p>change from baseline in anxiety (as measured by a validated anxiety scale, e.g. GAD‐7 (<a href="./references#CD013766-bbs2-0183" title="SpitzerRL , KroenkeK , WilliamsJBW , LöweB . A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine2006;166(10):1092-7. [DOI: 10.1001/archinte.166.10.1092]">Spitzer 2006</a>)); </p> </li> <li> <p>change from baseline in depression (as measured by a validated depression scale, e.g. PHQ‐8 (<a href="./references#CD013766-bbs2-0143" title="KroenkeK , StrineTW , SpritzerRL , WilliamsJB , BerryJT , MokdadAH . The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders2009;114(1-3):163-73. [DOI: 10.1016/j.jad.2008.06.026]">Kroenke 2009</a>)); </p> </li> <li> <p>change from baseline in QoL (as measured by a validated QoL questionnaire, e.g. CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>)); </p> </li> <li> <p>change from baseline in FEV<sub>1</sub> % predicted; </p> </li> <li> <p>number of pulmonary exacerbations, as measured using the measure specified in the methodology of each trial, e.g. modified Fuchs criteria (<a href="./references#CD013766-bbs2-0093" title="BiltonD , CannyG , ConwayS , DumciusS , HjelteL , ProesmansM , et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. Journal of Cystic Fibrosis2011;10(2):S79-81. [DOI: 10.1016/S1569-1993(11)60012-X]">Bilton 2011</a>). </p> </li> </ol> </p> <p>We used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each outcome, and to draw conclusions about the certainty of evidence in the review (<a href="./references#CD013766-bbs2-0178" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al, editor(s). Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Schünemann 2022</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013766-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013766-sec-0039"></div> <section id="CD013766-sec-0040"> <h3 class="title">Description of studies</h3> <p>For further details, please see the tables: <a href="./references#CD013766-sec-0124" title="">Characteristics of included studies</a>; <a href="./references#CD013766-sec-0125" title="">Characteristics of excluded studies</a>; and <a href="./references#CD013766-sec-0126" title="">Characteristics of ongoing studies</a>. </p> <section id="CD013766-sec-0041"> <h4 class="title">Results of the search</h4> <p>We identified a total of 5551 trials (5716 references) through our electronic search strategies (<a href="./appendices#CD013766-sec-0115">Appendix 1</a>). We identified a further five records through other sources (e.g. checking the reference lists of included trials). After removing 2566 duplicate references, we screened the titles and abstracts of the remaining 3155 references. From these, we identified 84 trials (192 references) as potentially eligible for inclusion and obtained the full‐texts (including clinical trial register records and conference abstracts). We excluded 69 trials (114 references) which did not meet the inclusion criteria, and have listed five trials (nine references) as ongoing (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>; <a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>; <a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>; <a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>). This leaves 10 trials (69 references) for inclusion in this review (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Nine of these 10 trials could also be included in limited quantitative syntheses (meta‐analyses) (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). We have shown the details of the selection process in a PRISMA diagram (<a href="#CD013766-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013766-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013766-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013766-sec-0042"> <h4 class="title">Included studies</h4> <p>Eight of the 10 trials included in this review (published between 1996 and 2021) were available as full‐texts published in peer‐reviewed journals (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). The results of one trial were reported in a symposium summary only (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>), and one trial was reported in a PhD thesis and a conference abstract (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). Further information on the included trials is provided in the table '<a href="./references#CD013766-sec-0124" title="">Characteristics of included studies</a>'. </p> </section> <section id="CD013766-sec-0043"> <h4 class="title">Trial design</h4> <p>Nine RCTs used a parallel design (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>) and one was a cluster‐RCT (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). The <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a> trial was a quasi‐RCT as participants were consecutively assigned to the intervention and control group, but from baseline data provided by the trial authors, we could reasonably assume that the baseline characteristics were similar in both groups. </p> <p>Six trials were single‐centre (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>), and four trials were multicentre (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Three trials were conducted in the UK (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), four in the USA (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>), one in Denmark (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>), one in Israel (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>), and one in Australia (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). </p> </section> <section id="CD013766-sec-0044"> <h4 class="title">Participants</h4> <p>A total of 1642 participants (approximately 54.3% female) were recruited and randomised across the 10 trials. The number of participants recruited in each trial ranged from five (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) to 641 (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). All interventions targeted people with CF (or caregiver/parent‐child dyads). No interventions specifically included MDTs or families of people with CF as the target participants of an intervention aimed at improving adherence to inhaled therapies in people with CF. </p> <p>One trial included 18 participants aged eight years and over (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). Four trials (745 participants) included only children or adolescents: one trial included five participants aged 10 to 14 years (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>); one trial included 34 participants aged 8 to 18 years (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>); one trial included 641 participants aged 11 to 20 years (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>); and one trial included 65 caregiver/parent‐child dyads where the children were aged 6 to 11 years (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). </p> <p>Five trials (879 participants) included only adults with CF: three trials included 800 participants aged 16 years and older (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>); one trial included 40 adults aged 18 to 30 years (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>); and one trial randomised 39 adults aged 18 years and older (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). </p> </section> <section id="CD013766-sec-0045"> <h4 class="title">Interventions</h4> <p>All included trials were two‐arm RCTs. The types of psychological interventions described were wide‐ranging and varied. One trial compared a psychological intervention (motivational interviewing (MI)) to an active comparator or attention control group (education plus problem solving (EPS)) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). The remaining nine trials compared a psychological intervention (as described below) to a usual care or 'treatment as usual' control group (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Psychological interventions included: a brief MI phone intervention (behaviour change counselling (BCC)) (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>); a clinic‐based, problem‐solving intervention (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>); a life‐coaching intervention (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>); a telehealth intervention comprising WhatsApp messages and Skype‐based video calls (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>); and a digital intervention involving self‐monitoring of lung function and medication reminders delivered by a home spirometer (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). Four trials described a 'self‐management' intervention (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), although the content and mode of delivery of these interventions varied. One of these interventions included training sessions focused on the nature of CF, principles of self‐management, types of medications and their appropriate use etc. (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>); another included a paper‐based, self‐management intervention completed by the parent or caregiver and child at home (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>); and two trials described a complex intervention comprising a digital platform (CFHealthHub website and smartphone app) and behaviour change sessions with a trained interventionist (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>In three trials, interventions focused solely on improving adherence to inhaled therapies (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), whereas in two trials, interventions focused on improving adherence to multiple CF treatments, e.g. aerosol treatments and airway clearance techniques (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>), or inhaled hypertonic saline, dornase alfa and CF multivitamins (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). In five trials, interventions were non‐specific and focused on improving adherence to CF treatments in general (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). In at least three of these trials, participants could choose the focus of the intervention, such as improving adherence to a treatment other than inhaled therapies (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>), or on a topic other than adherence (e.g. work‐life balance, stress management) (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). </p> <p>A range of healthcare professionals delivered the interventions, including psychologists or registered nurses (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>), or a trainee clinical psychologist (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). One intervention was delivered by a certified life coach (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). Some of the included trials involved delivery of the intervention by one trained professional (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). Other interventions were delivered by multiple, trained healthcare professionals or researchers (e.g. registered nurses, physiotherapists, social workers, psychologists, research co‐ordinators etc.) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), where there is likely to be more variation in terms of fidelity of the intervention. </p> <p>The mode of intervention delivery varied across trials. Interventions were delivered face‐to‐face (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>), over the telephone (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>), or using a combination of face‐to‐face and telephone sessions (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). Two interventions involved the use of digital technology: home spirometers that also delivered medication reminders (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>); and a telehealth intervention comprising WhatsApp messages and Skype video calls with members of the CF team (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). One intervention was delivered in the form of a paper workbook (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>), and two trials combined digital technology with face‐to‐face sessions (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Most interventions were delivered to participants on a 1:1 or individual basis (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), with only one delivered in a group setting (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>). </p> <p>Intervention duration ranged from 10 weeks (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) to 12 months (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). The 'dose' or intensity of interventions was also wide‐ranging and included: six sessions over five months (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>); six 30‐minute Skype video calls and WhatsApp messages sent twice each week over a period of three to six months (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>); daily medication reminders and weekly home spirometry over a period of three months (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>); or a workbook chapter per week over a period of 10 weeks (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). Two interventions were designed to be brief, comprising four, 10‐ to 15‐minute sessions delivered during clinics over 12 months (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>); or up to six fortnightly sessions lasting approximately 15 to 30 minutes each and delivered over three months (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). Two interventions were more intense in the early stages (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial scheduled up to 10 coaching sessions (lasting 60 to 90 minutes) to take place every one to two weeks early in the 12‐month programme and every two to four weeks later on (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). In the second trial, the intensity of the intervention varied depending on participants' adherence at baseline: participants with over 80% adherence were offered three sessions, with phase reviews every 12 weeks thereafter; participants with 80% or lower adherence followed a 'normal' pathway of six sessions over 12 weeks, with phase reviews every 12 weeks thereafter; and those with low adherence of 25% or less were offered more regular sessions (every six weeks) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Additional sessions were also offered if participants requested further support; if adherence decreased by 20% or more in a four‐week period; or if participants received IV antibiotics for an exacerbation (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). In two trials, the duration and intensity of the intervention was unclear; either because no details were provided on the scheduling of the two six‐hour training sessions (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>), or because it was unclear if the information provided (one clinic session and eight phone sessions over six months) was in reference to the intervention or active comparator arm, or both (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). </p> <p>Five trials stated that they had conducted fidelity assessments, usually using audio‐recordings from intervention sessions (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Fidelity assessments are important in psychological intervention trials to assess whether an intervention is delivered as conceived and intended (<a href="./references#CD013766-bbs2-0182" title="SongMK , HappMB , SandelowskiM . Development of a tool to assess fidelity to a psycho-educational intervention. Journal of Advanced Nursing2010;66(3):673-82. [DOI: 10.1111/j.1365-2648.2009.05216.x]">Song 2010</a>). Two trials provided limited details (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). There was also variation in the approaches used, ranging from assessing intervention fidelity for the first session only (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>), to assessing a sample of sessions throughout the trial, using two independent reviewers (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <section id="CD013766-sec-0046"> <h5 class="title">Intervention content in terms of BCTs (coded using the BCT Taxonomy)</h5> <p>Overall, we identified 41 out of the possible 93 BCTs (44.1%) across all trials (drawn from 15 out of the 16 different categories of BCTs within the taxonomy). Interventions were generally multi‐component or complex, and contained an average of 9.6 BCTs. The minimum number of BCTs used in an intervention was one (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>) and the maximum number was 28 (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). The BCTs used most frequently included '1.2 Problem solving' (coded in seven trials); '4.1 Instruction on how to perform the behaviour' (coded in five trials); and '3.1 Social support (unspecified)', '5.1 Information about health consequences', '7.1 Prompts/cues', '9.1 Credible source', and '12.5 Adding objects to the environment' (each coded in four trials). The remaining BCTs were coded in three trials or fewer. </p> <p>The nine trials provided no description of the 'usual care' comparator, which precluded BCT coding of the control groups (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial compared a psychological intervention (MI) with an active comparator intervention (EPS) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). BCTs were coded in both of these groups, and there was no overlap of the four BCTs used in the intervention group ('2.2 Feedback on behaviour'; 'Feedback on outcome(s) of behaviour'; '3.1 Social support (unspecified)'; and '5.1 Information about health consequences') with the three used in the active comparator arm ('1.2 Problem solving'; '4.1 Instruction on how to perform the behaviour'; and '10.4 Social reward'). </p> <p>Two of the included trials were coded by the trial authors in the published reports, and we made no amendments (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>We have presented further information on the BCTs present in the included trials in the additional tables (<a href="#CD013766-tbl-0003">Table 1</a>). A further table provides definitions and illustrative quotations for each BCT (<a href="#CD013766-tbl-0004">Table 2</a>). </p> <div class="table" id="CD013766-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Behaviour change techniques present in included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention arm</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control arm</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0011"> <li> <p>1.2 Problem solving</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> <li> <p>9.1 Credible source</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0012"> <li> <p>1.1 Goal setting (behaviour)</p> </li> <li> <p>1.2 Problem solving</p> </li> <li> <p>1.3 Goal setting (outcome)</p> </li> <li> <p>1.4 Action planning</p> </li> <li> <p>1.6 Discrepancy between current behaviour and goal</p> </li> <li> <p>1.9 Commitment</p> </li> <li> <p>2.3 Self‐monitoring of behaviour</p> </li> <li> <p>3.1 Social support (unspecified)</p> </li> <li> <p>3.2 Social support (practical)</p> </li> <li> <p>3.3 Social support (emotional)</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> <li> <p>5.1 Information about health consequences</p> </li> <li> <p>5.2 Salience of consequences</p> </li> <li> <p>6.1 Demonstration of the behaviour</p> </li> <li> <p>6.3 Information about others' approval</p> </li> <li> <p>7.1 Prompts/cues</p> </li> <li> <p>8.1 Behavioural practice/rehearsal</p> </li> <li> <p>8.3 Habit formation</p> </li> <li> <p>9.1 Credible source</p> </li> <li> <p>9.2 Pros and cons</p> </li> <li> <p>10.3 Non‐specific reward</p> </li> <li> <p>10.4 Social reward</p> </li> <li> <p>10.7 Self‐incentive</p> </li> <li> <p>10.9 Self‐reward</p> </li> <li> <p>11.2 Reduce negative emotions</p> </li> <li> <p>12.5 Adding objects to the environment</p> </li> <li> <p>13.2 Framing/ reframing</p> </li> <li> <p>15.1 Verbal persuasion about capability</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0013"> <li> <p>1.2 Problem‐solving</p> </li> <li> <p>2.1 Monitoring of behaviour by others without feedback</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0014"> <li> <p>1.1 Goal setting (behaviour)</p> </li> <li> <p>1.2 Problem solving</p> </li> <li> <p>1.4 Action planning</p> </li> <li> <p>1.5 Review behavioural goal(s)</p> </li> <li> <p>1.6 Discrepancy between current behaviour and goal</p> </li> <li> <p>2.2 Feedback on behaviour</p> </li> <li> <p>2.3 Self‐monitoring of behaviour</p> </li> <li> <p>3.2 Social support (practical)</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> <li> <p>5.1 Information about health consequences</p> </li> <li> <p>5.2 Salience of consequences</p> </li> <li> <p>6.1 Demonstration of the behaviour</p> </li> <li> <p>7.1 Prompts/cues</p> </li> <li> <p>8.1 Behavioural practice/rehearsal</p> </li> <li> <p>8.3 Habit formation</p> </li> <li> <p>8.7 Graded tasks</p> </li> <li> <p>9.1 Credible source</p> </li> <li> <p>10.4 Social reward</p> </li> <li> <p>12.1 Restructure the physical environment</p> </li> <li> <p>12.5 Adding objects to the environment</p> </li> <li> <p>15.3 Focus on past success</p> </li> <li> <p>15.4 Self‐talk</p> </li> <li> <p>16.3 Vicarious consequences</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0015"> <li> <p>3.1 Social support (unspecified)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0016"> <li> <p>1.2 Problem solving</p> </li> <li> <p>3.1 Social support (unspecified)</p> </li> <li> <p>9.2 Pros and cons</p> </li> <li> <p>13.3 Incompatible beliefs</p> </li> <li> <p>12.1 Restructuring the physical environment</p> </li> <li> <p>12.2 Restructuring the social environment</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0017"> <li> <p>1.2 Problem solving;</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0018"> <li> <p>2.2 Feedback on behaviour</p> </li> <li> <p>2.7 Feedback on outcome(s) of behaviour</p> </li> <li> <p>3.1 Social support (unspecified)</p> </li> <li> <p>5.1 Information about health consequences</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0019"> <li> <p>1.2 Problem solving</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> <li> <p>10.4 Social reward</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0020"> <li> <p>2.4 Self‐monitoring of outcome(s) of behaviour</p> </li> <li> <p>2.6 Biofeedback</p> </li> <li> <p>7.1 Prompts/cues</p> </li> <li> <p>12.5 Adding objects to the environment</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0021"> <li> <p>1.1 Goal setting (behaviour)</p> </li> <li> <p>1.2 Problem solving</p> </li> <li> <p>1.4 Action planning</p> </li> <li> <p>1.5 Review behavioural goal(s)</p> </li> <li> <p>1.6 Discrepancy between current behaviour and goal</p> </li> <li> <p>2.2 Feedback on behaviour</p> </li> <li> <p>2.3 Self‐monitoring of behaviour</p> </li> <li> <p>3.2 Social support (practical)</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> <li> <p>5.1 Information about health consequences</p> </li> <li> <p>5.2 Salience of consequences</p> </li> <li> <p>6.1 Demonstration of the behaviour</p> </li> <li> <p>7.1 Prompts/cues</p> </li> <li> <p>8.1 Behavioural practice/rehearsal</p> </li> <li> <p>8.3 Habit formation</p> </li> <li> <p>8.7 Graded tasks</p> </li> <li> <p>9.1 Credible source</p> </li> <li> <p>10.4 Social reward</p> </li> <li> <p>12.1 Restructure the physical environment</p> </li> <li> <p>12.5 Adding objects to the environment</p> </li> <li> <p>15.3 Focus on past success</p> </li> <li> <p>15.4 Self‐talk</p> </li> <li> <p>16.3 Vicarious consequences</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Used TIDiER description supplied by authors in study protocol ‐ note these behaviour change techniques were assigned by the authors and we have made no amendments. </p> </div> </div> <div class="table" id="CD013766-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Definitions and illustrative quotations of behaviour change techniques present in one or more of the included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BCT present</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BCT category</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BCT definition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of studies present in</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative quotations</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1. Goal setting (behavior)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Set or agree on a goal defined in terms of the behavior to be achieved</p> <p><i>Note: only code goal‐setting if there is sufficient evidence that goal set as part of intervention; if goal unspecified or a behavioral outcome, code 1.3, Goal setting (outcome); if the goal defines a specific context, frequency, duration or intensity for the behavior, also code 1.4, Action planning</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0022"> <li> <p>Indication of goal line on charts of adherence</p> </li> <li> <p>Visual indication of goal met on CFHealthHub</p> </li> <li> <p>(Optional) weekly push notifications indicating whether goal was met</p> </li> <li> <p>(Optional) reward messages sent when goal met</p> </li> </ul> </p> <p>Interventionist:</p> <p> <ul id="CD013766-list-0023"> <li> <p>Discussion and agreement of goals with interventionist." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2. Problem solving</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analyse, or prompt the person to analyse, factors influencing the behavior and generate or select strategies that include overcoming barriers and/or increasing facilitators (includes Relapse Prevention and Coping Planning) </p> <p><i>Note: barrier identification without solutions is not sufficient. If the BCT does not include analysing the behavioral problem, consider 12.3, Avoidance/changing exposure to cues for the behavior, 12.1, Restructuring the physical environment, 12.2, Restructuring the social environment, or 11.2, Reduce negative emotions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This intervention involves a member of the multidisciplinary team working with the adolescent to identify barriers to daily treatments and brainstorm solutions to those barriers with their parent." (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3. Goal setting (outcome)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Set or agree on a goal defined in terms of a positive outcome of wanted behavior</p> <p><i>Note: only code guidelines if set as a goal in an intervention context; if goal is a behavior, code 1.1, Goal setting (behavior); if goal unspecified code 1.3, Goal setting (outcome)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Plan</p> <p>What you want to get out of something is called a goal.</p> <p>What would you like to get out of doing this program?</p> <p>Set goals about doing chest treatments and doing this program.</p> <p>Some goals are already written into the boxes below. Highlight the goals you would like and write any others you’d like in the empty boxes." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4. Action planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt detailed planning of performance of the behavior (must include at least one of context, frequency, duration and intensity). Context may be environmental (physical or social) or internal (physical, emotional or cognitive) (includes Implementation Intentions) </p> <p><i>Note: evidence of action planning does not necessarily imply goal setting, only code latter if sufficient evidence</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:<br/>• Action planning tool and storage within<br/>CFHealthHub." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5. Review behavior goal(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review behavior goal(s) jointly with the person and consider modifying goal(s) or behavior change strategy in light of achievement. This may lead to re‐setting the same goal, a small change in that goal or setting a new goal instead of (or in addition to) the first, or no change </p> <p><i>Note: if goal specified in terms of behavior, code 1.5, Review behavior goal(s), if goal unspecified, code 1.7, Review outcome goal(s); if discrepancy created consider also 1.6, Discrepancy between current behavior and goal</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Interventionist:<br/>• Discussion and agreement of goals with<br/>interventionist<br/>• Review of goals<br/>• Suggested steady increase in goal as improvements are made<br/>• Feedback and social reward on progress." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6. Discrepancy between current behavior and goal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Draw attention to discrepancies between a person's current behavior (in terms of the form, frequency, duration, or intensity of that behavior) and the person's previously set outcome goals, behavioral goals or action plans (goes beyond self‐monitoring of behavior) </p> <p><i>Note: if discomfort is created, only code:</i> <br/><i>13.3, Incompatible beliefs and not 1.6, Discrepancy between current behavior and goal; if goals are modified, also code</i> <br/><i>1.5, Review behavior goal(s) and/or 1.7, Review outcome goal(s); if feedback is provided, also code 2.2, Feedback on behaviour</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0024"> <li> <p>Indication of goal line on charts of adherence</p> </li> <li> <p>Visual indication of goal met on CFHealthHub</p> </li> <li> <p>(Optional) Weekly push notifications indicating whether goal was met</p> </li> <li> <p>(Optional) Reward messages sent when goal met</p> </li> </ul> </p> <p>Interventionist:</p> <p> <ul id="CD013766-list-0025"> <li> <p>Discussion and agreement of goals with interventionist</p> </li> <li> <p>Review of goals</p> </li> <li> <p>Suggested steady increase in goal as improvements are made." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9. Commitment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ask the person to affirm or reaffirm statements indicating commitment to change the behavior </p> <p><i>Note: if defined in terms of the behavior to be achieved also code 1.1, Goal setting (behavior)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Practise remembering, fitting in and doing your puffer, nebuliser and ACT treatments.</p> <p>The chest treatments that I need to remember, fit in and do are: ___________________, ____times/day." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1 Monitoring of behaviour by others without feedback</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observe or record behaviour with the person's knowledge as part of a behaviour change strategy. </p> <p><i>Note: if monitoring is part of a data collection procedure rather than a strategy aimed at changing behaviour, do not code; if feedback given, code only 2.2, Feedback on behaviour, and not 2.1, Monitoring of behaviour by others without feedback; if monitoring outcome(s) code 2.5, Monitoring outcome(s) of behaviour by others without feedback; if self‐monitoring behaviour, code 2.3, Self‐monitoring of behaviour.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The interviewer will assess adherence over the week prior to the chat..." (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2. Feedback on behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monitor and provide informative or evaluative feedback on performance of the behavior <i>(e.g. form, frequency, duration, intensity)</i> </p> <p><i>Note: if Biofeedback, code only 2.6, Biofeedback and not 2.2, Feedback on behavior; if feedback is on outcome(s) of behavior, code 2.7, Feedback on outcome(s) of behavior; if there is no clear evidence that feedback was given, code 2.1, Monitoring of behavior by others without feedback; if feedback on behaviour is evaluative e.g. praise, also code 10.4, Social reward</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic‐level figures showing the association between adherence and health outcomes." (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3. Self‐monitoring of behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Establish a method for the person to monitor and record their behavior(s) as part of a behavior change strategy </p> <p><i>Note: if monitoring is part of a data collection procedure rather than a strategy aimed at changing behavior, do not code; if monitoring of outcome of behavior, code 2.4, Self‐monitoring of outcome(s) of behavior; if monitoring is by someone else (without feedback), code 2.1, Monitoring of behavior by others without feedback</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0026"> <li> <p>Charts and tables of objective adherence data presented within CFHealthHub</p> </li> </ul> </p> <p>Interventionist:</p> <p> <ul id="CD013766-list-0027"> <li> <p>Introducing and explaining charts and tables to participants." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4. Self‐monitoring of outcome(s) of behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Establish a method for the person to monitor and record the outcome(s) of their behavior as part of a behavior change strategy </p> <p><i>Note: if monitoring is part of a data collection procedure rather than a strategy aimed at changing behavior, do not code ; if monitoring behavior, code 2.3, Self‐monitoring of behavior; if monitoring is by someone else (without feedback), code 2.5, Monitoring outcome(s) of behavior by others without feedback</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Subjects in this group were asked to use the Spiro PD personal spirometer to check their lung function once a week for 3 months." (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6. Biofeedback</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provide feedback about the body (e.g. physiological or biochemical state) using an external monitoring device as part of a behavior change strategy </p> <p><i>Note: if Biofeedback, code only 2.6, Biofeedback and not 2.2, Feedback on behavior or 2.7, Feedback on outcome(s) of behaviour</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Participants were trained on the appropriate use of their device at the time of enrollment. They also <b>r</b>eceived weekly telephone calls from a respiratory therapist to review that week's lung function results." (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7. Feedback on outcome(s) of behavior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monitor and provide feedback on the outcome of performance of the behavior</p> <p><i>Note: if Biofeedback, code only 2.6, Biofeedback and not 2.7, Feedback on outcome(s) of behavior; if feedback is on behavior code 2.2, Feedback on behavior; if there is no clear evidence that feedback was given code 2.5, Monitoring outcome(s) of behavior by others without feedback; if feedback on behaviour is evaluative e.g. praise, also code 10.4, Social reward</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g. trajectory of lung function values, frequency of exacerbations) as well as clinic‐level figures showing the association between adherence and health outcomes." (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1. Social support (unspecified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Social support</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise on, arrange or provide social support (e.g. from friends, relatives, colleagues, 'buddies' or staff) or noncontingent praise or reward for performance of the behavior. It includes encouragement and counselling, but only when it is directed at the behavior </p> <p><i>Note: attending a group class and/or mention of 'follow‐up' does not necessarily apply this BCT, support must be explicitly mentioned; if practical, code 3.2, Social support (practical); if emotional, code 3.3, Social support (emotional) (includes 'Motivational interviewing' and 'Cognitive Behavioral Therapy')</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The coaching intervention included the following elements: client‐centeredness, empathy and collaboration, focus on preferences, reflective dialogue, use of positive language, and promotion of capacity and self‐determination. Sessions included different tools; for example, “the wheel of life” on which coachees could rate their level of satisfaction in different life areas." (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2. Social support (practical)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Social support</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise on, arrange, or provide practical help (e.g. from friends, relatives, colleagues, 'buddies' or staff) for performance of the behavior </p> <p><i>Note: if emotional, code 3.3, Social support (emotional); if general or unspecified, code 3.1, Social support (unspecified) If only restructuring the physical environment or adding objects to the environment, code 12.1, Restructuring the physical environment or 12.5, Adding objects to the environment; attending a group or class and/or mention of 'follow‐up' does not necessarily apply this BCT, support must be explicitly mentioned.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Find Solutions</p> <p>Remembering: Tick the boxes for the different ways that you could use to remember to do your treatment. Write down more ways that you think of. </p> <p>Put a timetable on fridge;</p> <p>Ask a family member to remind me;</p> <p>Put a sign up in my parent’s bedroom;</p> <p>Put a sign up in my bedroom;</p> <p>I just remember;</p> <p>Other ____________." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3. Social support (emotional)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Social support</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise on, arrange, or provide emotional social support (e.g. from friends, relatives, colleagues, 'buddies' or staff) for performance of the behavior </p> <p><i>Note: if practical, code 3.2, Social support (practical); if unspecified, code 3.1, Social support (unspecified)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Team partners have a big responsibility for chest treatments. Your role includes: doing and helping your child to do regular chest assessment and treatment; teaching your child about treatment and encouraging them to stick with it; being an important role model of a healthy lifestyle; being able to talk and deal with problems when they arise. It is a big job and not always easy." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1. Instruction on how to perform the behavior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Shaping knowledge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise or agree on how to perform the behavior (includes 'Skills training')</p> <p><i>Note: when the person attends classes such as exercise or cookery, code 4.1, Instruction on how to perform the behavior, 8.1, Behavioral practice/rehearsal and 6.1, Demonstration of the behavior</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The intervention also includes provision of a written, Prescribed Treatment Plan, assessment and remediation of gaps in Knowledge of Disease Management, and evaluation and re‐instruction/ re‐training of skills needed to perform daily treatments." (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1. Information about health consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Natural consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provide information (e.g. written, verbal, visual) about health consequences of performing the behavior </p> <p><i>Note: consequences can be for any target, not just the recipient(s) of the intervention; emphasising importance of consequences is not sufficient; if information about emotional consequences, code 5.6, Information about emotional consequences; if about social, environmental or unspecified consequences code 5.3, Information about social and environmental consequences</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic‐level figures showing the association between adherence and health outcomes." (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2. Salience of consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Natural consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use methods specifically designed to emphasise the consequences of performing the behaviour with the aim of making them more memorable (goes beyond informing about consequences) </p> <p><i>Note: if information about consequences, also code 5.1, Information about health consequences, 5.6, Information about emotional consequences or 5.3, Information about social and environmental consequences</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Some children also need to use nebulisers and puffers. Don’t wait until you get sick before you do your treatments. BE A GERM BUSTER and BUST GERMS TODAY! Draw some more germs in the box below." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1. Demonstration of the behavior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Comparison of behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provide an observable sample of the performance of the behaviour, directly in person or indirectly e.g. via film, pictures, for the person to aspire to or imitate (includes 'Modelling'. </p> <p><i>Note: if advised to practice, also code, 8.1, Behavioural practice and rehearsal; If provided with instructions on how to perform, also code 4.1, Instruction on how to perform the behaviour</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0028"> <li> <p>Solution bank within CFHealthHub (including advice to problem solve, restructure the physical environment, engage social support) </p> </li> <li> <p>Coping planning, Day planner and Party planner tools and storage within CFHealthHub</p> </li> <li> <p>Videos demonstrating correct use of nebulisers within CFHealthHub." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3. Information about others' approval</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Comparison of behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provide information about what other people think about the behavior. The information clarifies whether others will like, approve or disapprove of what the person is doing or will do </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This is what one child said. “Don’t say “It will be OK, I’ll sort it out tomorrow”, because infections can happen slowly. Once I feel tired and have less energy, then I don’t want to do my chest treatments at all.” (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1. Prompts/cues</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Associations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance </p> <p><i>Note: when a stimulus is linked to a specific action in an if‐then plan including one or more of frequency, duration or intensity also code 1.4, Action planning.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Devices were programmed to provide daily medication reminders for inhaled hypertonic saline, dornase alfa, and CF multivitamins." (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1. Behavioral practice/rehearsal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Repetition and substitution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt practice or rehearsal of the performance of the behavior one or more times in a context or at a time when the performance may not be necessary, in order to increase habit and skill </p> <p><i>Note: if aiming to associate performance with the context, also code 8.3, Habit formation</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0029"> <li> <p>Solution bank within CFHealthHub (including advice to problem solve, restructure the physical environment, engage social support) </p> </li> <li> <p>Coping planning, day planner and party planner tools and storage within CFHealthHub</p> </li> <li> <p>Videos demonstrating correct use of nebulisers within CFHealthHub</p> </li> </ul> </p> <p>Interventionist:</p> <p> <ul id="CD013766-list-0030"> <li> <p>Tailored problem‐solving guided by interventionist</p> </li> <li> <p>Support to create day plans/party plans where appropriate</p> </li> <li> <p>Support to construct if‐then coping plans including identifying self‐talk where appropriate." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3. Habit formation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Repetition and substitution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt rehearsal and repetition of the behavior in the same context repeatedly so that the context elicits the behavior </p> <p><i>Note: also code 8.1, Behavioral practice/rehearsal</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Interventionist:</p> <p> <ul id="CD013766-list-0031"> <li> <p>Help to focus on identifying consistent cues and linking to behaviour (habit formation)</p> </li> <li> <p>Discussion and identification of appropriate cues ‐ and how to add to the environment (if necessary)." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7. Graded tasks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Repetition and substitution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Set easy‐to‐perform tasks, making them increasingly difficult, but achievable, until behavior is performed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Interventionist:</p> <p> <ul id="CD013766-list-0032"> <li> <p>Discussion and agreement of goals with interventionist</p> </li> <li> <p>Review of goals</p> </li> <li> <p>Suggested steady increase in goal as improvements are made." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1. Credible source</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Comparison of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Present verbal or visual communication from a credible source in favour of or against the behavior </p> <p><i>Note: code this BCT if source generally agreed on as credible e.g., health professionals, celebrities or words used to indicate expertise or leader in field and if the communication has the aim of persuading; if information about health consequences, also code 5.1, Information about health consequences, if about emotional consequences, also code 5.6, Information about emotional consequences; if about social, environmental or unspecified consequences also code 5.3, Information about social and environmental consequences</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0033"> <li> <p>Information about CF, the need for treatment, how each treatment works and the importance of adherence </p> </li> <li> <p>Information presented in a variety of ways though written text, patient stories, 'talking heads' and animation videos, with links to external content including Cochrane reviews </p> </li> <li> <p>Range of different credible information sources including people CF, clinicians, links to scientific papers." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2. Pros and cons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Comparison of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise the person to identify and compare reasons for wanting (pros) and not wanting to (cons) change the behavior (includes 'Decisional balance') </p> <p><i>Note: if providing information about health consequences, also code 5.1, Information about health consequences; if providing information about emotional consequences, also code 5.6, Information about emotional consequences; if providing information about social, environmental or unspecified consequences also code 5.3, Information about social and environmental consequences</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"An important aspect of this work is the weighing up of the pros and cons of the problem and the solution, for example, helping them to make positive evaluations of increasing their nebuliser use (looking for the benefits) and weighing them as more important than the ‘costs’ of increasing their nebuliser use (time consumption, inconvenience etc.)." (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.3. Non‐specific reward</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Reward and threat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arrange delivery of a reward if and only if there has been effort and/or progress in performing the behavior (includes 'Positive reinforcement') </p> <p><i>Note: if reward is material, code 10.2, Material reward (behavior), if social, code 10.4, Social reward, and not 10.3, Nonspecific reward; if reward is for outcome code 10.10, Reward (outcome). If informed of reward in advance of rewarded behaviour, also code one of: 10.1, Material incentive (behaviour); 10.5, Social incentive; 10.6, Non‐specific incentive; 10.7, Self‐incentive; 10.8, Incentive (outcome)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This week’s activity is to fill the waves with sea creatures for doing all your chest treatments... Did you complete 5 or more waves last week? If you didn’t, do the activity again this week. If you did, enjoy your reward for learning about chest treatments. My reward for learning more about chest treatments is ___<b>_</b>". (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4. Social reward</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Reward and threat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arrange verbal or non‐verbal reward if and only if there has been effort and/or progress in performing the behavior (includes 'Positive reinforcement') </p> <p><i>Note: if reward is material, code 10.2, Material reward (behavior), if unspecified code 10.3, Non‐specific reward, and not 10.4, Social reward; if reward is for outcome code 10.10, Reward (outcome). If informed of reward in advance of rewarded behaviour, also code one of: 10.1, Material incentive (behaviour); 10.5, Social incentive; 10.6, Non‐specific incentive; 10.7, Self‐incentive; 10.8, Incentive (outcome)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This intervention is designed to increase knowledge and enhance the skills needed to optimize CF‐management. The strategies used to achieve improved adherence include providing didactic education and skills training, and proscriptively using behavioral modification strategies, such as positive reinforcement for desired behaviors, and problem‐solving training to overcome barriers." (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7. Self‐incentive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Reward and threat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plan to reward self in future if and only if there has been effort and/or progress in performing the behavior </p> <p><i>Note: if self‐reward is material, also code 10.1, Material incentive (behavior), if social, also code 10.5, Social incentive, if unspecified, also code 10.6, Non‐specific incentive; if incentive is for outcome code 10.8, Incentive (outcome). If reward is delivered also code one of: 10.2, Material reward (behavior); 10.3, Non‐specific reward; 10.4, Social reward, 10.9, Selfreward; 10.10, Reward (outcome)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This week’s activity is to fill the waves with sea creatures for doing all your chest treatments. Find the activity sheet with the picture of the sea. Draw and colour a sea creature in each day’s wave when you have remembered, fitted in and done all your treatments. Enjoy watching it fill up." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9. Self‐reward</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Reward and threat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt self‐praise or self‐reward if and only if there has been effort and/or progress in performing the behavior </p> <p><i>Note: if self‐reward is material, also code 10.2, Material reward (behavior), if social, also code 10.4, Social reward, if unspecified, also code 10.3, Non‐specific reward; if reward is for outcome code 10.10, Reward (outcome). If informed of reward in advance of rewarded behaviour, also code one of: 10.1, Material incentive (behaviour); 10.5, Social incentive; 10.6, Non‐specific incentive; 10.7, Selfincentive; 10.8, Incentive (outcome)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This week’s activity is to fill the waves with sea creatures for doing all your chest treatments. Find the activity sheet with the picture of the sea. Draw and colour a sea creature in each day’s wave when you have remembered, fitted in and done all your treatments. Enjoy watching it fill up." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2. Reduce negative emotions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Regulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise on ways of reducing negative emotions to facilitate performance of the behavior (includes 'Stress management') </p> <p><i>Note: if includes analysing the behavioural problem, also code 1.2, Problem solving</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The chapters contain information and exercises to explore the clinical nature of the respiratory aspect of CF; the promotion of co‐operative behaviour and teamwork; the use of cognitive theories that promote optimism and help the child cope with negative feelings about long‐term treatments; and issues pertaining to recommended aerosol and ACT treatments." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.1. Restructuring the physical environment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Antecedents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change, or advise to change the physical environment in order to facilitate performance of the wanted behavior or create barriers to the unwanted behavior (other than prompts/cues, rewards and punishments) </p> <p><i>Note: this may also involve 12.3, Avoidance/reducing exposure to cues for the behavior; if restructuring of the social environment code 12.2, Restructuring the social environment; if only adding objects to the environment, code 12.5, Adding objects to the environment</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"In the Action stage, the person actively modifies their behaviour, experience or environment in order to improve their nebuliser use." (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2. Restructuring the social environment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Antecedents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change, or advise to change the social environment in order to facilitate performance of the wanted behavior or create barriers to the unwanted behavior (other than prompts/cues, rewards and punishments) </p> <p><i>Note: this may also involve 12.3, Avoidance/reducing exposure to cues for the behavior; if also restructuring of the physical environment also code 12.1, Restructuring the physical environment</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"In the Action stage, the person actively modifies their behaviour, experience or environment in order to improve their nebuliser use." (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5. Adding objects to the environment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Antecedents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Add objects to the environment in order to facilitate performance of the behavior</p> <p><i>Note: Provision of information (e.g. written, verbal, visual) in a booklet or leaflet is insufficient. If this is accompanied by social support, also code 3.2, Social support (practical); if the environment is changed beyond the addition of objects, also code 12.1, Restructuring the physical environment</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"...we also conducted a pilot study to assess the feasibility of a portable personal spirometer device that also provided medication reminders among pediatric CF patients." (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2. Framing/reframing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Identity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suggest the deliberate adoption of a perspective or new perspective on behavior (e.g. its purpose) in order to change cognitions or emotions about performing the behavior (includes 'Cognitive structuring'); <i>If information about consequences then code 5.1, Information about health consequences, 5.6, Information about emotional consequences or 5.3, Information about social and environmental consequences instead of 13.2, Framing/reframing</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Write 1 of your negative thoughts about chest treatments in the top thought bubble. Draw a face to show how this makes you feel. Then, think of a positive thought that will help you to feel better about treatment and write this in the bottom thought bubble. Draw a face to show how this might make you feel." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3. Incompatible beliefs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Identity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Draw attention to discrepancies between current or past behavior and self‐image, in order to create discomfort (includes 'Cognitive dissonance') </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The intervention uses dialogue from the patient to create dissonance when ambivalent about behaviour change by weighing the importance of change against the costs of not changing." (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.1. Verbal persuasion about capability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Self‐belief</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tell the person that they can successfully perform the wanted behavior, arguing against self‐doubts and asserting that they can and will succeed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Getting mucus out of your lungs helps you to stay healthy. You CAN learn how to do your chest treatments well." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.3. Focus on past success</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Self‐belief</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise to think about or list previous successes in performing the behavior (or parts of it) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Interventionist:</p> <p> <ul id="CD013766-list-0034"> <li> <p>Interventionist encouraging focus on periods of higher adherence on charts." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.4. Self‐talk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Self‐belief</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt positive self‐talk (aloud or silently) before and during the behavior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Interventionist:</p> <p> <ul id="CD013766-list-0035"> <li> <p>Interventionist introducing and highlighting relevant content on CFHealthHub</p> </li> <li> <p>Interventionist eliciting self‐talk through discussion of motivation." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3. Vicarious consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3. Vicarious consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt observation of the consequences (including rewards and punishments) for others when they perform the behavior </p> <p><i>Note: if observation of health consequences, also code 5.1, Information about health consequences; if of emotional consequences, also code 5.6, Information about emotional consequences, if of social, environmental or unspecified consequences, also code 5.3, Information about social and environmental consequences</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0036"> <li> <p>Demonstration of techniques for nebuliser use, cleaning and treatment mixing</p> </li> <li> <p>Information about CF, the need for treatment, how each treatment works, and the importance of adherence </p> </li> <li> <p>Information presented in a variety of ways though written text, patient stories, ‘talking heads’, and animation videos, with links to external content including Cochrane Reviews </p> </li> <li> <p>Range of different credible information sources including PWCF, Clinicians, links to scientific papers </p> </li> </ul> </p> <p>Interventionist:</p> <p> <ul id="CD013766-list-0037"> <li> <p><b>I</b>nterventionist introducing and highlighting relevant content on CFHealthHub." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BCT: behaviour change technique</p> <p>BCT definitions taken from the BCT Taxonomy (v1) (<a href="./references#CD013766-bbs2-0151" title="MichieS , RichardsonM , JohnstonM , AbrahamC , FrancisJ , HardemanW , et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Annals of Behavioral Medicine2013;46(1):81-95. [DOI: 10.1007/s12160-013-9486-6]">Michie 2013</a>). </p> <p><sup>a</sup>The same intervention was used in two included studies but with different populations (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a> was a feasibility trial conducted in two CF centres; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a> was a larger RCT conducted in 19 different CF centres). </p> </div> </div> </section> </section> <section id="CD013766-sec-0047"> <h4 class="title">Outcomes</h4> <section id="CD013766-sec-0048"> <h5 class="title">Adherence</h5> <p>All trials measured adherence to inhaled therapies; this was as a primary outcome in four trials (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>), a secondary outcome in three trials (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), and three trials did not specify between primary and secondary outcomes (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). The measures of adherence used varied across trials, as detailed below. </p> <p>Three trials used objective recorded measures (e.g. dose‐counting nebulisers) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial monitored adherence electronically using an Adaptive Aerosol Delivery device (Prodose) and reported data at two time points (baseline (measured for three months prior to the intervention) and at three months (measured for three months post‐intervention) (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). Investigators calculated adherence using four methods; please see '<a href="./references#CD013766-sec-0124" title="">Characteristics of included studies</a>' for further details. </p> <p>Two trials assessed adherence to inhaled therapies using the PARI eFlow rapid nebuliser system with an eTrack Controller<sup>®</sup> at baseline and five months (plus or minus one month) from consent visit (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), or at baseline and 12 months (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). These trials calculated and reported adherence in five ways; again, please see '<a href="./references#CD013766-sec-0124" title="">Characteristics of included studies</a>' for further details. </p> <p>Three trials measured adherence using objective count measures (e.g. MPR) (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). These trials all reported a composite MPR (cMPR) measure in which the MPRs of each medication were averaged across all included medications (<a href="./references#CD013766-bbs2-0118" title="EakinMN , BilderbackA , BoyleMP , MogayzelPJ , RiekertKA . Longitudinal association between medication adherence and lung health in people with cystic fibrosis. Journal of Cystic Fibrosis2011;10(4):258-64. [DOI: 10.1016/j.jcf.2011.03.005]">Eakin 2011</a>); but the included medications varied. Two trials reported a cMPR measure of 'chronic pulmonary medications' which included inhaled therapies (e.g. dornase alfa, tobramycin, hypertonic saline, aztreonam lysine), as well as one non‐inhaled treatment (e.g. azithromycin), but individual MPRs were not available (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). Another trial reported a cMPR of two inhaled therapies (hypertonic saline and dornase alfa) and one non‐inhaled therapy (CF multivitamins), but it was possible to estimate MPR for individual treatments from a chart in the paper (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). One trial reported results for cMPR at baseline and three months (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) and two trials at baseline and 12 months (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>), although the time frames used to calculate MPR seemed to vary (see '<a href="./references#CD013766-sec-0124" title="">Characteristics of included studies</a>'). </p> <p>Four trials measured adherence using subjective measures (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). Two of these trials assessed adherence using self‐report in participant diaries and converted the information from the diaries into the % of prescribed aerosol treatments taken (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). Two trials assessed adherence to dornase alfa and inhaled antibiotics, with <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a> assessing participant scores on the Morisky Medication Adherence Scale (MMAS‐8) (<a href="./references#CD013766-bbs2-0155" title="MoriskyDE , AngA , Krousel-WoodM , WardHJ . Predictive validity of a medication adherence measure in an outpatient setting. Journal of Clinical Hypertension2008;10(5):348-54. [DOI: 10.1111/j.1751-7176.2008.07572.x]">Morisky 2008</a>), and <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a> using a questionnaire with a five‐point Likert scale. In addition to dornase alfa and inhaled antibiotics, <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a> assessed adherence to inhaled steroids, hypertonic saline, and bronchodilators. These trials assessed adherence at different time points: <a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a> reported at baseline and six to eight weeks post‐assessment; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a> reported at baseline and three to five months post‐assessment; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a> reported at pre‐intervention, post‐intervention (three to four months after pre‐intervention assessment for control group and immediately after completion of 'Airways' for intervention group), six‐month follow‐up (six months after post‐intervention assessment), and 12‐month follow‐up (six months after six‐month follow‐up assessment; and <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a> reported at baseline, five months (midway), 11 months (post‐intervention) and one year post‐intervention (follow‐up). </p> <p>Two trials assessed adherence in multiple ways (e.g. using data‐logging nebulisers and participant self‐report) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </section> <section id="CD013766-sec-0049"> <h5 class="title">Treatment‐related adverse events (depression and anxiety)</h5> <p>Four trials included depression as a secondary outcome (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>, <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), and three trials included anxiety (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Both outcomes were assessed using a variety of measures. Two trials assessed depression using scores on the PHQ‐8 (<a href="./references#CD013766-bbs2-0143" title="KroenkeK , StrineTW , SpritzerRL , WilliamsJB , BerryJT , MokdadAH . The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders2009;114(1-3):163-73. [DOI: 10.1016/j.jad.2008.06.026]">Kroenke 2009</a>); one assessed at baseline and five months (plus or minus one month) from consent visit (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), and the second at baseline and 12 months (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial assessed depression using both the Major Depression Inventory (MDI) (<a href="./references#CD013766-bbs2-0089" title="BechP , RasmussenNA , OlsenLR , NoerholmV , AbildgaardW . The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. Journal of Affective Disorders2001;66(2-3):159-64. [DOI: 10.1016/S0165-0327(00)00309-8]">Bech 2001</a>) and the Center for Epidemiologic Studies Depression Scale (CES‐D) (<a href="./references#CD013766-bbs2-0167" title="RadloffLS . The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Applied Psychological Measurement1977;1(3):385-401. [DOI: 10.1177/014662167700100306]">Radloff 1977</a>) at baseline, five months (midway), 11 months (post‐intervention) and one year post‐intervention (follow‐up) (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). </p> <p>Quinn measured depression and anxiety using the hospital anxiety and depression scale (HADS) (<a href="./references#CD013766-bbs2-0195" title="ZigmondAS , SnaithRP . The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica1983;67(6):361-70. [DOI: 10.1111/j.1600-0447.1983.tb09716.x]">Zigmond 1983</a>), and measured anxiety using the State‐Trait Anxiety Inventory‐short form (STAI‐short form) (<a href="./references#CD013766-bbs2-0147" title="MarteauTM , BekkerH . The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). British Journal of Clinical Psychology1992;31:301-6. [DOI: 10.1111/j.2044-8260.1992.tb00997.x]">Marteau 1992</a>); investigators assessed both outcomes at pre‐intervention and post‐intervention (three months later) (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). </p> <p>Two further trials measured anxiety as score on the GAD‐7 (<a href="./references#CD013766-bbs2-0183" title="SpitzerRL , KroenkeK , WilliamsJBW , LöweB . A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine2006;166(10):1092-7. [DOI: 10.1001/archinte.166.10.1092]">Spitzer 2006</a>) at baseline and five months (plus or minus one month) from consent visit in one trial (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), or at baseline and 12 months in the second trial (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>All trials expressed depression or anxiety results, or both, as means and SDs (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial also reported unadjusted MDs between groups (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), and two trials reported adjusted MDs, adjusting for baseline and CF centre (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), or baseline, CF centre and past‐year IV days (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </section> <section id="CD013766-sec-0050"> <h5 class="title">QoL</h5> <p>Nine trials included QoL as an outcome using a range of measures (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>One trial (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>) assessed QoL using the Quality of Wellbeing scale (<a href="./references#CD013766-bbs2-0142" title="KaplanRM , AndersonJP , WuAW , MathewsWC , KozinF , OrensteinDM . The Quality of Well-Being Scale: applications in AIDS, cystic fibrosis, and arthritis. Medical Care1989;27:S27-43. [DOI: 10.1097/00005650-198903001-00003]">Kaplan 1989</a>). One trial (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>) assessed QoL using scores on the CFQoL (<a href="./references#CD013766-bbs2-0120" title="GeeL , AbbottJ , ConwaySP , EtheringtonC , WebbAK . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax2000;55(11):946-54. [DOI: 10.1136/thorax.55.11.946]">Gee 2000</a>). </p> <p>Seven trials used scores on the CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) to assess QoL (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Three trials assessed QoL across all domains of the CFQ‐R (Teen/Adult version) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>), or both the Teen/Adult and Older Child versions depending on participant ages (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). Three trials assessed QoL using only some domains of the CFQ‐R (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a> used eight domains of the Teen/Adult version of the questionnaire (physical functioning, emotional functioning, social functioning, eating disturbance, body image, treatment burden, respiratory symptoms, digestive symptoms). <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a> used three domains (treatment burden, respiratory symptoms, and physical functioning), and <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a> used the treatment burden domain only. Neither <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a> nor <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a> specified which version they used, but we presumed that <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a> used the Teen/Adult version (as they included participants aged 16 years and older); and <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a> used the Older Child version (as they included participants aged 10 to 14 years), as well as the Parent/Caregiver version. Investigators of one trial reported using age‐appropriate versions of the CFQ‐R (Parent/Caregiver and Teen/Adult versions), but they did not specify which domains were used (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). </p> <p>Trials assessed QoL at a range of different time points, including: baseline (pre‐intervention) and six to eight weeks post‐intervention (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>); baseline (pre‐intervention) and three months (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>); baseline and five months (plus or minus one month) from consent visit (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>); baseline and three to five months post‐intervention (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>); baseline, five months (midway), 11 months (post‐intervention), and one year post‐intervention (follow‐up) (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>); baseline and 12 months (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>); and baseline, six months and 12 months (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). </p> <p>Eight trials expressed QoL results as means and SDs (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial also reported unadjusted MDs between groups (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), and two trials reported adjusted MD, adjusting for baseline and CF centre (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), or baseline, CF centre and past‐year IV days (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial reported only medians and interquartile ranges (IQRs) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>), so we describe results narratively below. </p> </section> <section id="CD013766-sec-0051"> <h5 class="title">Lung function</h5> <p>Seven trials reported lung function (FEV<sub>1</sub> % predicted) at a range of different time points: baseline and three months (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>); baseline and five months (plus or minus one month) from consent visit (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>); baseline, five months (midway), 11 months (post‐intervention), and one year post‐intervention (follow‐up) (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>); and baseline and 12 months (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Two trials extracted lung function data from CF registry databases (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>), one from medical records (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>), and in one trial it was recorded on the home spirometer used as part of the intervention (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). In three trials, FEV<sub>1</sub> was taken for the purposes of the trial at each assessment time point (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), in addition to during routine clinic visits in two trials (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Five trials expressed results for FEV<sub>1</sub> % predicted as means and SDs (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), while one trial reported means and SDs at baseline only (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). One trial also reported unadjusted MDs between groups (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), and two trials reported adjusted MDs, adjusting for baseline and CF centre (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), or baseline, CF centre and past‐year IV days (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial reported only medians and IQRs (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>), so we have described results narratively. None of the included trials reported lung function in litres (i.e. FEV<sub>1</sub> L). </p> </section> <section id="CD013766-sec-0052"> <h5 class="title">Pulmonary exacerbations</h5> <p>Two trials included pulmonary exacerbations as a primary outcome (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>) and three trials as a secondary outcome (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). Three of these trials assessed the total number of exacerbations during the trial periods of three months (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>), six months (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), or 12 months (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). This was defined as the "number of exacerbations treated with IV antibiotics with at least one modified Fuchs’ criteria (e.g. change in sputum, increased cough)" (<a href="./references#CD013766-bbs2-0168" title="RatjenF , DurhamT , NavratilT , SchabergA , AccursoFJ , Wainwright C et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis2012;11(6):539-49. [DOI: 10.1016/j.jcf.2012.05.003]">Ratjen 2012</a>) in two trials (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial did not provide a definition for an exacerbation (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). </p> <p>One trial reported the total number of exacerbations in each group only (no means, SDs or ratio data) (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>), while two trials reported the total number of exacerbations in each group along with unadjusted and adjusted exacerbation rates (incidence rate ratios; 95% CI), adjusted for CF centre and past year IV antibiotic days (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Hind also reported the mean (SD) and median (IQR) number of exacerbations per group, and the number of participants experiencing one or more exacerbations per group (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>). </p> <p>Two further trials measured exacerbations, although the results were more difficult to interpret (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). Riekert measured exacerbations as "pulmonary exacerbations (1+ in past year)" with results expressed as percentages. <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a> measured pulmonary exacerbations as "IV antibiotic treatment (extracted from the CF Registry)" but it was unclear how this was defined (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). The percentage of participants receiving "1+ course of IV antibiotics in the past year" was reported at baseline only. </p> <p>None of the included trials reported the time to next exacerbation or the duration of exacerbations (total number of IV days). </p> </section> </section> <section id="CD013766-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded 2963 records by screening titles and abstracts. We excluded a further 69 trials (114 references) following full‐text screening, with reasons for each listed in the tables (<a href="./references#CD013766-sec-0125" title="">Characteristics of excluded studies</a>) and summarised as follows. There were 11 references which did not relate to a trial (e.g. they were a commentary or an editorial) (<a href="./references#CD013766-bbs2-0011" title="AbbottJ , BiltonD . Adherence to ivacaftor is suboptimal. Journal of Cystic Fibrosis2015;14:547-8. [DOI: 10.1016/j.jcf.2015.08.001]">Abbott 2015</a>; <a href="./references#CD013766-bbs2-0022" title="DanielsT , MillsN , WhitakerP . Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database of Systematic Reviews2013, Issue 4. Art. No: CD007639. [DOI: 10.1002/14651858.CD007639.pub2]">Daniels 2013</a>; <a href="./references#CD013766-bbs2-0024" title="DoddME , WebbK . Understanding non-compliance with treatment in adults with cystic fibrosis. Journal of the Royal Society of Medicine2000;93(38):2-8. ">Dodd 2000</a>; <a href="./references#CD013766-bbs2-0026" title="DuffAJ , LatchfordG . Adherence in cystic fibrosis; care teams need to change first. Lancet: Respiratory Medicine2014;2(9):683-5. [DOI: 10.1016/S2213-2600(14)70162-6]">Duff 2014</a>; <a href="./references#CD013766-bbs2-0030" title="GellerDE , MadgeS . Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis. Respiratory Medicine2011;105(S2):S24-31. ">Geller 2011</a>; <a href="./references#CD013766-bbs2-0036" title="HawkinsKS . Adherence to treatment in adolescents with cystic fibrosis. The role of illness perception and treatment beliefs. Doctorate in Clinical Psychology Thesis2002. [www.elibrary.ru/item.asp?id=8827177]">Hawkins 2002</a>; <a href="./references#CD013766-bbs2-0046" title="MeyersA , Dolan TF Jr, MuellerD . Compliance and self-medication in cystic fibrosis. American Journal of Diseases of Children1975;129:1011-3. [DOI: 10.1001/archpedi.1975.02120460005002]">Meyers 1975</a>; <a href="./references#CD013766-bbs2-0066" title="OhnM , FitzgeraldDA . Question 12: What do you consider when discussing treatment adherence in patients with cystic fibrosis?Paediatric Respiratory Reviews2018;25:33-6. [DOI: 10.1016/j.prrv.2017.04.002]">Ohn 2018</a>; <a href="./references#CD013766-bbs2-0068" title="PendletonDA , DavidTJ . The compliance conundrum in cystic fibrosis. Journal of the Royal Society of Medicine2000;93(38):9-13. ">Pendleton 2000</a>; <a href="./references#CD013766-bbs2-0074" title="SadprasidB , EddyE , TaborA , SchemeE , BatemanS . Percussion Hero: a chest physical therapy game for people with cystic fibrosis and their caregivers. In: Annual Symposium on Computer-Human Interaction in Play (CHI PLAY '21); 2021; Association for Computing Machinery, New York, NY, USA. 2021:361-7. [DOI: 10.1145/3450337.3483508]">Sadprasid 2021</a>; <a href="./references#CD013766-bbs2-0076" title="StrawhackerMT , WellendorfJ . Caring for children with cystic fibrosis: a collaborative clinical and school approach. Journal of School Nursing2004;20(1):5-15. [DOI: 10.1177/10598405040200010301]">Strawhacker 2004</a>), and 17 trials were non‐randomised or single‐arm trials (<a href="./references#CD013766-bbs2-0013" title="ACTRN12619001730190. Implementing a comprehensive adherence protocol for children and adolescents living with cystic fibrosis – an implementation study [Implementing a comprehensive adherence protocol for children and adolescents living with cystic fibrosis – feasibility, appropriateness and acceptability]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12619001730190 (date of registration 9 December 2019). Implementing a comprehensive adherence protocol for children and adolescents living with cystic fibrosis – An implementation study [Implementing a comprehensive adherence protocol for children and adolescents living with cystic fibrosis – feasibility, appropriateness and acceptability]. anzctr.org.au/ACTRN12619001730190.aspx (date registered 9 December 2019). ">ACTRN12619001730190</a>; <a href="./references#CD013766-bbs2-0031" title="GoldbeckL , HebestreitH , JungeS , SensB , SmacznyC , FrankM , et al. Vemse-CF - A prospective controlled care-research study investigating the effects of a comprehensive psychosocial intervention. Pediatric Pulmonology2013;48 Suppl 36:430. [ABSTRACT NO.: 608] [CENTRAL: CN-00875655] [CFGD REGISTER: MH39] NCT03423576. Effects of a comprehensive patient-centered health service in cystic fibrosis (VEMSE-CF) [Effects of a comprehensive patient-centered health service with a focus on psychosocial services for patients with are diseases using cystic fibrosis as an example (Evaluation Eines Ganzheitlichen Patientenzentrierten Versorgungsmodells für Patienten Mit Seltenen Erkrankungen Unter Besonderer Berücksichtigung Der Psychosozialen Versorgung am Beispiel Mukoviszidose)]. clinicaltrials.gov/ct2/show/NCT03423576 (first posted 06 February 2018). ">Goldbeck 2013</a>; <a href="./references#CD013766-bbs2-0033" title="GrossoehmeDH , ColeAG , LewisK , StamperSM , TeetersA , JosephPM . Adults with cystic fibrosis: spiritual coping with lifelong disease. Journal of Health Care Chaplaincy2020;26(2):45-57. [CENTRAL: CN-02098160] [EMBASE: 631260321] [PMID: 32172686]GrossoehmeDH , DimitriouS , JosephP . Relationship of treatment adherence, exercise and spirituality in CF adults. Pediatric Pulmonology2015;50:434-5. [CENTRAL: CN-01198255] [EMBASE: 72081916]">Grossoehme 2020</a>; <a href="./references#CD013766-bbs2-0042" title="LandauE , MussaffiH , KalamaroV , QuittnerA , TaiziT , KadoshD , et al. Efficacy of problem-solving intervention to improve adherence in adolescents and adults with cystic fibrosis. Israel Medical Association Journal2021;23(9):584-9. ">Landau 2021</a>; <a href="./references#CD013766-bbs2-0049" title='NCT00688051. Changes in adherence after playing "My Life With CF" game [Changes in adherence to diet, treatment and medication in the cystic fibrosis patient as a result of participation in a simulation game]. clinicaltrials.gov/ct2/show/NCT00688051 (first posted 02 June 2008). '>NCT00688051</a>; <a href="./references#CD013766-bbs2-0050" title="NCT01025258. Improving adherence and clinical outcome in cystic fibrosis (CF) patients [Improving adherence and clinical outcomes of cystic fibrosis patients through a collaborative active intervention program of a multidisciplinary team]. clinicaltrials.gov/ct2/show/NCT01025258 (first posted 03 December 2009). ">NCT01025258</a>; <a href="./references#CD013766-bbs2-0051" title="NCT02286050. Effect of a nursing program for patients with cystic fibrosis on disease management [Auswirkung Eines CF Nursing-Programms Auf Das Krankheitsmanagement Und Die Erfahrungen Der Behandlung Von Patientinnen Und Patienten]. clinicaltrials.com/trialdetails.aspx?p=NCT02286050 (first posted 27 October 2014). ">NCT02286050</a>; <a href="./references#CD013766-bbs2-0052" title="NCT02501369. Investigating the use of a positive parenting programme to improve treatment adherence in cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02501369 (first posted 17 July 2015). ">NCT02501369</a>; <a href="./references#CD013766-bbs2-0053" title="NCT02906826. Adherence to airway clearance: novel approaches to improving adherence. clinicaltrials.gov/ct2/show/NCT02906826 (first posted 20 September 2016). ">NCT02906826</a>; <a href="./references#CD013766-bbs2-0055" title="NCT03226795. Improving therapeutic adherence with a co-constructed program involving both patients and health care professionals [Improving therapeutic adherence of adult patients with cystic fibrosis: impact of a co-constructed program by patients and health caregivers]. clinicaltrials.gov/ct2/show/NCT03226795 (first posted 24 July 2017). ">NCT03226795</a>; <a href="./references#CD013766-bbs2-0057" title="NCT03518697. Effects of an individualized exercise program on health-related and skill/performance-related fitness in CF [Effects of an individualized and partially supervised exercise program on parameters of physical fitness, lung function, habitual physical activity in daily life and quality of life in children, adolescents and adults with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT03518697 (first posted 8 May 2018). ">NCT03518697</a>; <a href="./references#CD013766-bbs2-0060" title="NCT04017559. Clinical impact of MI on inhaled antibiotic adherence in cystic fibrosis [Assessing the clinical impact of Motivational Interviewing on inhaled antibiotic adherence in cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT04017559 (first posted 12 July 2019). ">NCT04017559</a>; <a href="./references#CD013766-bbs2-0062" title="NCT04217889. Cystic Fibrosis Adherence Study KINOBS [Study of the adherence to chest physiotherapy in patients with cystic fibrosis (CF) at the adult CF center in Lyon]. trialsearch.who.int/Trial2.aspx?TrialID=NCT04217889 (date of registration 2 January 2020). NCT04217889. Study of the adherence to chest physiotherapy in patients with cystic fibrosis (CF) at the adult CF center in Lyon [Cystic Fibrosis Adherence Study (KINOBS)]. clinicaltrials.gov/ct2/show/NCT04217889 (first posted 6 January 2020). ">NCT04217889</a>; <a href="./references#CD013766-bbs2-0064" title="NCT04696484. Feasibility of a goal-based agenda setting intervention [Feasibility of a goal-based agenda setting intervention for informing conversations in adult cystic fibrosis care]. clinicaltrials.gov/ct2/show/NCT04696484 (first posted 6 January 2021). NCT04696484. Feasibility of a goal-based agenda setting intervention [Feasibility of a goal-based agenda setting intervention for informing conversations in adult cystic fibrosis care]. trialsearch.who.int/Trial2.aspx?TrialID=NCT04696484 (date of registration 4 January 2021). ">NCT04696484</a>; <a href="./references#CD013766-bbs2-0065" title="O'HayerCF , EdouardG , BennettDS , TaylorDN , Hem LeeMA , WolfeWM , et al. ACT via telehealth: acceptance-based behavioral therapy for anxiety and depression among individuals with cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:476. [CENTRAL: CN-01449303] [CFGD REGISTER: MH63] O’HayerCV , O’LoughlinCM , NurseCN , SmithPJ , StephenMJ . ACT with CF: a telehealth and in-person feasibility study to address anxiety and depressive symptoms among people with cystic fibrosis. Journal of Cystic Fibrosis2021;20:133-9. [CFGD REGISTER: MH177b] [DOI: 10.1016/j.jcf.2020.11.013]">O'Hayer 2021</a>; <a href="./references#CD013766-bbs2-0070" title="DuncanC , MutherE , LindwallJ , RiekertK , GoodmanA , PsoterK , PolineniD . Protocol for a feasibility and acceptability pilot trial of a tele-coaching intervention to promote adherence in adolescents and young adults with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl:S141-2. [CFGD REGISTER: MH57b] NCT03921229. Tele-coaching intervention to improve treatment adherence in cystic fibrosis [Feasibility, acceptability, and pilot randomized controlled trial of a tele-coaching intervention to improve treatment adherence in cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT03921229 (first posted 19 April 2019). PolineniD , ChenGJ , LindwallJ , MitchellM , MutherE , PrickettM , et al. A stakeholder-informed feasibility study of tele-coaching to improve treatment adherence in patients with cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:479. [CENTRAL: CN-01430913] [CFGD REGISTER: MH57a] [EMBASE: 619068564]PolineniD , LindwallJ , MutherE , DurkinK , Ahrabi-NejadC , RuvalcabaE , et al. Development of a pilot trial of a novel tele-coaching intervention to improve treatment adherence in cystic fibrosis. Journal of Cystic Fibrosis2020;19 Suppl 2:P342. ">Polineni 2017</a>; <a href="./references#CD013766-bbs2-0075" title="Van SchandevylG , CasimirG , HanssensL . A medication adherence–enhancing simulation intervention in pediatric cystic fibrosis. Journal of Child Health Care2022;26(2):275-89. [DOI: 10.1177/13674935211013924]">Schandevyl 2021</a>). A total of 13 trials were not focused on inhaled therapies (<a href="./references#CD013766-bbs2-0012" title="ACTRN12607000234415. Improving self-management in adolescents and adults with cystic fibrosis [The use of mentoring to improve self-efficacy and management in adolescents and adults with cystic fibrosis]. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12607000234415 (date registered 3 May 2007). ACTRN12607000234415. Improving self-management in adolescents and adults with cystic fibrosis [The use of mentoring to improve self-efficacy and management in adolescents and adults with cystic fibrosis]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12607000234415 (date of registration 3 May 2007). ">ACTRN12607000234415</a>; <a href="./references#CD013766-bbs2-0025" title='DRKS00027569. Applying the "MukoHelp" manual to improve psychopathological symptoms and therapy adherence among affected persons with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00027569 (date of registration 26 January 2022). '>DRKS00027569</a>; <a href="./references#CD013766-bbs2-0029" title="DRKS00016714. Feasibility trial of an online intervention for symptoms of depression and anxiety in adolescents with chronic medical conditions (youthCOACH-CD). trialsearch.who.int/Trial2.aspx?TrialID=DRKS00016714 (date registered 25 March 2019). DRKS00017161. Effectiveness and cost-effectiveness of guided internet-and mobile-based CBT for adolescents and young adults with chronic somatic conditions and comorbid depression and anxiety symptoms (youthCOACHcd): a multicentre randomized controlled trial with a 12-month follow-up. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00017161 (date registered 17 September 2019). GeirhosA , DomhardtM , LunkenheimerF , TemmingS , HollRW , MindenK , et al. Feasibility and potential efficacy of a guided internet- and mobile-based CBT for adolescents and young adults with chronic medical conditions and comorbid depression or anxiety symptoms (youthCOACH CD): a randomized controlled pilot trial. BMC Pediatrics2022;22(1):69. [DOI: 10.1186/s12887-022-03134-3]LunkenheimerF , DomhardtM , GeirhosA , KilianR , Mueller-StierlinAS , HollRW , et al. Effectiveness and cost-effectiveness of guided Internet- and mobile-based CBT for adolescents and young adults with chronic somatic conditions and comorbid depression and anxiety symptoms (youthCOACHCD): study protocol for a multicentre randomized controlled trial. Trials2020;21(1):253. LunkenheimerF , DomhardtM , GeirhosA , KilianR , Mueller-StierlinAS , HollRW , et al. Effectiveness and cost-effectiveness of guided Internet- and mobile-based CBT for adolescents and young adults with chronic somatic conditions and comorbid depression and anxiety symptoms (youthCOACHCD): study protocol for a multicentre randomized controlled trial. Trials2020;21(1):253. Online Supplementary Materials: Additional file 1 SPIRIT 2013 Checklist. ">Geirhos 2022</a>; <a href="./references#CD013766-bbs2-0032" title="GoodillSW . Dance/movement therapy for adults with cystic fibrosis: pilot data on mood and adherence. Alternative Therapies in Health and Medicine2005;11(1):76-7. [CENTRAL: CN-00502675] [CFGD REGISTER: MH16] [DOI: 10.1016/S0954-6111(11)70024-5] [PMID: 15712769]">Goodill 2005</a>; <a href="./references#CD013766-bbs2-0044" title="Martinez RodriguezME , Suarez CortinaL , Maiz CarroL , Ruiz-De-ValbuenaM , Jimenez CosmesL . A pulmonary rehabilitation program to increase adherence to airway clearance techniques for children and adults with cystic fibrosis. Journal of Cystic Fibrosis2017;16 Suppl 1:S58. [CENTRAL: CN-01461867] [CFGD REGISTER: PE248] [EMBASE: 620749723]">Martinez 2017</a>; <a href="./references#CD013766-bbs2-0047" title="AccursoFJ , SontagMK , KoenigJM , QuittnerAL . Multi-center airway secretion clearance study in cystic fibrosis. Pediatric Pulmonology2004;38 Suppl 27:314. [ABSTRACT NO.: 363] [CENTRAL: CN-00507886] [CFGD REGISTER: PE152a] ModiAC , CassedyAE , QuittnerAL , AccursoF , SontagM , KoenigJM , et al. Trajectories of adherence to airway clearance therapy for patients with cystic fibrosis. Journal of Pediatric Psychology2010;35(9):1028-37. [CENTRAL: CN-00770406] [CFGD REGISTER: PE152e] [PMID: 20304772]ModiAC , SontagMK , KoenigJM , AccursoFJ , QuittnerAL , Investigators and Coordinators of the Airway Secretion Clearance Study. Adherence to airway clearance therapies in patients with cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl 1:S97. [ABSTRACT NO.: 436] [CENTRAL: CN-00593164] [CFGD REGISTER: PE152c] QuittnerAL , ModiAC , AccursoFJ , KoenigJM , SontagMK , OermannC , et al. Treatment satisfaction, health-related quality of life and airway clearance therapies in patients with cystic fibrosis. Pediatric Pulmonology2004;38 Suppl 27:314. [ABSTRACT NO.: 364] [CENTRAL: CN-00507916] [CFGD REGISTER: PE152b] SontagMK , QuittnerAL , ModiAC , KoenigJM , GilesD , OermannCM , et al. Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis. Pediatric Pulmonology2010;45(3):291-300. [CFGD REGISTER: PE152d] [PMID: 20146387]">Modi 2010</a>; <a href="./references#CD013766-bbs2-0056" title="NCT03304028. Use of home-based connected devices to early detect and treat pulmonary exacerbations: feasibility and clinical validity in CF patients [MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique (MucoExocet)]. clinicaltrials.gov/ct2/show/NCT03304028 (first posted 06 October 2017). ">NCT03304028</a>; <a href="./references#CD013766-bbs2-0058" title="NCT03938324. Peer i-Coaching for Activated Self-management Optimization in adolescents and young adults with chronic conditions (PiCASO). clinicaltrials.gov/ct2/show/NCT03938324 (first received 6 May 2019). ">NCT03938324</a>; <a href="./references#CD013766-bbs2-0059" title="NCT03992027. Preventing depression and anxiety: A randomized controlled trial of a CF-specific CBT intervention. clinicaltrials.gov/ct2/show/NCT03992027 (first received 19 June 2019). ">NCT03992027</a>; <a href="./references#CD013766-bbs2-0061" title="NCT04096664. Home airway clearance in CF patients (HomeCareSIMEOX) [Efficiency and acceptability of SIMEOX® used autonomously at home for bronchial clearance in patients with cystic fibrosis: prospective, randomized controlled study]. clinicaltrials.gov/ct2/show/study/NCT04096664 (first posted 20 September 2019). ">NCT04096664</a>; <a href="./references#CD013766-bbs2-0063" title="NCT04453358. Cystic fibrosis remote monitoring system [Cystic fibrosis remote monitoring system to support resource-limited communities]. clinicaltrials.gov/ct2/show/NCT04453358 (first posted 01 July 2020). ">NCT04453358</a>; <a href="./references#CD013766-bbs2-0067" title="ParkinsVM , ParkinsMD , PeetsAD , MontgomeryM , BragerNP , RabinHR . Effect of an educational intervention designed to promote cystic fibrosis knowledge in specialty residents. Pediatric Pulmonology2008;43 Suppl 31:462. [ABSTRACT NO.: 713] [CENTRAL: CN-00867600] [CFGD REGISTER: MH32] ">Parkins 2008</a>; <a href="./references#CD013766-bbs2-0078" title="VivianiL , BossiA , MilaniS , GagliardiniR , GrzincichG , QuattrucciS , et al. Can telemonitoring improve quality of life in CF patients? An RCT protocol to assess the effectiveness of a telemedicine intervention. Pediatric Pulmonology2006;41 Suppl 29:366. [CENTRAL: CN-00593140] [CFGD REGISTER: MH21] ">Viviani 2006</a>), and 11 trials did not consider a relevant intervention (i.e. not examining a psychological intervention) (<a href="./references#CD013766-bbs2-0015" title="BinghamPM , BatesJH , Thompson FigueroaJ , LahiriT . A breath biofeedback computer game for children with cystic fibrosis. Clinical Pediatrics2010;49(4):337-42. [CENTRAL: CN-01412346] [CFGD REGISTER: PE228a] [DOI: 10.1177/0009922809348022]BinghamPM , LahiriT , AshikagaT . Pilot trial of spirometer games for airway clearance practice in cystic fibrosis. Respiratory Care2012;57(8):1278-84. [CENTRAL: CN-00899635] [CFGD REGISTER: PE228b] [EMBASE: 365403977]">Bingham 2012</a>; <a href="./references#CD013766-bbs2-0017" title="CannonC , BenitezJ , ScarbaryJ , TaylorK , GuillM . In-home videoconferencing for cystic fibrosis patient education. Pediatric Pulmonology1999;28 Suppl 19:333. [CENTRAL: CN-00291235] [CFGD REGISTER: MH6] ">Cannon 1999</a>; <a href="./references#CD013766-bbs2-0027" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis- a randomised controlled trial. Pediatric Pulmonology2004;38 Suppl 27:329. [CENTRAL: CN-00507890] [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl 1:S111. [CENTRAL: CN-00593155] [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:268. [CENTRAL: CN-00593023] [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyCP , MarksGB , et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CENTRAL: CN-00532707] [CFGD REGISTER: BD114b] [EMBASE: 2006038601] [PMID: 16421364]RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: CN-01253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006</a>; <a href="./references#CD013766-bbs2-0014" title="BetzJ , SzczesniakR , LewisK , PestianT , BennethumAS , McBrideJ , et al. Feasibility and acceptability of a telephone‑based chaplaincy intervention to decrease parental spiritual struggle. Journal of Religion and Health2019;58:2065–85. [DOI: 10.1007/s10943-019-00921-8]GrossoehmeDH , SzczesniakRD , LewisKP . Guidess CF: intervention feasibility and acceptability decrease spiritual struggle. Pediatric Pulmonology2017;52 Suppl 47:482. [ABSTRACT NO.: 688] [CENTRAL: CN-01430898] [CFGD REGISTER: MH62] [EMBASE: 619069114]">Betz 2019</a>; <a href="./references#CD013766-bbs2-0034" title="HagelbergM , DooleyMJ , PooleSG , LeungD , BaileyM , FinlaysonF , et al. Direct dispensing of dornase alpha improves adherence and lung function in cystic fibrosis. Journal of Cystic Fibrosis2008;7 Suppl 2:S27. [CENTRAL: CN-00651989] [CFGD REGISTER: MH25] ">Hagelberg 2008</a>; <a href="./references#CD013766-bbs2-0035" title="HatziagorouE , ChrysochoouEA , KirvassilisF , TsanakasJ . Home visits vs. telephone monitoring among patients with cystic fibrosis: which is superior?Journal of Cystic Fibrosis2017;16 Suppl 1:S50. [CENTRAL: CN-01411946] [CFGD REGISTER: MH54] ">Hatziagorou 2017</a>; <a href="./references#CD013766-bbs2-0048" title="Frias JP , Montero-RuizA , GalvezLA , Perez-RuizE , HuelamoMP , Martin-MontanezE . A music therapy intervention as an adjunct to chest physiotherapy in children with cystic fibrosis. European Respiratory Journal2018;52(Suppl 62):PA4626. ISRCTN11161411. Effects of music therapy as complement of chest physiotherapy in patients with cystic fibrosis [Comparing use of specific therapeutic music AS an adjunct to chest physiotherapy versus commercial music or no music in cystic fibrosis children]. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN11161411 (date of registration 15 June 2019). [CENTRAL: CN-01974319] [CFGD REGISTER: PE286] Montero-RuizA , FuentesLA , Perez RuizE , Garcia-Agua SolerN , Rius-DiazF , Caro AguileraP , Perez FriasJ , Martin-MontanezE . Effects of music therapy as an adjunct to chest physiotherapy in children with cystic fibrosis: a randomized controlled trial. PLOS One2020;15(10):e0241334. ">Montero‐Ruiz 2020</a>; <a href="./references#CD013766-bbs2-0072" title="RodeC . Adherence and quality of life variations among cystic fibrosis patients [Eléments de variation de l’observance et de la qualité de vie des patients atteints de mucoviscidose]. www.opengrey.eu/item/display/10068/813394 (accessed prior to 29 June 2022). ">Rode 2008</a>; <a href="./references#CD013766-bbs2-0073" title="NCT01325766. Study of yoga as a therapy for cystic fibrosis (CF) patients [Yoga as a therapy for adolescents and young adults with cystic fibrosis: a pilot study]. clinicaltrials.gov/ct2/show/NCT01325766 (first posted 30 March 2011). RuddyJ , EmersonJ , McNamaraS , GenatossioA , BreunerC , WeberT , RosenfeldM . Yoga as a therapy for adolescents and young adults with cystic fibrosis: a pilot study. Global Advances in Health and Medicine2015;4(6):32-6. [DOI: 10.7453/gahmj.2015.061]">Ruddy 2015</a>; <a href="./references#CD013766-bbs2-0077" title="TrappM , BartonS , MorganH , LockyerL . Self-administration of drugs for cystic fibrosis. Professional Nurse1998;14(3):199-203. [CENTRAL: CN-00161186] [CFGD REGISTER: MH12a] [PMID: 10095691]TrappM . Self-administration of drugs for cystic fibrosis. www.cfdb.eu/en/database/pdf/code/pm10095691 (accessed 25 August 2017). [CENTRAL: CN-01402508] [CFGD REGISTER: MH12b] ">Trapp 1998</a>; <a href="./references#CD013766-bbs2-0079" title='HooZH , WildmanMJ . Regarding the article entitled "A smartphone application for reporting symptoms in adults with cystic fibrosis improves the detection of exacerbations: results of a randomised controlled trial". Journal of Cystic Fibrosis2020;19(2):e9. [CFGD REGISTER: MH68f] WoodJ , JenkinsS , PutrinoD , MulrennanS , MoreyS , CecinsN , et al. A smartphone application for reporting symptoms in adults with cystic fibrosis improves the detection of exacerbations: results of a randomised controlled trial. Journal of Cystic Fibrosis2020;19(2):271-6. [CFGD REGISTER: MH68e] WoodJ , JenkinsS , PutrinoD , MulrennanS , MoreyS , CecinsN , et al. A smartphone application for reporting symptoms in adults with cystic fibrosis improves the detection of respiratory exacerbations. Respirology2019;24:23. [CFGD REGISTER: MH68d] WoodJ , JenkinsS , PutrinoD , MulrennanS , MoreyS , CecinsN , et al. A smartphone application for reporting symptoms in adults with cystic fibrosis: a randomised controlled trial. Journal of Cystic Fibrosis2018;17 Suppl 3:S22-3. [CENTRAL: CN-01609040] [CFGD REGISTER: MH68b] [EMBASE: 622930894]WoodJ , JenkinsS , PutrinoD , MulrennanS , MoreyS , CecinsN , et al. A smartphone application for reporting symptoms in adults with cystic fibrosis: protocol of a randomised controlled trial. BMJ Open2018;8(4):e021136. [CENTRAL: CN-01925508] [CFGD REGISTER: MH68a] [EMBASE: 625044262] [PMID: 29680812]WoodJ , JenkinsS , PutrinoD , MulrennanS , MoreyS , CecinsN , et al. Adherence to a smartphone application for reporting symptoms in CF. Respirology2018;23(Suppl 1):140. [CENTRAL: CN-01607202] [CFGD REGISTER: MH68c] [EMBASE: 622091379]'>Wood 2020</a>). Eight trials did not measure adherence to inhaled therapies (<a href="./references#CD013766-bbs2-0019" title="ChanS , TullisE , CortesD . The added value of a pharmacist in identifying drug-related needs of cystic fibrosis patients in a large adult clinic. Pediatric Pulmonology2013;48 Suppl 36:400. [ABSTRACT NO.: 528] [CENTRAL: CN-00875969] [CFGD REGISTER: MH41] ">Chan 2013</a>; <a href="./references#CD013766-bbs2-0020" title="ACTRN12611000802909. A randomised, controlled trial of behavioural modifications using an Information Technology (IT) tool to improve self-management in adolescents and adults with Cystic Fibrosis: A pilot study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336025&amp;isReview=true2010. [CFGD REGISTER: MH24p] ACTRN12611000802909. A randomised, controlled trial of behavioural modifications using an Information Technology (IT) tool to improve self-management in adolescents and adults with Cystic Fibrosis: a pilot study. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000802909 (registered 29 Jul 2011). [CFGD REGISTER: MH24r] Cameron-TuckerHL , JosephL , CummingsE , Cystic Fibrosis Research Team led by Reid D. Outcomes of health-mentor training to improve self-management by people with cystic fibrosis (CF). Respirology2009;14(s1):A58. [CFGD REGISTER: MH24l] ChauS , CummingsE , TurnerP . Experiences and insights from the development of a mobile self management system for cystic fibrosis sufferers in Tasmania. In: 12th World Congress on Health (Medical) Informatics; 2007; Brisbane, Queensland. Brisbane, 2007:P002. [CFGD REGISTER: MH24m] CummingsE , HauserJ , Cameron-TuckerH , FitzpatrickP , JessupM , WaltersEH , et al. Enhancing self-efficacy for self-management in people with cystic fibrosis. Studies in Health Technology and Informatics2011;169:33-7. [CENTRAL: CN-00806050] [CFGD REGISTER: MH24e] [PMID: 21893709]CummingsEA , Courtney-PrattHM , ReidDW , RobinsonA , TurnerP , WaltersEH , et al. Issues and experiences with technology supported development of patient self-efficacy and self-managed of chronic disease. Australasian Journal on Ageing2006;25 Supp 1:A14-5. [CFGD REGISTER: MH24n] CummingsEA , TurnerP . Pathways Home: considerations for technology solutions aimed at supporting self-management of chronic illness. In: HIC 2005 &amp; HINZ; 2005 July 31 - August 02, Melbourne, Australia. Melbourne Convention Centre, Australia, 2005:1-9. [CFGD REGISTER: MH24f] CummingsEA , TurnerP . Pathways Home: developing &amp; deploying technology to support patient empowerment in the self-management of chronic illness in the community. In: CollECTeR Europe, 2006 June 9-10, Basel, Switzerland. Basel, Switzerland, 2006:261-9. [CFGD REGISTER: MH24g] CummingsEA , TurnerP . Pathways home project: patient self-management and self-efficacy through the deployment of ICTs, eValues. In: 19th Bled eConference, 2006 June 5-7, Bled, Slovenia. 2006. [CFGD REGISTER: MH24h] JessupM , BuschJ , FitzpatrickP , TurnerP , Cameron-TuckerH , JosephL , et al. Pathways home project; a pilot study of chronic disease self management in cystic fibrosis. Respirology2007;12 Suppl 4:A155. [CENTRAL: CN-00651971] [CFGD REGISTER: MH24b] JessupM , BuschJ , TurnerP , CummingsE , Cameron-TuckerH , FitzpatrickP , et al. Pathways Home Project: a pilot study of chronic disease self management in cystic fibrosis. Journal of Cystic Fibrosis2008;7 Suppl 2:S103. [CENTRAL: CN-00651986] [CFGD REGISTER: MH24a] JessupM , Cameron-TuckerH , CummingsE , HauserJ , JosephL , SaddingtonH , et al. Someone to talk to: adolescent and adult feedback on their experience of mentoring and I. Journal of Cystic Fibrosis2010;9 Suppl 1:s107. [CFGD REGISTER: MH24o] JessupMM , HauserJ , Cameron-TuckerH , CummingsE , TurnerP , BlizzardL , et al. Facilitating self-management in adolescents and adults with cystic fibrosis: a pilot study. Pediatric Pulmonology2011;46 Suppl 34:405. [ABSTRACT NO.: 530] [CENTRAL: CN-01003737] [CFGD REGISTER: MH24d] [EMBASE: 70555402]TurnerP , CummingsE , BuschJ , ReidDW , FitzpatrickP , Cameron-TuckerH , et al. Pathways home project: the development of an IT support tool to aid chronic disease self management in cystic fibrosis (CF). In: 7th Australasian Cystic Fibrosis Conference 2007, August 11-14, Sydney, Australia. 2007. [CFGD REGISTER: MH24i] TurnerP , CummingsE , BuschJ , ReidDW , FitzpatrickP , Cameron-TuckerH , et al. Pathways home project: the development of an IT support tool to aid chronic disease self management in cystic fibrosis (CF). In: Primary Health Care Research, Evaluation and Development (PHCRED) Symposium; 2007 Nov 27; Melbourne, Australia. 2007. [CFGD REGISTER: MH24j] WainwrightC , SaddingtonH , BuschJ , BlizzardL , Cameron-TuckerH , CheneyJ , et al. Improving self efficacy in adolescents and young adults with cystic fibrosis. Journal of Cystic Fibrosis2009;8 Suppl 2:S93. [ABSTRACT NO.: 374] [CENTRAL: CN-00744111] [CFGD REGISTER: MH24c] ">Cummings 2011</a>; <a href="./references#CD013766-bbs2-0023" title="DavisMA , QuittnerAL , StackC . Controlled evaluation of the STARBRIGHT Explorer Series CD-Rom program for children and adolescents with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:351. [CENTRAL: CN-00404026] DavisMA , QuittnerAL , StackCM , YangMC . Controlled evaluation of the STARBRIGHT CD-ROM program for children and adolescents with cystic fibrosis. Journal of Pediatric Psychology2004;29(4):259-67. [CENTRAL: CN-00482821] [CFGD REGISTER: MH10b] [PMID: 15148348]">Davis 2004</a>; <a href="./references#CD013766-bbs2-0037" title="HebestreitH , KieserS , JungeS , BallmannM , HebestreitA , SchindlerC , et al. Long-term effects of a partially supervised conditioning programme in cystic fibrosis. European Respiratory Journal2010;35(3):578-83. [CFGD REGISTER: PE145b] HebestreitH , LandsLC , AlarieN , SchaeffJ , KarilaC , OrensteinDM , et al. Effects of a partially supervised conditioning programme in cystic fibrosis: an international multi-centre randomised controlled trial (ACTIVATE-CF): study protocol. BMC Pulmonary Medicine2018;18(1):31. [CENTRAL: CN-01913839] [CFGD REGISTER: PE145a] [EMBASE: 620583585] [PMID: 29422091]HebestreitH , SchmidK , KieserS , JungeS , BallmannM , RothK , et al. Quality of life is associated with physical activity and fitness in cystic fibrosis. BMC Pulmonary Medicine2014;14:26. [CFGD REGISTER: PE145c] NCT00231686. Effects of a 6-months physical conditioning program in patients with cystic fibrosis. clinicaltrials.gov/show/NCT00231686 (first posted 04 October 2005). [CFGD REGISTER: PE145d] ">Hebestreit 2010</a>; <a href="./references#CD013766-bbs2-0038" title="HebestreitH , KriemlerS , SchindlerC , SteinL , KarilaC , UrquhartDS , et al. Effects of a partially supervised conditioning program in cystic fibrosis: an international multi-centre, randomised controlled trial (ACTIVATE-CF). Journal of Cystic Fibrosis2021;20 Suppl:S8. [CFGD REGISTER: PE244e] HebestreitH , KriemlerS , SchindlerC , SteinL , KarilaC , UrquhartDS , et al. Effects of a partially supervised conditioning program in cystic fibrosis: an international multicenter, randomized controlled trial (ACTIVATE-CF). American Journal of Respiratory and Critical Care Medicine2022;205(3):330-9. [CFGD REGISTER: PE244d] HebestreitH , LandsLC , AlarieN , SchaeffJ , KarilaC , OrensteinDM , et al. Effects of a partially supervised conditioning programme in cystic fibrosis: an international multi-centre randomised controlled trial (ACTIVATE-CF): study protocol. BMC Pulmonary Medicine2018;18(1):31. [CFGD REGISTER: PE244b] HebestreitH . How to counsel patients regarding exercise and habitual physical activity?Pediatric Pulmonology2016;51 Suppl 45:188-9. [ABSTRACT NO.: S20.4] [CENTRAL: CN-01212584] [CFGD REGISTER: PE244a] [EMBASE: 612358802]NCT01744561. Effects of a partially supervised conditioning program in CF: an international multi-centre, randomized controlled trial. clinicaltrials.gov/show/nct01744561 (first posted 06 December 2012). [CENTRAL: CN-01343886] [CFGD REGISTER: PE244c] RadtkeT , KriemlerS , SteinL , KarilaC , UrquhartDS , OrensteinDM , et al. Cystic fibrosis related diabetes is not associated with maximal aerobic exercise capacity in cystic fibrosis: a cross-sectional analysis of an international multicenter trial. Journal of Cystic Fibrosis 2022 July 5 [Epub ahead of print]. [CFGD REGISTER: PE244f] [DOI: 10.1016/j.jcf.2022.06.012]">Hebestreit 2022</a>; <a href="./references#CD013766-bbs2-0039" title="HlelaH , CarpenterK , BrodeckiD , Chen-LimM . Creating developmentally appropriate literature for children with cystic fibrosis. Pediatric Pulmonology2018;53 Suppl 2:435-6. [CENTRAL: CN-01738598] [CFGD REGISTER: PC15] [EMBASE: 624049579]">Hlela 2018</a>; <a href="./references#CD013766-bbs2-0040" title="HuangJS , TerronesL , TompaneT , DillonL , PianM , GottschalkM , et al. Preparing adolescents with chronic disease for transition to adult care: a technology program. Pediatrics2014;133(6):e1639-46. [CENTRAL: CN-01053774] [CFGD REGISTER: MH35b] [EMBASE: 2014382824] [PMID: 24843066]NCT01253733. TAHLC - Texting to promote Adolescent Health Liaisons and Chronic disease management. clinicaltrials.gov/show/nct01253733 (first posted 03 December 2010). [CENTRAL: CN-01412376] [CFGD REGISTER: MH35a] ">Huang 2014</a>; <a href="./references#CD013766-bbs2-0069" title="PetzelSV , FinkelsteinS , BuddJ , EllisLB . Adherence in CF. Pediatric Pulmonology1991;11 Suppl 6:308. [CENTRAL: CN-00291510] [CFGD REGISTER: MH2] ">Petzel 1991</a>). We excluded the remaining nine trials either because there was a lack of information, or the trials were not available after multiple attempts to contact the trial authors (<a href="./references#CD013766-bbs2-0016" title="BryonM , BurtonJ , TostevinM , MadgeS . A home visit programme to improve health status and psychosocial functioning of families with child with CF. Pediatric Pulmonology2000;30 Suppl 20:336. [CENTRAL: CN-00315352] [CFGD REGISTER: MH9] ">Bryon 2000</a>; <a href="./references#CD013766-bbs2-0018" title="ChadelatI . Comprehensive management of children with cystic fibrosis [Prise en charge globale des enfants atteints de mucoviscidose]. opengrey.eu/item/display/10068/773400 (accessed prior to 19 June 2022). ">Chadelat 2005</a>; <a href="./references#CD013766-bbs2-0021" title="CzajkowskiDR . The use of psychosocial competency/coping skills model to assess and predict the medical compliance of cystic fibrosis adolescents. www.opengrey.eu (accessed 14 November 2020). ">Czajkowski 1985</a>; <a href="./references#CD013766-bbs2-0028" title="FischerR , NaehrigS , SchellingJS , HornM , HuberRM . Telemonitoring in adult cystic fibrosis patients. Pediatric Pulmonology2003;36 Suppl 25:371. [CENTRAL: CN-00451898] [CFGD REGISTER: MH11] ">Fischer 2003</a>; <a href="./references#CD013766-bbs2-0041" title="JacksonA , KirwanL , JeleniewskaP , FletcherG , McKoneE , DoyleG . Examining the effect of CF view: an electronic registry patient portal for people with cystic fibrosis in Europe. Pediatric Pulmonology2017;52 Suppl 47:424. [CENTRAL: CN-01430893] [CFGD REGISTER: MH58] [EMBASE: 619069167]">Jackson 2017</a>; <a href="./references#CD013766-bbs2-0045" title="McDonaldL , QuittnerAL , GrimleyME , BotteriM , BarkerDH . Effects of a clinic-based intervention on caregiving stress for parents of children with CF. Journal of Cystic Fibrosis2007;6 Suppl 1:S75. [CENTRAL: CN-00614342] [CFGD REGISTER: MH67] ">McDonald 2007</a>; <a href="./references#CD013766-bbs2-0054" title="NCT03052231. Interactive mobile health information to enhance patient care at a cystic fibrosis center (MOMMI3CFCM) [Evaluating the feasibility of interactive mobile health information to enhance patient care at a cystic fibrosis center]. clinicaltrials.gov/ct2/show/NCT03052231 (first posted 14 February 2017). ">NCT03052231</a>; <a href="./references#CD013766-bbs2-0071" title="CruzI , SnellC , BarkerDH , QuittnerAL , DrotarD . Effects of behavioral-family systems therapy on family conflict and communication in adolescents with CF and their parents. Pediatric Pulmonology2007;42 Suppl 30:403-4. [CENTRAL: CN-00643113] [CFGD REGISTER: MH22b] DeLamboKE , Ievers-LandisCE , DrotarD , QuittnerAL . Association of observed family relationship quality and problem-solving skills with treatment adherence in older children and adolescents with cystic fibrosis. Journal of Pediatric Psychology2004;29(5):343-53. [CENTRAL: CN-00875650] [CFGD REGISTER: MH22a] [PMID: 15187173]QuittnerAL , DrotarD , IeversC , SeidnerD , SlocumN , JacobsenJ , et al. Interventions to increase adolescent adherence to treatment: preliminary comparisons of family therapy and CF family education. Pediatric Pulmonology1998;26(17):113-4. [CENTRAL: CN-00291524] [CFGD REGISTER: MH22c] RomeroSL , BlackwellLS , ArmenterosE , QuittnerAL . Patient and parent-reported conflict: age and gender differences and associations with disease severity. Pediatric Pulmonology2010;45 Suppl 33:446. [ABSTRACT NO.: 623] [CENTRAL: CN-00867923] [CFGD REGISTER: MH22d] ">Quittner 1998</a>; <a href="./references#CD013766-bbs2-0043" title="BlackwellLS , RomeroSL , RomeroCV , McLeanKA , DawkinsK , HoagJ , et al. CFfone: a social networking site for adolescents and young adults with CF. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 562] [CENTRAL: CN-01004539] [CFGD REGISTER: MH33b] [EMBASE: 70892308]MarcielKK , SaimanL , QuittellLM , DawkinsK , QuittnerAL . Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives. Pediatric Pulmonology2010;45(2):157-64. [CENTRAL: CN-00867599] [CFGD REGISTER: MH33c] [PMID: 20054860]McLeanKA , MadanA , MonzonA , QuittnerAL . Trajectories of depression and anxiety in adolescents with CF. Pediatric Pulmonology2014;49 Suppl 38:442. [ABSTRACT NO.: 611] [CENTRAL: CN-01008988] [CFGD REGISTER: MH33g] [EMBASE: 71616663]NCT01183286. CFfone: a cell phone support program for adolescents with cystic fibrosis. clinicaltrials.gov/show/NCT01183286 (first received 17 August 2010). QuittnerAL , RomeroSL , BlackwellLS , MarcielKK , RomeroCV , DawkinsK , et al. Effect of CFfone on knowledge of disease management, psychological well-being, and health-related quality of life in adolescents and young adults with CF. Journal of Cystic Fibrosis2012;11 Suppl 1:S137. [ABSTRACT NO.: 313] [CENTRAL: CN-01005105] [CFGD REGISTER: MH33a] [EMBASE: 70793127]QuittnerAL , RomeroSL , BlackwellLS , McLeanKA , MarcielK , MonzonAD , et al. Preliminary data on the efficacy of an online social network for adolescents with CF. American Journal of Respiratory and Critical Care Medicine2013;187:A5036. [CENTRAL: CN-01135724] [CFGD REGISTER: MH33f] [EMBASE: 71984525]QuittnerAL , RomeroSL , BlackwellLS , McLeanKA , MonzonAD , DawkinsK . Efficacy of an online social networking site: CFFONE results. Pediatric Pulmonology2013;48 Suppl 36:135. [CENTRAL: CN-00875658] [CFGD REGISTER: MH33e] [EMBASE: 71321287] [SUMMARY NO.: S7.2]QuittnerAL , RomeroSL , BlackwellLS , RomeroCV , MarcielKK , DawkinsK , et al. Preliminary results on the efficacy of an online social network for adolescents with CF: age and disease severity group comparisons. Pediatric Pulmonology2012;47 Suppl 35:388. [ABSTRACT NO.: 450] [CENTRAL: CN-00852665] [CFGD REGISTER: MH33d] ">Marciel 2010</a>). </p> </section> <section id="CD013766-sec-0054"> <h4 class="title">Ongoing studies</h4> <p>To date, we have listed five trials as ongoing (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>; <a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>; <a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>; <a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>); we provide further information in the tables (<a href="./references#CD013766-sec-0126" title="">Characteristics of ongoing studies</a>). </p> <section id="CD013766-sec-0055"> <h5 class="title">Design</h5> <p>Four ongoing trials are parallel in design (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>; <a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>; <a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>) and one trial is a cross‐over trial (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>). One trial is single‐centre (<a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>), and four are multicentre (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>; <a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>; <a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>). Two trials are being conducted in the USA (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>; <a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>), one in Germany (<a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>), one in the Czech Republic (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>), and one in the UK (<a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>). </p> </section> <section id="CD013766-sec-0056"> <h5 class="title">Participants</h5> <p>Participants include adults with CF, aged 18 years and above in one trial (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>), and aged between 16 and 60 years in a second trial (<a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>). Two trials include participants with CF aged 12 years and older (<a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>), and one trial includes children and adolescents but does not specify the age of eligible participants (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>). </p> </section> <section id="CD013766-sec-0057"> <h5 class="title">Interventions</h5> <p>All five ongoing trials are two‐arm RCTs, with three trials comparing a psychological intervention to usual care (<a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>; <a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>), and one trial comparing a psychological intervention (Acceptance and Commitment Therapy; ACT) with an active comparator arm (Supportive Psychotherapy) (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>). In the cross‐over trial, participants are randomised to the psychological intervention arm (CF Hero mobile application) for three months and then switch to not using the application for another three months. </p> <p>The psychological interventions described in the ongoing trials include a coaching and telemonitoring intervention (<a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>); an ACT intervention delivered via video calls (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>); a web‐based intervention comprising six interactive online modules (e.g. Respiratory, Antibiotics, Nutrition, etc.) (<a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>); a motivational (reward‐based) mobile application (CF Hero) (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>); and a web‐based, mobile medication management application designed to reinforce adherence and provide education about treatment regimens (<a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>). Intervention duration ranges from six weeks (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>) through three months (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>) and 24 weeks (<a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>) to 12 months (<a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>; <a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>). </p> <p>One intervention is focused on improving adherence to inhaled therapies only (<a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>). The other interventions are focused on improving adherence to CF treatments in general (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>), or multiple CF treatments, including inhaled therapies and oral medications (e.g. azithromycin) (<a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>), or inhaled therapies and physiotherapy (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>). One intervention involves participants identifying between one and three treatments from six areas of focus (nutrition, enzymes, liver medications, airways treatments, vitamins and antibiotics), such that participants may choose to focus on improving adherence to a treatment other than inhaled therapies (<a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>). </p> </section> <section id="CD013766-sec-0058"> <h5 class="title">Outcomes</h5> <p>Two trials include adherence as a primary outcome (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>; <a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>), while it is a secondary outcome in the remaining three trials (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>; <a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>). Two trials are using objective recorded measures (dose‐counting nebulisers) to assess adherence (<a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>); one trial is using a subjective measure (self‐reported medication adherence questionnaire) (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>); one trial is using an objective count measure whereby the prescribed amount of medication is compared with the amount consumed after collecting unused or empty medicine containers (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>); and one trial is using an objective count measure (MPR) or self‐report questionnaire (<a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>). </p> <p>Depression is included as a secondary outcome in two trials (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>), and anxiety in one trial (<a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>). QoL is a secondary outcome in three trials (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>; <a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>), and four trials include lung function as a secondary outcome (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>; <a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>; <a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>). The number of pulmonary exacerbations is a secondary outcome in two trials (<a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>; <a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>), and the time to first exacerbation is the primary outcome in one trial (<a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>). </p> </section> </section> </section> <section id="CD013766-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>A risk of bias summary is shown in <a href="#CD013766-fig-0002">Figure 2</a>. Please refer to the risk of bias tables for details for each individual trial (<a href="./references#CD013766-sec-0124" title="">Characteristics of included studies</a>). </p> <div class="figure" id="CD013766-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013766-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013766-sec-0060"> <h4 class="title">Allocation</h4> <section id="CD013766-sec-0061"> <h5 class="title">Sequence generation</h5> <p>We judged six trials to have a low risk of bias in relation to sequence generation (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial used a pseudo‐randomisation number‐generation technique carried out by a member of staff independent to the trial (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). Four trials used randomised permuted blocks (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), with three of these specifying that this was computer‐generated (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial stratified randomisation by age (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) and two trials by CF centre and number of IV days in the previous 12 months (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One cluster‐RCT used the CF centre as the unit of randomisation, to minimise cross‐contamination risks from within‐site randomisation (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). In this trial, randomisation was completed by the trial statistician, with centres stratified by size (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). </p> <p>One trial consecutively assigned participants to the intervention or control group (by order of recruitment), therefore, we judged this to have a high risk of bias (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). The three remaining trials were described as randomised, but no details of the actual randomisation process were given; therefore, we judged these trials to have an unclear risk of bias (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). </p> </section> <section id="CD013766-sec-0062"> <h5 class="title">Allocation concealment</h5> <p>We judged three trials to have a low risk of bias from allocation concealment (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One of these stated that allocation remained concealed until the participant was ready for Phase 2 of the trial (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>); the remaining two trials used a remote, secure internet‐based randomisation system which concealed allocation from investigators (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). We judged five trials to have an unclear risk of bias as they did not report on allocation concealment (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). We judged the remaining two trials to have a high risk of bias (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). One of these trials reported that participants were consecutively assigned to the intervention or control group by one of the physicians during a routine clinic visit (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>), and the final trial did not provide details of allocation concealment in the published report, but information provided by the lead author on request states that allocation was not concealed (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). </p> </section> </section> <section id="CD013766-sec-0063"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel is typically not possible in trials of psychological interventions; as such, the assessment of blinding included only the outcome assessors, as specified in the protocol (<a href="./references#CD013766-bbs2-0196" title="DawsonS , CowapL , Clark-CarterD , GirlingC . Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD013766. [DOI: 10.1002/14651858.CD013766]">Dawson 2020</a>). </p> <p>We judged the risk of bias from the blinding of outcome assessors to be unclear in six trials (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). Three trials failed to provide any details on the blinding of outcome assessors (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). One trial did not provide details of blinding in the published report, but we judged this to have an unclear risk of bias on receipt of information provided by the trial author on request (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). One trial attempted to blind outcome assessors (i.e. physiotherapists), but an evaluation as part of the trial revealed that one of the outcome assessors was aware of two allocations into the intervention arm, although both participants had completed the intervention by this time (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). In two trials, outcome assessors were blinded to at least some of the outcomes (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). In four trials, outcome assessors (i.e. researchers or healthcare professionals involved in conducting the trials and collecting the outcome data) were not blinded, hence we judged there to be a high risk of bias (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </section> <section id="CD013766-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>Two trials conducted an intention‐to‐treat analysis with all participants entering the trial; we therefore judged these trials to have a low risk of bias for incomplete outcome data (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial conducted an intention‐to‐treat analysis with 35 out of 36 participants (one participant was transferred for heart‐lung transplantation), so we also judged this trial to have a low risk of bias (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). </p> <p>Two trials did not describe withdrawals, and we judged these to have an unclear risk of bias (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). We also judged a further trial to have an unclear risk of bias after investigators confirmed they did not have any dropouts, yet three participants originally assigned to the intervention group said they would prefer to be in the control group (two were not interested in performing Skype video chats due to busy schedules, and one did not have an Internet connection), so were transferred to the control group (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). </p> <p>We judged four trials to have a high risk of bias for incomplete outcome data (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). In one trial, 20 out of 34 enrolled participants were analysed, but it is unclear whether the four reported withdrawals occurred pre‐ or post‐randomisation and there was no further information on the 10 additional participants who dropped out (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>). In the <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a> trial, only 28 out of 40 participants (nine from the intervention arm and 19 from the control arm) completed the post‐intervention follow‐up, and 24 out of 40 participants (12 in each arm) completed the one‐year post‐intervention follow‐up. Reasons for withdrawal were only given for the intervention arm and included lack of time, poor health, coaching not helpful, lack of motivation, no need for further coaching, and unknown reasons. <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a> reported significant attrition from the trial and the potential for bias. An intention‐to‐treat analysis was conducted which included data from participants in the intervention group who commenced the intervention and later withdrew (n = 8). However, 11 participants (seven in the intervention arm and four in the control arm) did not complete pre‐test assessments or withdrew from the trial prior to commencing intervention, and so were not included in intention‐to‐treat analysis (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). In the <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a> trial, there were challenges obtaining pharmacy records, which resulted in a significant amount of missing adherence data. Of the 641 participants who consented, 308 (51%) had analysable pharmacy records at baseline (n = 156 intervention; n = 152 control), and 436 (72%) had analysable pharmacy records at 12 months (n = 205 intervention; n = 231 control). The report states that intervention effects were evaluated based on the intention‐to‐treat principle, but it is unclear whether this included all participants entering the trial or whether some were excluded. </p> </section> <section id="CD013766-sec-0065"> <h4 class="title">Selective reporting</h4> <p>We were able to compare two published trials with their protocols and found no evidence of selective reporting, hence we judged these trials to have a low risk of bias (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). We judged six trials to have an unclear risk of bias for selective reporting (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). We were unable to access protocols to assess selective reporting for three trials (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). One trial reported all outcomes listed on the clinical trial register in the full trial paper, but the listed trial duration changed from 12 to three months, with no further details provided (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). We contacted the authors of one trial who provided a copy of the unpublished trial protocol (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). Adherence results were not presented in the published report, but results were provided by the trial authors on request. Scores on each CFQ‐R domain were not available, however (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). Finally, one trial reported additional outcomes not listed on the clinical trial register (e.g. HRQoL, pulmonary exacerbations) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). We judged two trials to have a high risk of bias as each listed an additional secondary outcome on the clinical trial register that was not reported in the published papers (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). </p> </section> <section id="CD013766-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other potential sources of bias in six trials (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>However, we judged one trial to have an unclear risk bias from another source as the unpublished protocol provided by the authors stated they had planned to recruit 66 participants, whereas only 18 were recruited according to the published report (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). </p> <p>We judged three trials to have a high risk of bias from other sources (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). In one trial, participants received financial incentives for attending intervention sessions and completing assessments as acknowledgement for participation (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). In addition, this trial was a cluster‐RCT in which CF centres interested in adherence‐promoting strategies were invited to participate (no other eligibility criteria for CF centres was applied). The first 18 CF centres to sign a contract and obtain relevant approvals were enroled, so it is likely that there could have been differences between those CF centres who volunteered to take part, compared to those who did not (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). </p> <p>Two trials reported baseline imbalances (which were unadjusted in the results) (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). As highlighted in a previous Cochrane Review (<a href="./references#CD013766-bbs2-0173" title="SavageE , BeirnePV , Ni ChroininM , DuffA , FitzgeraldT , FarrellD . Self-management education for cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD007641. [DOI: 10.1002/14651858.CD007641.pub3]">Savage 2014</a>), in one trial, the mean (SD) baseline weight measurement for participants in the intervention group was 89.15 (29.29) lb and for participants in the control group was 101.4 (32.17) lb, which, for CF, indicates a clinically important baseline imbalance (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>). In another trial, the authors reported that the intervention group had higher cMPR scores than the control group (P = 0.07) at baseline, and greater perceived treatment burden (P &lt; 0.01) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). </p> </section> </section> <section id="CD013766-sec-0067"> <h3 class="title" id="CD013766-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD013766-tbl-0001"><b>Summary of findings 1</b> Summary of findings: psychological interventions compared with usual care</a>; <a href="./full#CD013766-tbl-0002"><b>Summary of findings 2</b> Summary of findings: psychological interventions compared with an active comparator</a> </p> <p>We have graded the certainty of the evidence for those outcomes included in the summary of findings tables (at the 'over six months and up to 12 months' time point). For the definitions of these gradings, please refer to the summary of findings tables (<a href="./full#CD013766-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013766-tbl-0002">summary of findings Table 2</a>). </p> <p>We only report below those of our predefined outcomes that the included trials reported on. For the first comparison of psychological interventions versus usual care, results were not available for some planned lung function measures (absolute values for FEV<sub>1</sub> L and change from baseline measured either in % predicted or L), or for the time to next exacerbation or duration of exacerbations. For the comparison of active interventions, results were not available for either objective recorded measures of adherence or for subjective measures, for the treatment‐related adverse events of anxiety and depression, for some lung function measures (absolute values for FEV<sub>1</sub> L and change from baseline measured either in % predicted or L), or for the time to next exacerbation or duration of exacerbations. For each outcome measure, the number of participants differed due to incomplete data. </p> <section id="CD013766-sec-0068"> <h4 class="title">Psychological interventions versus usual care</h4> <p>Nine trials (approximately 1514 participants) contributed data to the comparison of psychological interventions versus usual care (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). We have graded the certainty of the evidence for those outcomes at the 'over six months and up to 12 months' time point (<a href="./full#CD013766-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD013766-sec-0069"> <h5 class="title">Primary outcomes</h5> <section id="CD013766-sec-0070"> <h6 class="title">1. Adherence to inhaled therapies</h6> <section id="CD013766-sec-0071"> <p><b>a. Objective recorded measures</b></p> <p>Three trials assessed adherence to inhaled therapies using objective recorded measures (e.g. data‐logging nebulisers) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). One trial (35 participants) assessed this outcome at the 'up to three months' time point (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>); one trial (55 participants) at over three months and up to six months (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>); and one trial (588 participants) at over six months and up to 12 months (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). There was insufficient information available to calculate the change from baseline in one trial (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). Therefore, we present results as endpoint (i.e. post‐intervention) data for three trials (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>There was no evidence of a difference in the percentage of prescribed inhaled medications taken between intervention and control arms at up to three months (MD 4.32, 95% CI ‐26.77 to 35.41) (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>) or over three months and up to six months (MD 10.00, 95% CI ‐6.12 to 26.12) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>). Results did, however, show 18% more medication taken in the intervention group than the control group at the 'over six months and up to 12 months' time point (MD 18.00, 95% CI 12.90 to 23.10; <a href="./references#CD013766-fig-0003" title="">Analysis 1.1</a>) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). The Wildman trial also reported adjusted data, which showed a 9.50% difference in adherence in favour of the intervention at the 'over six months and up to 12 months' time point (95% CI 8.60 to 10.40; moderate‐certainty evidence; <a href="./references#CD013766-fig-0004" title="">Analysis 1.2</a>) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </section> <section id="CD013766-sec-0072"> <p><b>b. Objective count measures</b></p> <p>One trial (5 participants) assessed this outcome at the 'up to three months' time point (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>), and a second trial (436 participants) reported at over six months and up to 12 months (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). Both trials reported a cMPR measure which included a combination of inhaled therapies and one non‐inhaled therapy (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). We were not able to combine results in the data analyses since MPR data for individual drugs were not reported or there were missing data. We therefore describe the results narratively below. </p> <p><a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a> reported mean values (but no SDs) for a cMPR measure comprising two inhaled therapies (hypertonic saline and dornase alfa) and CF multivitamins (not inhaled). After three months, the mean cMPR in the intervention group had increased from baseline by 0.05 and in the control group by 0.04. Mean MPRs for individual drugs in the two groups at baseline and the end of the trial were presented graphically, and we estimated the change in score from baseline. For dornase alfa, we estimated a 0.04 decrease in the intervention group compared to a 0.13 decrease in the control group; for hypertonic saline, we estimated the increase from baseline as 0.09 in the intervention group compared to a 0.13 drop in the control group (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). </p> <p><a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a> also reported a mean cMPR measure (without SDs) which included inhaled therapies (dornase alfa, hypertonic saline and inhaled antibiotics (tobramycin, colistin and aztreonam)) and oral azithromycin. Due to challenges in obtaining pharmacy records during the trial (procedures were changed halfway through which primarily affected collection of baseline data), cMPR scores were available for 436 participants at 12 months compared with 308 participants at baseline (baseline data were calculated from the baseline date back one year; and the 12‐month interval was the baseline date plus one year). After 12 months, the authors reported no intervention effects were found when cMPR fell by 0.181 (18%) in the intervention group compared to 0.170 (17%) in the control group (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). </p> </section> <section id="CD013766-sec-0073"> <p><b>c. Subjective measures</b></p> <p>Four trials measured adherence to inhaled therapies using subjective measures (e.g. questionnaires, participant diaries) (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). </p> <p>Two trials assessed adherence using self‐report in participant diaries, and the authors converted this to a percentage of prescribed aerosol treatments taken for each participant (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). One trial (20 participants) assessed this outcome at up to three months (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>), and one trial (intention‐to‐treat analysis with 51 participants) assessed this outcome at three time points: over three months and up to six months; over six months and up to 12 months; and over 12 months (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). </p> <p>There was insufficient information available to calculate the change from baseline in these trials and results are presented as post‐intervention data (<a href="./references#CD013766-fig-0005" title="">Analysis 1.3</a>). There was no evidence of a difference between groups at up to three months (MD 13.00, 95% CI ‐20.11 to 46.11) (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>). More aerosol treatments were taken by the intervention group at the 'over three months and up to six months' time point (MD 16.60, 95% CI 0.22 to 32.98), but this was not sustained at over six months and up to 12 months (MD 8.60, 95% CI ‐7.90 to 25.10), or over 12 months (MD 7.10, 95% CI ‐6.73 to 20.93) (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). </p> <p>Two trials assessed adherence to dornase alfa and to inhaled antibiotics (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>); <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a> reported the mean score on a self‐reported adherence questionnaire and <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a> reported participant scores on the MMAS‐8 (<a href="./references#CD013766-bbs2-0155" title="MoriskyDE , AngA , Krousel-WoodM , WardHJ . Predictive validity of a medication adherence measure in an outpatient setting. Journal of Clinical Hypertension2008;10(5):348-54. [DOI: 10.1111/j.1751-7176.2008.07572.x]">Morisky 2008</a>). Both trials assessed these outcomes at over three months and up to six months; one trial further reported at over six months and up to 12 months and again at over 12 months (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). Since these outcomes were measured using different scales across trials (all in the same direction, whereby a higher score indicated higher adherence), we calculated SMDs with 95% CIs. For dornase alfa, there was no evidence of a difference between groups at over three months and up to six months (SMD 0.02, 95% CI ‐0.62 to 0.67; 2 trials, 46 participants; <a href="./references#CD013766-fig-0006" title="">Analysis 1.4</a>), or at over six months and up to 12 months (SMD 0.43, 95% CI ‐0.41 to 1.27; 2 trials, 24 participants; <a href="./references#CD013766-fig-0006" title="">Analysis 1.4</a>), but there was higher adherence in the intervention group at over 12 months (SMD 0.91, 95% CI ‐0.00 to 1.81; 2 trials, 21 participants; <a href="./references#CD013766-fig-0006" title="">Analysis 1.4</a>) (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). For inhaled antibiotics, there was no evidence of differences between groups at over three months and up to six months (SMD 0.49, 95% CI ‐1.01 to 1.98; 2 trials, 43 participants; <a href="./references#CD013766-fig-0007" title="">Analysis 1.5</a>), at over six months and up to 12 months (SMD ‐0.13, 95% CI ‐0.99 to 0.72; 2 trials, 23 participants; <a href="./references#CD013766-fig-0007" title="">Analysis 1.5</a>), nor at over 12 months (SMD 0.00, 95% CI ‐0.91 to 0.91; 2 trials, 19 participants; <a href="./references#CD013766-fig-0007" title="">Analysis 1.5</a>) (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). </p> <p><a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a> also assessed adherence to inhaled steroids, hypertonic saline, and bronchodilators at over three months and up to six months. There was no evidence of a difference between groups for inhaled steroids (MD 1.09, 95% CI ‐0.66 to 2.84; 1 trial, 17 participants; <a href="./references#CD013766-fig-0008" title="">Analysis 1.6</a>), hypertonic saline (MD ‐0.12, 95% CI ‐1.84 to 1.60; 1 trial, 16 participants; <a href="./references#CD013766-fig-0009" title="">Analysis 1.7</a>), or bronchodilators (MD ‐1.13, 95% CI ‐3.00 to 0.74; 1 trial, 16 participants; <a href="./references#CD013766-fig-0010" title="">Analysis 1.8</a>). </p> </section> </section> <section id="CD013766-sec-0074"> <h6 class="title">2. Treatment‐related adverse events</h6> <section id="CD013766-sec-0075"> <p><b>a. Anxiety</b></p> <p>This result was reported in three trials. One trial (35 participants) assessed anxiety at up to three months (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>), one trial (59 participants) at over three months and up to six months (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>) and one trial (535 participants) at over six months and up to 12 months (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Two trials explicitly included the outcome of anxiety as a safety measure (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>As anxiety was measured using different scales across trials (all in the same direction, whereby a higher score indicated greater anxiety), we calculated SMDs with 95% CIs. There was insufficient information available to calculate the change from baseline in one trial (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). Therefore, results are presented as post‐intervention data for the three trials that reported this outcome (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Since one trial measured anxiety using two outcome measures in the same participants, we have not reported any totals or summary statistics for this outcome (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). Instead, we have presented the data for each measure (<a href="./references#CD013766-fig-0011" title="">Analysis 1.9</a>). There was no evidence of a difference in anxiety between intervention and control groups on any measure at up to three months (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>); over three months and up to six months (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>); or at over six months and up to 12 months (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>) (<a href="./references#CD013766-fig-0011" title="">Analysis 1.9</a>). </p> <p>In addition, two trials reported the adjusted MD for anxiety (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), measured using the GAD‐7 (<a href="./references#CD013766-bbs2-0183" title="SpitzerRL , KroenkeK , WilliamsJBW , LöweB . A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine2006;166(10):1092-7. [DOI: 10.1001/archinte.166.10.1092]">Spitzer 2006</a>). These results showed that there was no evidence of a difference between groups either at over three months and up to six months (MD ‐0.31, 95% CI ‐1.90 to 1.28) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>) or at over six months and up to 12 months (MD 0.30, 95% CI ‐0.40 to 1.00; low‐certainty evidence; <a href="./references#CD013766-fig-0012" title="">Analysis 1.10</a>) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </section> <section id="CD013766-sec-0076"> <p><b>b. Depression</b></p> <p>This result was reported in four trials. One trial (35 participants) assessed depression at up to three months (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>); two trials (88 or 89 participants depending on the measure used) at over three months and up to six months (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>); two trials (559 or 560 participants depending on the measure used) at over six months and up to 12 months (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>); and one trial (24 participants) at over 12 months (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). Two trials explicitly included the outcome of depression as a safety measure (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p><a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a> firstly assessed depression using the 12‐item MDI, where scores range from 0 to 50; with scores of 21 to 25 indicating mild depression, 26 to 30 indicating moderate depression, and 31 to 50 indicating severe depression (<a href="./references#CD013766-bbs2-0089" title="BechP , RasmussenNA , OlsenLR , NoerholmV , AbildgaardW . The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. Journal of Affective Disorders2001;66(2-3):159-64. [DOI: 10.1016/S0165-0327(00)00309-8]">Bech 2001</a>); and secondly, using the 20‐item CES‐D where scores range from 0 to 60, with higher scores indicating greater depressive symptoms, and scores of 16 or more indicating depression (<a href="./references#CD013766-bbs2-0167" title="RadloffLS . The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Applied Psychological Measurement1977;1(3):385-401. [DOI: 10.1177/014662167700100306]">Radloff 1977</a>). </p> <p>As above, we calculated SMDs with 95% CIs. There was insufficient information available to calculate the change from baseline in two trials (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). Therefore, results are presented as post‐intervention data (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Since one trial used two outcome measures of depression in the same participants at three of the time points, we have not reported any totals or summary statistics (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). Instead, we have presented the data for each measure (<a href="./references#CD013766-fig-0013" title="">Analysis 1.11</a>). There was no evidence of a difference in depression between intervention and control groups on any measure at any time point (<a href="./references#CD013766-fig-0013" title="">Analysis 1.11</a>). </p> <p>In addition to the endpoint data, two trials reported the adjusted MD for depression (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Using the PHQ‐8 (where scores range from 0 to 24, with cut‐off scores of 5, 10, 15, and 20 indicating mild, moderate, moderately severe, and severe depression, respectively) (<a href="./references#CD013766-bbs2-0143" title="KroenkeK , StrineTW , SpritzerRL , WilliamsJB , BerryJT , MokdadAH . The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders2009;114(1-3):163-73. [DOI: 10.1016/j.jad.2008.06.026]">Kroenke 2009</a>), results showed no evidence of a difference between groups at either over three months and up to six months, MD 0.97 (95% CI ‐0.96 to 2.90; <a href="./references#CD013766-fig-0014" title="">Analysis 1.12</a>) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>), or over six months and up to 12 months, MD ‐0.10 (95% CI ‐0.80 to 0.60; low‐certainty evidence; <a href="./references#CD013766-fig-0014" title="">Analysis 1.12</a>) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </section> </section> </section> <section id="CD013766-sec-0077"> <h5 class="title">Secondary outcomes</h5> <section id="CD013766-sec-0078"> <h6 class="title">1. QoL</h6> <p>Eight trials assessed QoL (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>); the measures used varied across trials and included the Quality of Wellbeing scale (<a href="./references#CD013766-bbs2-0142" title="KaplanRM , AndersonJP , WuAW , MathewsWC , KozinF , OrensteinDM . The Quality of Well-Being Scale: applications in AIDS, cystic fibrosis, and arthritis. Medical Care1989;27:S27-43. [DOI: 10.1097/00005650-198903001-00003]">Kaplan 1989</a>), CFQoL (<a href="./references#CD013766-bbs2-0120" title="GeeL , AbbottJ , ConwaySP , EtheringtonC , WebbAK . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax2000;55(11):946-54. [DOI: 10.1136/thorax.55.11.946]">Gee 2000</a>) and CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>). </p> <p>We combined domains from the CFQoL (<a href="./references#CD013766-bbs2-0120" title="GeeL , AbbottJ , ConwaySP , EtheringtonC , WebbAK . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax2000;55(11):946-54. [DOI: 10.1136/thorax.55.11.946]">Gee 2000</a>) and CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) that had the same names (e.g. physical functioning, body image) and calculated SMDs with 95% CIs. For domains that could not obviously be combined with domains from other measures (e.g. career concerns, interpersonal relationships), we included these in separate data analyses and calculated MDs with 95% CIs. There was insufficient information available to calculate the change from baseline in five trials (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). Therefore, results are presented as post‐intervention data for the eight trials that reported this outcome (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), except where otherwise specified (e.g. two trials also reported adjusted data (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>)). </p> <section id="CD013766-sec-0079"> <p><b>Up to three months</b></p> <p>One trial (20 participants) assessed the mean score on the Quality of Wellbeing scale (<a href="./references#CD013766-bbs2-0142" title="KaplanRM , AndersonJP , WuAW , MathewsWC , KozinF , OrensteinDM . The Quality of Well-Being Scale: applications in AIDS, cystic fibrosis, and arthritis. Medical Care1989;27:S27-43. [DOI: 10.1097/00005650-198903001-00003]">Kaplan 1989</a>) at up to three months (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>). A further trial (35 participants) assessed the mean scores on all nine domains of the CFQoL (<a href="./references#CD013766-bbs2-0120" title="GeeL , AbbottJ , ConwaySP , EtheringtonC , WebbAK . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax2000;55(11):946-54. [DOI: 10.1136/thorax.55.11.946]">Gee 2000</a>) at up to three months using an intention‐to‐treat analysis (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). A third trial (five participants) assessed QoL using only the treatment burden domain of the CFQ‐R (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). </p> <p>There was no evidence of a difference between intervention and control groups in the mean score on the Quality of Wellbeing scale (MD ‐0.02, 95% CI ‐0.09 to 0.05; <a href="./references#CD013766-fig-0015" title="">Analysis 1.13</a>). The trial authors highlighted a possible ceiling effect, with participants scoring 0.7 or higher at baseline (on a scale of 0 to 1, where 0 is 'death' and 1 is 'perfect health'), suggesting that participants were already experiencing a relatively high QoL pre‐intervention (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>). </p> <p>There was no evidence of a difference between groups at three months for the following domains: physical functioning (<a href="./references#CD013766-fig-0016" title="">Analysis 1.14</a>); emotional functioning (<a href="./references#CD013766-fig-0018" title="">Analysis 1.16</a>); social functioning (<a href="./references#CD013766-fig-0020" title="">Analysis 1.18</a>); treatment burden (<a href="./references#CD013766-fig-0022" title="">Analysis 1.20</a>); respiratory or chest symptoms (<a href="./references#CD013766-fig-0034" title="">Analysis 1.32</a>); treatment issues (<a href="./references#CD013766-fig-0040" title="">Analysis 1.38</a>); career concerns (<a href="./references#CD013766-fig-0041" title="">Analysis 1.39</a>); interpersonal relationships (<a href="./references#CD013766-fig-0042" title="">Analysis 1.40</a>); or concerns for the future (<a href="./references#CD013766-fig-0043" title="">Analysis 1.41</a>). However, results favoured the intervention for body image (SMD 0.69, 95% CI 0.00 to 1.38; <a href="./references#CD013766-fig-0026" title="">Analysis 1.24</a>). The authors of the Quinn trial highlighted that mean scores were higher in the intervention group compared to usual care on most subscales at three months (excluding treatment issues and concerns for the future) (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). </p> </section> <section id="CD013766-sec-0080"> <p><b>Over three months and up to six months</b></p> <p>Two trials (87 to 89 participants) assessed the mean scores on all 12 domains of the CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) at this time point (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). There was no evidence of a difference between groups on any of the following QoL domains: physical functioning (<a href="./references#CD013766-fig-0016" title="">Analysis 1.14</a>); emotional functioning (<a href="./references#CD013766-fig-0018" title="">Analysis 1.16</a>); social functioning (<a href="./references#CD013766-fig-0020" title="">Analysis 1.18</a>); treatment burden (<a href="./references#CD013766-fig-0022" title="">Analysis 1.20</a>); role limitations (<a href="./references#CD013766-fig-0024" title="">Analysis 1.22</a>); body image (<a href="./references#CD013766-fig-0026" title="">Analysis 1.24</a>); vitality (<a href="./references#CD013766-fig-0028" title="">Analysis 1.26</a>); eating disturbance (<a href="./references#CD013766-fig-0030" title="">Analysis 1.28</a>); weight problems (<a href="./references#CD013766-fig-0032" title="">Analysis 1.30</a>); respiratory symptoms (<a href="./references#CD013766-fig-0034" title="">Analysis 1.32</a>); digestive symptoms (<a href="./references#CD013766-fig-0036" title="">Analysis 1.34</a>); or health perceptions (<a href="./references#CD013766-fig-0038" title="">Analysis 1.36</a>) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). </p> <p>In addition to the endpoint data, one trial also reported the adjusted MD between groups (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>). These results also showed no evidence of a difference in any of the following QoL domains: physical functioning (<a href="./references#CD013766-fig-0017" title="">Analysis 1.15</a>); emotional functioning (<a href="./references#CD013766-fig-0019" title="">Analysis 1.17</a>); social functioning (<a href="./references#CD013766-fig-0021" title="">Analysis 1.19</a>); treatment burden (<a href="./references#CD013766-fig-0023" title="">Analysis 1.21</a>); role limitations (<a href="./references#CD013766-fig-0025" title="">Analysis 1.23</a>); body image (<a href="./references#CD013766-fig-0027" title="">Analysis 1.25</a>); vitality (<a href="./references#CD013766-fig-0029" title="">Analysis 1.27</a>); eating disturbance (<a href="./references#CD013766-fig-0031" title="">Analysis 1.29</a>); weight problems (<a href="./references#CD013766-fig-0033" title="">Analysis 1.31</a>); respiratory symptoms (<a href="./references#CD013766-fig-0035" title="">Analysis 1.33</a>); digestive symptoms (<a href="./references#CD013766-fig-0037" title="">Analysis 1.35</a>); and health perceptions (<a href="./references#CD013766-fig-0039" title="">Analysis 1.37</a>). </p> <p>One trial calculated an average CFQ‐R score for each group (rather than reporting results for each domain separately), so we could not analyse the data (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). Mean (SD) overall CFQ‐R score post‐intervention was 62.39 (14.33) in the intervention group compared with 65.91 (18.09) in the control group. </p> </section> <section id="CD013766-sec-0081"> <p><b>Over six months and up to 12 months</b></p> <p>Three trials assessed QoL at this time point: two reported mean scores for all 12 domains of the CFQ‐R (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>), while the third trial used mean score on eight domains of the CFQ‐R (physical functioning, emotional functioning, social functioning, eating disturbance, body image, treatment burden, respiratory symptoms and digestive symptoms) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>There was no evidence of a difference between groups in any of the following CFQ‐R domains: physical functioning (1089 participants) (<a href="./references#CD013766-fig-0016" title="">Analysis 1.14</a>); emotional functioning (1089 participants) (<a href="./references#CD013766-fig-0018" title="">Analysis 1.16</a>); social functioning (1089 participants) (<a href="./references#CD013766-fig-0020" title="">Analysis 1.18</a>); treatment burden (1090 participants) (<a href="./references#CD013766-fig-0022" title="">Analysis 1.20</a>); role limitations (412 participants) (<a href="./references#CD013766-fig-0024" title="">Analysis 1.22</a>); body image (1089 participants) (<a href="./references#CD013766-fig-0026" title="">Analysis 1.24</a>); vitality (413 participants) (<a href="./references#CD013766-fig-0028" title="">Analysis 1.26</a>); eating disturbances (1089 participants) (<a href="./references#CD013766-fig-0030" title="">Analysis 1.28</a>); weight problems (413 participants) (<a href="./references#CD013766-fig-0032" title="">Analysis 1.30</a>); respiratory symptoms (1085 participants) (<a href="./references#CD013766-fig-0034" title="">Analysis 1.32</a>); digestive symptoms (1084 participants) (<a href="./references#CD013766-fig-0036" title="">Analysis 1.34</a>); or health perceptions (413 participants) (<a href="./references#CD013766-fig-0038" title="">Analysis 1.36</a>). Only one trial found a difference between groups in one domain of the CFQ‐R (treatment burden) at this time point, SMD 0.26 (95% CI 0.09 to 0.43; <a href="./references#CD013766-fig-0022" title="">Analysis 1.20</a>) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>In addition to the endpoint data, one trial also reported the adjusted MDs (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). These results showed no evidence of a difference between groups in any of the following QoL domains: physical functioning (<a href="./references#CD013766-fig-0017" title="">Analysis 1.15</a>); emotional functioning (<a href="./references#CD013766-fig-0019" title="">Analysis 1.17</a>); social functioning (<a href="./references#CD013766-fig-0021" title="">Analysis 1.19</a>); body image (<a href="./references#CD013766-fig-0027" title="">Analysis 1.25</a>); eating disturbance (<a href="./references#CD013766-fig-0031" title="">Analysis 1.29</a>); respiratory symptoms (low‐certainty evidence; <a href="./references#CD013766-fig-0035" title="">Analysis 1.33</a>); or digestive symptoms (<a href="./references#CD013766-fig-0037" title="">Analysis 1.35</a>) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). However, results did favour the intervention for the treatment burden domain (MD 3.90, 95% CI 1.20 to 6.60; low‐certainty evidence; <a href="./references#CD013766-fig-0023" title="">Analysis 1.21</a>). </p> </section> <section id="CD013766-sec-0082"> <p><b>Over 12 months</b></p> <p>Lastly, one trial (22 to 24 participants) assessed QoL using all 12 domains of the CFQ‐R at over 12 months (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). There was no evidence of a difference between groups in any of the following QoL domains: physical functioning (<a href="./references#CD013766-fig-0016" title="">Analysis 1.14</a>); emotional functioning (<a href="./references#CD013766-fig-0018" title="">Analysis 1.16</a>); social functioning (<a href="./references#CD013766-fig-0020" title="">Analysis 1.18</a>); treatment burden (<a href="./references#CD013766-fig-0022" title="">Analysis 1.20</a>); role limitations (<a href="./references#CD013766-fig-0024" title="">Analysis 1.22</a>); body image (<a href="./references#CD013766-fig-0026" title="">Analysis 1.24</a>); vitality (<a href="./references#CD013766-fig-0028" title="">Analysis 1.26</a>); eating disturbances (<a href="./references#CD013766-fig-0030" title="">Analysis 1.28</a>); weight problems (<a href="./references#CD013766-fig-0032" title="">Analysis 1.30</a>); respiratory symptoms (<a href="./references#CD013766-fig-0034" title="">Analysis 1.32</a>); digestive symptoms (<a href="./references#CD013766-fig-0036" title="">Analysis 1.34</a>); or health perceptions (<a href="./references#CD013766-fig-0038" title="">Analysis 1.36</a>). </p> </section> </section> <section id="CD013766-sec-0083"> <h6 class="title">% predicted</h6> <p>Five trials reported analysable data (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). There was insufficient information available to calculate the change from baseline in three trials (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). Therefore, we present results as endpoint (i.e. post‐intervention) data for the five trials (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). In addition to the endpoint data, two trials also reported the adjusted MD for FEV<sub>1</sub> % predicted (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Additionally, one trial reported means and SDs for this outcome at baseline only, meaning we could not include the data from this trial in the analysis (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). However, the authors report that no significant intervention effects were found for any of the secondary outcomes in this trial, compared to usual care (and FEV<sub>1</sub>% predicted was a secondary outcome in this trial) (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). </p> <section id="CD013766-sec-0084"> <p><b>Up to three months</b></p> <p>Two trials assessed FEV<sub>1</sub> % predicted at up to three months (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). There was no evidence of a difference between groups (MD ‐3.25, 95% CI ‐18.13 to 11.64; 2 trials, 40 participants; <a href="./references#CD013766-fig-0044" title="">Analysis 1.42</a>). </p> </section> <section id="CD013766-sec-0085"> <p><b>Over three months and up to six months</b></p> <p>Two trials reported FEV<sub>1</sub> % predicted at over three months and up to six months (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>); results showed no evidence of a difference between treatment and control (MD ‐2.98, 95% CI ‐12.50 to 6.55; 2 trials, 95 participants; <a href="./references#CD013766-fig-0044" title="">Analysis 1.42</a>). Adjusted results from one trial also showed no evidence of a difference between groups (MD 5.00, 95% CI ‐2.00 to 12.00; <a href="./references#CD013766-fig-0045" title="">Analysis 1.43</a>) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>). </p> </section> <section id="CD013766-sec-0086"> <p><b>Over six months and up to 12 months</b></p> <p>Two trials (593 participants) reported FEV<sub>1</sub> % predicted at over six months and up to 12 months (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>); results showed no evidence of a difference between groups (MD 3.20, 95% CI ‐0.59 to 6.99; 2 trials, 593 participants; <a href="./references#CD013766-fig-0044" title="">Analysis 1.42</a>). Adjusted results from one trial also showed no evidence of a difference between groups at over six months and up to 12 months (MD 1.40, 95% CI ‐0.20 to 3.00; moderate‐certainty evidence; <a href="./references#CD013766-fig-0045" title="">Analysis 1.43</a>) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </section> <section id="CD013766-sec-0087"> <p><b>Over 12 months</b></p> <p>One trial assessed this outcome (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>), finding no evidence of an effect at over 12 months (MD ‐4.20, 95% CI ‐19.31 to 10.91; 1 trial, 36 participants; <a href="./references#CD013766-fig-0044" title="">Analysis 1.42</a>). </p> </section> </section> <section id="CD013766-sec-0088"> <h6 class="title">3. Pulmonary exacerbations</h6> <section id="CD013766-sec-0089"> <p><b>Up to three months</b></p> <p>It was not possible to analyse the results of one trial (five participants) for this outcome (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>), as the authors do not report the means, SDs or ratio data. Investigators reported the total number of pulmonary exacerbations per group in the three‐month duration of the trial, rather than the number of people experiencing an exacerbation. There were two exacerbations in the intervention group compared with one in the control group (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). The trial reports that there was no change in the average number of pulmonary exacerbations in either group. </p> </section> <section id="CD013766-sec-0090"> <p><b>Over three months and up to six months</b></p> <p>One trial (60 participants) reported the total (and the mean (SD) and median (IQR)) number of exacerbations per group at over three months and up to six months (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>). There were a total of 35 exacerbations in the intervention group (mean (SD) 1.1 (1.1); median (range) 1 (0 to 2); 32 participants) compared with 25 (mean (SD) 0.9 (1.1); median (range) 0.5 (0 to 2); 28 participants) in the control arm over the six‐month trial. Analysed data showed no evidence of a difference in the mean number of exacerbations between groups (MD 0.20, 95% CI ‐0.36 to 0.76; <a href="./references#CD013766-fig-0046" title="">Analysis 1.44</a>) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>). The authors reported unadjusted data showing no evidence of a difference between groups (rate ratio 1.22, 95% CI 0.69 to 2.16; <a href="./references#CD013766-fig-0047" title="">Analysis 1.45</a>); the adjusted data also did not show a difference in exacerbation rates between groups at over three months and up to six months (rate ratio 1.12, 95% CI 0.66 to 1.90; <a href="./references#CD013766-fig-0048" title="">Analysis 1.46</a>). </p> <p>This trial also reported the number of participants per group who experienced one or more exacerbations over the six‐month trial (60 participants) (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>). A total of 19 out of 32 participants (59%) in the intervention group and 14 out of 28 participants (50%) in the control group experienced at least one exacerbation. </p> </section> <section id="CD013766-sec-0091"> <p><b>Over six months and up to 12 months</b></p> <p>One trial (607 participants) reported the number of exacerbations at over six months and up to 12 months, with no evidence of a difference in exacerbations between treatment or control arms (P = 0.64) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Over the 12‐month trial duration, there were 526 pulmonary exacerbations in the 303 participants in the usual care arm compared with 482 exacerbations in the 304 participants in the intervention arm. Analysis of the unadjusted data at over six months and up to 12 months generated the rate ratio 0.92 (95% CI 0.77 to 1.10; <a href="./references#CD013766-fig-0047" title="">Analysis 1.45</a>). When the adjusted data were analysed (adjusted rate 1.77/year in the usual care arm compared with an adjusted rate of 1.63/year in the intervention arm), there was also no evidence of a difference between groups, rate ratio 0.96 (95% CI 0.83 to 1.11; low‐certainty evidence; <a href="./references#CD013766-fig-0048" title="">Analysis 1.46</a>). </p> <p>One 12‐month trial measured pulmonary exacerbations as 'IV antibiotic treatment', but it was unclear how this outcome was defined, and investigators only reported the percentage of participants receiving '1+ course of IV antibiotics in the past year' at baseline (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). The authors of this trial did, however, report that they did not find any intervention effect for pulmonary exacerbations. </p> </section> </section> </section> </section> <section id="CD013766-sec-0092"> <h4 class="title">Psychological intervention (MI) versus active comparator (EPS)</h4> <p>One trial (128 participants) compared MI with an active comparator control arm (EPS) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). However, this trial only reported medians and IQRs, so we were not able to analyse data for this comparison and we describe results narratively below. We have graded the certainty of the evidence for those outcomes at the 'over six months and up to 12 months' time point (<a href="./full#CD013766-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD013766-sec-0093"> <h5 class="title">Primary outcomes</h5> <section id="CD013766-sec-0094"> <h6 class="title">1. Adherence to inhaled therapies</h6> <section id="CD013766-sec-0095"> <p><b>b. Objective count measures</b></p> <p>The included trial measured adherence to inhaled therapies using a cMPR measure, which included inhaled therapies (dornase alfa, hypertonic saline, inhaled tobramycin, and aztreonam), as well as one non‐inhaled treatment (azithromycin) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). At 12 months (95 participants), median (IQR) cMPR was 54 (37 to 73) in the MI group, compared with 51 (17 to 71) in the EPS group. The trial authors also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that no intervention effects were found for cMPR (P = 0.763; no effect size reported or calculable) or any of the individual drugs (very low‐certainty evidence). </p> </section> </section> </section> <section id="CD013766-sec-0096"> <h5 class="title">Secondary outcomes</h5> <section id="CD013766-sec-0097"> <h6 class="title">1. QoL</h6> <p>Riekert assessed this outcome using three domains of the CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) (respiratory, physical functioning, and treatment burden). At six months (112 participants), median (IQR) score was 67 (56 to 78) in the MI group and 64 (50 to 78) in the EPS group (respiratory); 81 (63 to 96) in the MI group and 77 (58 to 96) in the EPS group (physical functioning); and 56 (44 to 67) in the MI group and 56 (44 to 67) in the EPS group (treatment burden). At 12 months (95 participants), median (IQR) score was 67 (50 to 83) in the MI group and 67 (50 to 72) in the EPS group (respiratory); 79 (60 to 96) in the MI group and 79 (54 to 96) in the EPS group (physical functioning); and 56 (44 to 67) in the MI group and 56 (44 to 78) in the EPS group (treatment burden). </p> <p>The trialists assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months). They reported that no intervention effects were found for QoL, with the exception of the treatment burden domain where the MI group had an increase from baseline at six months relative to the EPS group (P = 0.006; no effect size reported or calculable; very low‐certainty evidence) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). </p> </section> <section id="CD013766-sec-0098"> <h6 class="title">2. Lung function</h6> <p>At 12 months (125 participants), median (IQR) FEV<sub>1</sub> % predicted was 66% (48% to 85%) in the MI group and 64% (49% to 84%) in the EPS group. The authors of the included trial also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that the intervention had no effect on lung function (P = 0.773; no effect size reported or calculable; very low‐certainty evidence). </p> </section> <section id="CD013766-sec-0099"> <h6 class="title">3. Pulmonary exacerbations</h6> <section id="CD013766-sec-0100"> <p><b>a. Number of exacerbations</b></p> <p>The included trial reported exacerbations as 'pulmonary exacerbations (1+ in past year)' as a percentage for each group. Using these percentages and the total number of participants in each group, we calculated that in the MI group, 12 out of 63 participants (19%) experienced an exacerbation over the 12‐month trial period compared with 12 out of 65 (18%) in the EPS group. The trial authors also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that the intervention had no effect on pulmonary exacerbations (P = 0.929; no effect size reported or calculable; very low‐certainty evidence). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013766-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013766-sec-0101"></div> <section id="CD013766-sec-0102"> <h3 class="title" id="CD013766-sec-0102">Summary of main results</h3> <p>We systematically reviewed available evidence comparing the efficacy of psychological interventions for improving adherence to inhaled therapies in people with CF. We included 10 trials (1642 participants) published between 1996 and 2021; four trials included children and adolescents (and their parents or caregivers) (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>), five trials included adults (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), and one trial included children and adults (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). No interventions specifically targeted the families of people with CF or MDTs. Nine trials compared a psychological intervention with a usual care control group (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), and one compared a psychological intervention (MI) with an active comparator (EPS) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). </p> <p>Given the heterogeneity of the participants, interventions, and outcome measures, statistical analysis was limited, and we have summarised the main outcomes at the 'over six months and up to 12 months' time point in the summary of findings tables (<a href="./full#CD013766-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013766-tbl-0002">summary of findings Table 2</a>). Due to the limited number of included trials and the variety of the interventions, we were unable to investigate the most effective components, or BCTs, for improving adherence. We have, however, identified a hierarchy of the most common BCTs that feature in these studies (<a href="#CD013766-tbl-0003">Table 1</a>). Psychological interventions were generally multi‐component and complex, containing an average of 9.6 BCTs; the most frequently used BCTs were 'problem solving' and 'instruction on how to perform the behaviour' (<a href="./references#CD013766-bbs2-0151" title="MichieS , RichardsonM , JohnstonM , AbrahamC , FrancisJ , HardemanW , et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Annals of Behavioral Medicine2013;46(1):81-95. [DOI: 10.1007/s12160-013-9486-6]">Michie 2013</a>). The 10 trials differed in the outcomes and the time points assessed (ranging from six to eight weeks post‐intervention (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>) to 23 months post‐intervention (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>)). </p> <section id="CD013766-sec-0103"> <h4 class="title">Psychological interventions versus usual care</h4> <p>All nine trials included in this comparison reported on our primary outcome of adherence, using a variety of outcome measures. Only three trials suggested evidence of an effect of psychological interventions for improving adherence to inhaled therapies in people with CF. When measured objectively, using data‐logging nebulisers, results from one large, 19‐centre trial (607 participants) showed that a digital intervention (CFHealthHub) combined with behaviour change sessions with trained interventionists, can increase adherence to inhaled therapies in adults with CF by 18% (9.5% increase from baseline) at 12 months, compared with usual care (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). This trial used 23 BCTs, the joint second highest of all included trials (see '<a href="#CD013766-tbl-0003">Table 1</a>'). </p> <p>A further two trials showed an increase in adherence between groups, but these were assessed using subjective measures (e.g. standardised questionnaires or participant diaries) (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). One of these trials (n = 51) assessed a 10‐week self‐management paper‐based workbook exercise completed by children with CF and their parents/caregivers at home (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). Results demonstrated that post‐intervention, adherence to aerosol treatments was 16.6% greater in the intervention group compared with usual care, but this was not sustained at six months and 12 months. This trial used 28 BCTs, the largest number of all included trials (see '<a href="#CD013766-tbl-0003">Table 1</a>'). Results from the second trial suggested that, compared with usual care, a life‐coaching intervention improved adherence to dornase alfa in adults with CF (n = 28) at one year‐post intervention (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). This trial used the fewest BCTs of all included trials (n = 1; <a href="#CD013766-tbl-0003">Table 1</a>). There was a difference of 1.72 in favour of the intervention on the MMAS‐8 (<a href="./references#CD013766-bbs2-0155" title="MoriskyDE , AngA , Krousel-WoodM , WardHJ . Predictive validity of a medication adherence measure in an outpatient setting. Journal of Clinical Hypertension2008;10(5):348-54. [DOI: 10.1111/j.1751-7176.2008.07572.x]">Morisky 2008</a>); however, it is unclear if the differences are of any clinical significance, as the scores on this measure would still meet the cut‐off for 'low adherence'. There was also no evidence of an effect of the intervention at any other reported time point, or for the other treatment measured (inhaled antibiotics). </p> <p>For our second primary outcome, treatment‐related adverse events, no trial found a difference between groups on anxiety or depression at any time point. </p> <p>For our secondary outcomes, there was no evidence of a difference between groups in terms of pulmonary exacerbations or lung function (measured using FEV<sub>1</sub>% predicted), although one trial found the rate of decline in FEV<sub>1</sub> over 12 months was less among intervention participants (0.1%) compared with usual care (1.4%) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). In terms of QoL, the adjusted data from the <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a> trial demonstrated a difference in favour of the CFHealthHub intervention on treatment burden at 12 months compared with usual care (MD 3.90, 95% CI 1.20 to 6.60; <a href="./references#CD013766-fig-0023" title="">Analysis 1.21</a>). A further trial found behaviour change counselling had a greater effect on body image at three months than usual care (<a href="./references#CD013766-fig-0026" title="">Analysis 1.24</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). No other trial reported a difference on any QoL domain. </p> <p>In summary, psychological interventions probably improve our primary outcome of adherence to inhaled therapies in people with CF at over six months and up to 12 months (one trial; 588 participants; moderate‐certainty evidence). There was no evidence to suggest they may have an effect on treatment‐related adverse events, anxiety or depression, at the same time point (one trial; 534 to 535 participants; low‐certainty evidence). For our secondary outcomes, psychological interventions probably make little or no difference to lung function measured by FEV<sub>1</sub> % predicted (one trial; 556 participants; moderate‐certainty evidence), pulmonary exacerbations (one trial; 607 participants; moderate‐certainty evidence), or the QoL domain of respiratory symptoms (one trial; 534 participants; low‐certainty evidence). There is, however, low‐certainty evidence to suggest that psychological interventions may improve the QoL domain of treatment burden (one trial; 539 participants) (<a href="./full#CD013766-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD013766-sec-0104"> <h4 class="title">Psychological intervention (MI) versus active comparator (EPS)</h4> <p>For our second comparison, we identified one trial involving 128 participants which compared an MI intervention with EPS (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). The authors reported medians and IQR, so we were unable to analyse the data in our review. The original paper reported that no intervention effects were found for adherence (cMPR), QoL, lung function, or pulmonary exacerbations at the 'over six months and up to 12 months' time point. The authors reported that the MI group had an improvement in treatment burden compared with the EPS group at six months (P = 0.006; no effect size reported; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>), but this was not sustained at 12 months. We found that the overall certainty of the evidence from this single trial was very low across outcomes. We are therefore uncertain whether an MI intervention (compared with EPS) improves adherence to inhaled therapies, lung function, or QoL in people with CF. We are also uncertain whether there is an effect on pulmonary exacerbations. The included trial for this comparison did not report on treatment‐related adverse events (anxiety and depression) (<a href="./full#CD013766-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> <section id="CD013766-sec-0105"> <h3 class="title" id="CD013766-sec-0105">Overall completeness and applicability of evidence</h3> <p>Many of the included trials had small sample sizes and were heterogenous in terms of participants (age), interventions (content and mode of delivery), and outcomes (measures, number and range of assessment time points). For these reasons, it was not possible to identify an overall intervention effect using meta‐analysis, which therefore limits the overall completeness and, ultimately, the generalisation of the evidence to the wider CF population at present. The results of five trials are awaited (<a href="./references#CD013766-bbs2-0080" title='JirasekM , HomolaL , PleskovaJ , GracovaZ , BenesovaK , HodkovaP , et al. "CF Hero" application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis. Journal of Cystic Fibrosis2022;21 Suppl 1:S130. [CFGD REGISTER: MH206] '>Jirasek 2022</a>; <a href="./references#CD013766-bbs2-0081" title="NCT04114227. Acceptance and Commitment Therapy vs. Supportive Psychotherapy with cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT04114227 (first posted 3 October 2019). O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . ACT with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. ">O'Hayer 2019</a>; <a href="./references#CD013766-bbs2-0082" title="NCT03637504. Feasibility of a mobile medication plan application in CF patient care (MAP). clinicaltrials.gov/ct2/show/NCT03637504 (first posted 20 August 2018). [CFGD REGISTER: MH186a] PhanH , DainesC , GreenA , CamickN , GoodmanA , WooT , et al. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a pilot, real-world, mobile health study in CF clinics. Journal of Cystic Fibrosis2021;20 Suppl:S140. [CFGD REGISTER: MH186b] ">Phan 2021</a>; <a href="./references#CD013766-bbs2-0083" title="DRKS00024642. Coaching and telemonitoring in patients with cystic fibrosis: ConneCT CF. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00024642 (date of registration 1 March 2021). TheeS , StahlM , FischerR , SutharsanS , BallmanM , MüllerA , et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmology Medicine2021;21(1):131. [DOI: 10.1186/s12890-021-01500-y]">Thee 2021</a>; <a href="./references#CD013766-bbs2-0084" title="ISRCTN37959826. Randomised trial of a web-based intervention for adherence in cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN37959826 (date of registration 11 November 2015). [CFGD REGISTER: MH59c] WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Evaluation of an RCT web based intervention for adherence in cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:503. [CENTRAL: CN-01430890] [CFGD REGISTER: MH59a] [EMBASE: 619069211]WhiteH , ShawN , GillgrassL , WoodA , ChadwickHK , PeckhamD . Randomized controlled trial of a webbased intervention for adherence in cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:420. [ABSTRACT NO.: 697] [CFGD REGISTER: MH59b] ">White 2017</a>). We will report on these trials in the next update of the review. </p> <p>Our planned subgroup analyses by types of participants (e.g. children and adolescents with CF; adults with CF; families of people with CF; or MDTs) or to compare trials assessing adherence to multiple CF treatments versus those that focused on inhaled therapies only were not possible due to the limited data available (<a href="#CD013766-sec-0036">Subgroup analysis and investigation of heterogeneity</a>). Although children and adolescents were included in four trials in this review (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>), two trials assessed short‐term outcomes (less than three months) (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>); one trial assessed only one of our outcomes, adherence (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>); and the results of one large, multicentre trial were difficult to interpret due to post‐intervention means (and SDs) not being reported for most outcomes (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). It is likely that an intervention will work in slightly different ways for children and adolescents (who may have high parent/caregiver involvement), compared with adults with CF. The overall completeness and applicability of evidence to children and adolescents with CF may therefore be limited. </p> <p>We had also planned to investigate which BCTs are most effective for improving adherence, and whether the number of BCTs used in an intervention can affect adherence. From the current available evidence, this was not possible. </p> <p>Many of the interventions were complex and multi‐component, and included a range of BCTs, and there was also variety in the types of psychological intervention delivered (<a href="#CD013766-sec-0042">Included studies</a>). It should be noted that some of the interventions were non‐specific and focused on either adherence to CF treatments in general (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>), or multiple CF treatments (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>); only three were focused on improving adherence to inhaled therapies only (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). This makes it challenging to draw conclusions on the efficacy of an intervention in relation to the primary or secondary outcomes of the review. </p> <p>Interventions were delivered in a variety of modes, and included individual; face‐to‐face; telephone‐ or paper‐based interventions; or the use of digital technology (e.g. website; mobile application or 'app'; device such as home spirometer). The oldest study in this review delivered the intervention in a group, face‐to‐face setting (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>), but face‐to‐face group interventions are no longer recommended for people with CF due to infection control guidelines (<a href="./references#CD013766-bbs2-0103" title="ConwayS . Segregation is good for patients with cystic fibrosis. Journal of the Royal Society of Medicine2008;101(1):31-5. [DOI: 10.1258/jrsm.2008.s18007]">Conway 2008</a>). </p> <p>A previous Cochrane Review highlighted likely inclusion bias in adherence trials, with participants having higher than average adherence at baseline (<a href="./references#CD013766-bbs2-0161" title="NieuwlaatR , WilczynskiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a>). Some of our included trials reported relatively large numbers of participants who had declined to take part (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>); whilst others did not report this information at all. Some trials also highlighted a possible ceiling effect (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), as their recruited participants had baseline adherence rates already higher than 'real world' adherence (<a href="./references#CD013766-bbs2-0109" title="DanielsT , GoodacreL , SuttonC , PollardK , ConwayS , PeckhamD . Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest2011;140(2):425-32. [DOI: 10.1378/chest.09-3074]">Daniels 2011</a>; <a href="./references#CD013766-bbs2-0132" title="HooZH , TottonN , WaterhouseS , HindD , GirlingC , BradburnM , et al. Understanding objective adherence to preventative inhaled therapies at a centre level for quality improvement - a CFHealthHub (CFHH) improvement collaborative study. Journal of Cystic Fibrosis2019;18:S51-2. [DOI: 10.1016/S1569-1993(19)30283-8]">Hoo 2019</a>; <a href="./references#CD013766-bbs2-0134" title="HooZH , CurleyR , WaltersSJ , CampbellMJ , WildmanMJ . Exploring the implications of different approaches to estimate centre-level adherence using objective adherence data in an adult cystic fibrosis centre – a retrospective observational study. Journal of Cystic Fibrosis2020;19(1):162-7. [DOI: 10.1016/j.jcf.2019.10.008]">Hoo 2020</a>; <a href="./references#CD013766-bbs2-0135" title="HooZH , TottonN , WaterhouseS , LewisJ , GirlingC , BradburnM , et al. Real-world adherence among adults with cystic fibrosis is low: a retrospective analysis of the CFHealthHub digital learning health system. Chest2021;160(6):2061-5. [DOI: 10.1016/j.chest.2021.06.039]">Hoo 2021</a>). If people with higher adherence at baseline are recruited, this reduces the statistical power of trials to detect a difference post‐intervention (as the intervention and control groups will be more similar). This could therefore influence the applicability of the evidence. </p> <p>Lastly, it should be noted that the included trials were conducted prior to the availability of highly‐effective CF transmembrane conductance regulator (CFTR) modulator treatments for many people with CF (e.g. ivacaftor‐tezacaftor‐elexacaftor). These treatments have changed the landscape of CF care, including the relationship that people with CF (and their families) may have with their condition and treatments, their patterns of adherence, as well as clinician views and prescribing practices (<a href="./references#CD013766-bbs2-0123" title="GrangerE , DaviesG , KeoghRH . Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?Journal of Cystic Fibrosis2022;21(2):316-22. [DOI: 10.1016/j.jcf.2021.08.014]">Granger 2022</a>). An ongoing observational study in the UK, the National Efficacy‐Effectiveness Modulator Optimisation (NEEMO) programme, is exploring adherence to inhaled therapies in people with CF before and after commencing modulator treatments, and in those not prescribed modulator treatments (<a href="./references#CD013766-bbs2-0159" title="NCT05519020. Inhaled therapy adherence and outcomes to Kaftrio in cystic fibrosis [Exploring adherence to preventative inhaled therapy and outcomes for people with cystic fibrosis who take ivacaftor/tezacaftor/elexacaftor]. clinicaltrials.gov/ct2/show/NCT05519020 (first posted 29 August 2022).">NCT05519020</a>). It will also look at the relationship between adherence to inhaled therapies and outcomes (e.g. lung function) among adults with CF who are prescribed modulator treatments. Another observational study, the Home‐Reported Outcomes (HERO‐2) study, is taking place in the USA to investigate the changes in lung function among individuals who have made treatment changes after initiating ivacaftor‐tezacaftor‐elexacaftor treatment (<a href="./references#CD013766-bbs2-0158" title="NCT04798014. Home-Reported Outcomes in People With Cystic Fibrosis Taking Highly Effective CFTR Modulator Therapy. clinicaltrials.gov/ct2/show/NCT04798014 (first posted 15 March 2021).">NCT04798014</a>). Additionally, there are ongoing trials investigating the withdrawal of mucolytic treatments following the introduction of CFTR modulator therapy, including CF STORM in the UK (<a href="./references#CD013766-bbs2-0139" title="ISRCTN14081521. Can people with cystic fibrosis safely stop taking some of their nebulised treatments if they are established on the new modulator therapy, Kaftrio?isrctn.com/ISRCTN14081521 (first received 31 March 2021).">ISRCTN14081521</a>) and SIMPLIFY in the USA (<a href="./references#CD013766-bbs2-0157" title="NCT04378153. Impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY) [A master protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY)]. clinicaltrials.gov/ct2/show/NCT04378153 (first posted 7 May 2020).">NCT04378153</a>). </p> </section> <section id="CD013766-sec-0106"> <h3 class="title" id="CD013766-sec-0106">Quality of the evidence</h3> <p>This review draws on data from 10 trials (1642 participants) which include children and adolescents with CF (and their parents or caregivers) or adults with CF. We have concerns regarding risk of bias in several domains in the included trials (<a href="#CD013766-sec-0059">Risk of bias in included studies</a>; <a href="#CD013766-fig-0002">Figure 2</a>). The generation of allocation sequence was unclear in three trials (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) and high in one trial (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>), while allocation concealment was at high risk of bias in two trials (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>) and unclear in five trials (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). Blinding of outcome assessors was unclear in six trials (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>) and high risk in four trials (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). Only three trials had a low risk of bias from incomplete outcome data (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), three trials had an unclear risk (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>), and four trials had a high risk of bias (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). We judged only two trials to have a low risk of bias from selective reporting (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>); the remainder of studies had an unclear (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) or high (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>) risk of bias on this domain. We judged three studies to have a high risk of bias from other potential sources (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>; <a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>), and one had an unclear risk (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). </p> <p>Treatment arms (both intervention and control) were not always described in sufficient detail in terms of the frequency, scheduling, duration, and content of the sessions. Additionally, nine out of 10 included trials reported that participants in the control or comparison group received 'treatment as usual' or 'usual care', but they did not describe what this consisted of, and this is known to vary across countries, across CF centres within countries, and even across individuals within the same CF centre. </p> <p>Most included trials had small sample sizes; seven trials had fewer than 100 participants and many stated they were underpowered (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>). Underpowered trials are more likely to miss a meaningful difference in adherence, even when improving adherence substantially, and showing an effect on clinical outcomes is likely even harder (<a href="./references#CD013766-bbs2-0161" title="NieuwlaatR , WilczynskiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a>). Some trials were feasibility studies but no larger, follow‐on RCT was conducted. Even the largest trial in this review was underpowered to find a difference in medication adherence, due to missing data and attrition (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). </p> <p>Lastly, in some trials, the intervention that was delivered deviated from what was planned in the protocol, e.g. in one trial, most participants only completed 2.5 of the planned four sessions (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>); in another trial, the average use of the daily medication reminder feature of the intervention was only 50.23% (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>); and in two trials, the number of cancelled sessions meant it was not possible to follow the original schedule of intervals between intervention sessions and the programmes had to be extended (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). One trial also reported some challenges with recruitment, with some participants not wanting to commit to Skype video calls or WhatsApp messages (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>). In trials that reported intervention fidelity assessments, scores ranged from 67% (covering a 51% to 80% range across different CF centres) (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>) to 93‐97% (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). This variation could influence the effectiveness of the intervention, as well as the reliability and validity of conclusions drawn. </p> <p>Using GRADE, we found that the overall certainty of the evidence for the comparison of psychological interventions versus usual care at the 'over six months and up to 12 months' time point ranged from low to moderate (<a href="./full#CD013766-tbl-0001">summary of findings Table 1</a>). We deemed the outcomes, adherence to inhaled therapies, lung function, and pulmonary exacerbations to provide moderate‐certainty evidence, downgraded only for indirectness as there was only one trial included at this time point which exclusively included adults (aged 16 years and over), whereas our review question was broader and focused on people with CF of all ages. We deemed the certainty of evidence for treatment‐related adverse events (anxiety and depression) and QoL (treatment burden and respiratory symptoms) to be low, downgraded due to indirectness (as above) and an unclear risk of detection bias. </p> <p>For our second comparison of a psychological intervention (MI) versus an active comparator arm (EPS), we found that the overall certainty of the evidence from a single trial was very low across outcomes at the 'over six months and up to 12 months' time point (<a href="./full#CD013766-tbl-0002">summary of findings Table 2</a>). The outcomes adherence to inhaled therapies, QoL, lung function and pulmonary exacerbations were downgraded due to: imprecision stemming from low participant numbers; indirectness because the trial included only adults (aged 16 years and above); and an unclear risk of selection and attrition bias (and detection bias for QoL, due to outcome assessors not being blinded). The trial did not measure our primary outcome of treatment‐related adverse events (anxiety and depression). </p> </section> <section id="CD013766-sec-0107"> <h3 class="title" id="CD013766-sec-0107">Potential biases in the review process</h3> <p>Any deviations from our published protocol (<a href="./references#CD013766-bbs2-0196" title="DawsonS , CowapL , Clark-CarterD , GirlingC . Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD013766. [DOI: 10.1002/14651858.CD013766]">Dawson 2020</a>) are noted with reasons in '<a href="#CD013766-sec-0122">Differences between protocol and review</a>'. </p> <p>We are confident that our search strategies have identified all relevant trials. The selection of trials, data extraction, risk of bias assessment and BCT coding were independently conducted by at least two authors. Disagreements were resolved by discussion or by consultation with a third review author as necessary. Two review authors who are or were involved with a wider programme of work linked to two included trials, though not the trials themselves, were not involved in the selection, data extraction, risk of bias assessments or BCT coding for these trials (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>While we were successful in obtaining additional information from the authors of five trials (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>; <a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>; <a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), some trials were excluded due to a lack of available information and no response from investigators to our queries. We were unable to obtain additional information or data for some outcomes, e.g. MPR data for individual drugs, or results for participants on inhaled therapies only in trials that reported a composite adherence measure. </p> <p>A strength of the review is the use of the BCT taxonomy to code the 'active ingredients' or components of the interventions. The taxonomy aims to standardise terminology across research and so was useful in categorising the components of the interventions. Previous Cochrane Reviews on adherence (<a href="./references#CD013766-bbs2-0161" title="NieuwlaatR , WilczynskiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a>) and CF‐specific reviews (<a href="./references#CD013766-bbs2-0122" title="GoldbeckL , FidikaA , HerleM , QuittnerAL . Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD003148. [DOI: 10.1002/14651858.CD003148.pub3]">Goldbeck 2014</a>; <a href="./references#CD013766-bbs2-0173" title="SavageE , BeirnePV , Ni ChroininM , DuffA , FitzgeraldT , FarrellD . Self-management education for cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD007641. [DOI: 10.1002/14651858.CD007641.pub3]">Savage 2014</a>) have not used a coding framework, so this review has improved on existing methodologies. Understanding the 'active ingredients' of promising interventions will make it easier to replicate effective interventions; will reduce the potential waste of time and resources on trials of ineffective techniques (<a href="./references#CD013766-bbs2-0149" title="MichieS , FixsenD , GrimshawJM , EcclesMP . Specifying and reporting complex behaviour change interventions: the need for a scientific method. Implementation Science2009;4(40). [DOI: 10.1186/1748-5908-4-40]">Michie 2009</a>); and will inform adherence research in the future (<a href="./references#CD013766-bbs2-0161" title="NieuwlaatR , WilczynskiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a>). </p> <p>However, the coding of BCTs is limited to information reported in the included trials. We contacted all trial authors to request further information (e.g. protocols); only two provided intervention manuals (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>), and the lead author of one trial provided the intervention worksheets which could be coded (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>). Consequently, we could not code some potential BCTs in the included trials due to there being insufficient details reported. This might mean that some BCTs were used in the interventions but have not been described in this review. This highlights the need for more clarity and transparency in the reporting of interventions (<a href="./references#CD013766-bbs2-0149" title="MichieS , FixsenD , GrimshawJM , EcclesMP . Specifying and reporting complex behaviour change interventions: the need for a scientific method. Implementation Science2009;4(40). [DOI: 10.1186/1748-5908-4-40]">Michie 2009</a>). </p> </section> <section id="CD013766-sec-0108"> <h3 class="title" id="CD013766-sec-0108">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, this is the only systematic review to investigate the effectiveness of psychological interventions for improving adherence to inhaled therapies in people with CF. This is also the first review to examine the BCTs used in interventions with people with CF. </p> <p>Three of our included trials were also included in two other Cochrane Reviews. Two trials (<a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a>; <a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) were included in a review of self‐management education for CF (<a href="./references#CD013766-bbs2-0173" title="SavageE , BeirnePV , Ni ChroininM , DuffA , FitzgeraldT , FarrellD . Self-management education for cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD007641. [DOI: 10.1002/14651858.CD007641.pub3]">Savage 2014</a>). In contrast to the <a href="./references#CD013766-bbs2-0173" title="SavageE , BeirnePV , Ni ChroininM , DuffA , FitzgeraldT , FarrellD . Self-management education for cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD007641. [DOI: 10.1002/14651858.CD007641.pub3]">Savage 2014</a> review, we judged these two studies to have a high risk of bias from incomplete outcome data (attrition bias), whereas <a href="./references#CD013766-bbs2-0173" title="SavageE , BeirnePV , Ni ChroininM , DuffA , FitzgeraldT , FarrellD . Self-management education for cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD007641. [DOI: 10.1002/14651858.CD007641.pub3]">Savage 2014</a> judged them to have an unclear risk of bias for this domain. We also assessed treatment‐related adverse events (anxiety and depression) in our review, which <a href="./references#CD013766-bbs2-0173" title="SavageE , BeirnePV , Ni ChroininM , DuffA , FitzgeraldT , FarrellD . Self-management education for cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD007641. [DOI: 10.1002/14651858.CD007641.pub3]">Savage 2014</a> did not. The <a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a> trial was included in a review of psychological interventions for individuals with CF and their families (<a href="./references#CD013766-bbs2-0122" title="GoldbeckL , FidikaA , HerleM , QuittnerAL . Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD003148. [DOI: 10.1002/14651858.CD003148.pub3]">Goldbeck 2014</a>). The <a href="./references#CD013766-bbs2-0122" title="GoldbeckL , FidikaA , HerleM , QuittnerAL . Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD003148. [DOI: 10.1002/14651858.CD003148.pub3]">Goldbeck 2014</a> review judged the Quinn trial to have an unclear risk of bias from allocation concealment (selection bias), and a low risk of bias from blinding (performance bias and detection bias). In contrast, we judged this trial to have a low risk of bias in relation to allocation concealment, and an unclear risk of bias from blinding of outcome assessors (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). These discrepancies might be explained by us being able to obtain additional information from unpublished data (thesis), in addition to the conference abstract for this trial (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>). </p> <p>This review is in agreement with other, CF‐related reviews and general adherence reviews, which have highlighted the limitations of many included trials in terms of having small sample sizes and being underpowered to detect a meaningful difference in adherence (<a href="./references#CD013766-bbs2-0122" title="GoldbeckL , FidikaA , HerleM , QuittnerAL . Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD003148. [DOI: 10.1002/14651858.CD003148.pub3]">Goldbeck 2014</a>; <a href="./references#CD013766-bbs2-0161" title="NieuwlaatR , WilczynskiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a>). </p> <p>Our review was more specific and focused on adherence to inhaled therapies in CF in particular, more so than the Cochrane Review of psychological interventions for individuals with CF and their families (<a href="./references#CD013766-bbs2-0122" title="GoldbeckL , FidikaA , HerleM , QuittnerAL . Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD003148. [DOI: 10.1002/14651858.CD003148.pub3]">Goldbeck 2014</a>). The <a href="./references#CD013766-bbs2-0122" title="GoldbeckL , FidikaA , HerleM , QuittnerAL . Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD003148. [DOI: 10.1002/14651858.CD003148.pub3]">Goldbeck 2014</a> review was more general and, although adherence to treatment was assessed as a secondary outcome, interventions were focused on a range of outcomes, e.g. well‐being and functioning, lung function, weight and height or body mass index (BMI), adherence to treatment etc. (<a href="./references#CD013766-bbs2-0122" title="GoldbeckL , FidikaA , HerleM , QuittnerAL . Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD003148. [DOI: 10.1002/14651858.CD003148.pub3]">Goldbeck 2014</a>). The authors in that review categorised the different types of interventions into 1. Cognitive behavioural; 2. Cognitive; 3. Family systems or systemic; 4. Psychodynamic; or 5. Other interventions. We did not predefine the eligible types of psychological interventions in our protocol (<a href="./references#CD013766-bbs2-0196" title="DawsonS , CowapL , Clark-CarterD , GirlingC . Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD013766. [DOI: 10.1002/14651858.CD013766]">Dawson 2020</a>), as psychological interventions are often wide‐ranging and varied, and we did not want to limit the scope of the review. We did, however, look beyond psychological interventions in the traditional sense (such as cognitive behavioural therapy) and included psychological interventions delivered via therapy, as well as those focused more specifically on behaviour change. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013766-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013766-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013766-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 1: Adherence ‐ percentage of prescribed inhaled therapies taken (objective recorded measures)" data-id="CD013766-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 1: Adherence ‐ percentage of prescribed inhaled therapies taken (objective recorded measures) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 2: Adherence ‐ percentage of prescribed inhaled therapies taken (objective recorded measures ‐ adjusted mean difference)" data-id="CD013766-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 2: Adherence ‐ percentage of prescribed inhaled therapies taken (objective recorded measures ‐ adjusted mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 3: Adherence ‐ percentage of prescribed inhaled therapies taken (subjective measures)" data-id="CD013766-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 3: Adherence ‐ percentage of prescribed inhaled therapies taken (subjective measures) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 4: Adherence to dornase alfa" data-id="CD013766-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 4: Adherence to dornase alfa </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 5: Adherence to inhaled antibiotics (mean score on MMAS‐8)" data-id="CD013766-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 5: Adherence to inhaled antibiotics (mean score on MMAS‐8) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 6: Adherence to inhaled steroids (subjective measure)" data-id="CD013766-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 6: Adherence to inhaled steroids (subjective measure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 7: Adherence to hypertonic saline (subjective measure)" data-id="CD013766-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 7: Adherence to hypertonic saline (subjective measure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 8: Adherence to bronchodilators (subjective measure)" data-id="CD013766-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 8: Adherence to bronchodilators (subjective measure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 9: Anxiety (endpoint data)" data-id="CD013766-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 9: Anxiety (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 10: Anxiety (adjusted mean difference)" data-id="CD013766-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 10: Anxiety (adjusted mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 11: Depression (endpoint data)" data-id="CD013766-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 11: Depression (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 12: Depression (adjusted mean difference)" data-id="CD013766-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 12: Depression (adjusted mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 13: QoL: Quality of Well‐being scale (mean score)" data-id="CD013766-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 13: QoL: Quality of Well‐being scale (mean score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 14: QoL: Physical functioning (endpoint data)" data-id="CD013766-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 14: QoL: Physical functioning (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 15: QoL: Physical functioning (adjusted data)" data-id="CD013766-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 15: QoL: Physical functioning (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 16: QoL: Emotional functioning (endpoint data)" data-id="CD013766-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 16: QoL: Emotional functioning (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 17: QoL: Emotional functioning (adjusted data)" data-id="CD013766-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 17: QoL: Emotional functioning (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 18: QoL: Social functioning (endpoint data)" data-id="CD013766-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 18: QoL: Social functioning (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 19: QoL: Social functioning (adjusted data)" data-id="CD013766-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 19: QoL: Social functioning (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 20: QoL: Treatment burden (endpoint data)" data-id="CD013766-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 20: QoL: Treatment burden (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 21: QoL: Treatment burden (adjusted data)" data-id="CD013766-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 21: QoL: Treatment burden (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 22: QoL: Role limitations (endpoint data)" data-id="CD013766-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 22: QoL: Role limitations (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 23: QoL: Role limitations (adjusted data)" data-id="CD013766-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 23: QoL: Role limitations (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 24: QoL: Body image (endpoint data)" data-id="CD013766-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 24: QoL: Body image (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 25: QoL: Body image (adjusted data)" data-id="CD013766-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 25: QoL: Body image (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 26: QoL: Vitality (endpoint data)" data-id="CD013766-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 26: QoL: Vitality (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 27: QoL: Vitality (adjusted data)" data-id="CD013766-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 27: QoL: Vitality (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 28: QoL: Eating disturbance (endpoint data)" data-id="CD013766-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 28: QoL: Eating disturbance (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 29: QoL: Eating disturbance (adjusted data)" data-id="CD013766-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 29: QoL: Eating disturbance (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 30: QoL: Weight problems (endpoint data)" data-id="CD013766-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 30: QoL: Weight problems (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 31: QoL: Weight problems (adjusted data)" data-id="CD013766-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 31: QoL: Weight problems (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 32: QoL: Respiratory symptoms (endpoint data)" data-id="CD013766-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 32: QoL: Respiratory symptoms (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 33: QoL: Respiratory symptoms (adjusted data)" data-id="CD013766-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 33: QoL: Respiratory symptoms (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 34: QoL: Digestive symptoms (endpoint data)" data-id="CD013766-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 34: QoL: Digestive symptoms (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 35: QoL: Digestive symptoms (adjusted data)" data-id="CD013766-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 35: QoL: Digestive symptoms (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 36: QoL: Health perceptions (endpoint data)" data-id="CD013766-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 36: QoL: Health perceptions (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 37: QoL: Health perceptions (adjusted data)" data-id="CD013766-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 37: QoL: Health perceptions (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 38: QoL: Treatment issues (endpoint data)" data-id="CD013766-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 38: QoL: Treatment issues (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 39: QoL: Career concerns (endpoint data)" data-id="CD013766-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 39: QoL: Career concerns (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.40" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 40: QoL: Interpersonal relationships (endpoint data)" data-id="CD013766-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.40.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.40.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 40: QoL: Interpersonal relationships (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.40.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.41" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 41: QoL: Concerns for the future (endpoint data)" data-id="CD013766-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.41.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.41.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 41: QoL: Concerns for the future (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.41.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.42" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 42: FEV1 % predicted (endpoint data)" data-id="CD013766-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.42.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.42.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 42: FEV1 % predicted (endpoint data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.42.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.43" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 43: FEV1 % predicted (adjusted mean difference)" data-id="CD013766-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.43.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.43.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 43: FEV1 % predicted (adjusted mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.43.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.44" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 44: Number of pulmonary exacerbations" data-id="CD013766-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.44.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.44.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 44: Number of pulmonary exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.44.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.45" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 45: Pulmonary exacerbations incidence rate (unadjusted data)" data-id="CD013766-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.45.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.45.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 45: Pulmonary exacerbations incidence rate (unadjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.45.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013766-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/urn:x-wiley:14651858:media:CD013766:CD013766-CMP-001.46" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological interventions versus usual care, Outcome 46: Pulmonary exacerbations incidence rate (adjusted data)" data-id="CD013766-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.46.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_t/tCD013766-CMP-001.46.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1: Psychological interventions versus usual care, Outcome 46: Pulmonary exacerbations incidence rate (adjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/media/CDSR/CD013766/image_n/nCD013766-CMP-001.46.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013766-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: psychological interventions compared with usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychological interventions compared with usual care for improving adherence to inhaled therapies in people with CF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children, adolescents or adults with CF </p> <p><b>Settings</b>: single or multicentre; UK‐, USA‐ or Denmark‐based; hospital, clinic or community </p> <p><b>Intervention</b>: psychological interventions (self‐management intervention comprising digital platform and behaviour change sessions; life coaching intervention; problem‐solving intervention) </p> <p><b>Comparison</b>: usual care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Usual care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Psychological interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adherence to inhaled therapies: % of prescribed inhaled therapies taken</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The adjusted mean % of prescribed inhaled therapies taken was 9.50% higher in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.50 (8.60 to 10.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>588 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An objective recorded measure (using data‐logging nebulisers) where a higher score indicates higher adherence. </p> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐related adverse events</b> </p> <p><b>Anxiety:</b> </p> <p>GAD‐7 (<a href="./references#CD013766-bbs2-0183" title="SpitzerRL , KroenkeK , WilliamsJBW , LöweB . A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine2006;166(10):1092-7. [DOI: 10.1001/archinte.166.10.1092]">Spitzer 2006</a>) </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The adjusted mean anxiety score was 0.3 higher in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.30 (‐0.40 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>535 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Scale from: 0 to 21 (higher score indicates greater anxiety).</p> <p>No evidence of treatment‐related adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐related adverse events</b> </p> <p><b>Depression</b> </p> <p>PHQ‐8 (<a href="./references#CD013766-bbs2-0143" title="KroenkeK , StrineTW , SpritzerRL , WilliamsJB , BerryJT , MokdadAH . The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders2009;114(1-3):163-73. [DOI: 10.1016/j.jad.2008.06.026]">Kroenke 2009</a>) </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The adjusted mean depression score was 0.10 lower in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.10 (‐0.80 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>534 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Scale from: 0 to 24 (higher score indicates greater depression).</p> <p>No evidence of treatment‐related adverse events.</p> <p>One other study assessed depression using 2 measures at this time point (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). This study also found no difference between groups on any depression measure. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>QoL</b> </p> <p>CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Treatment burden</b> </p> <p>The adjusted mean treatment burden score was 3.90 higher in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.90 (1.20 to 6.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>539 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Scale from: 0 to 100 (higher score indicates better QoL).</p> <p>2 other studies assessed treatment burden at this time point (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). These 2 studies found no difference between groups. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Respiratory symptoms</b> </p> <p>The adjusted mean score for respiratory symptoms was 0.70 higher in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.70 (‐2.40 to 3.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>534 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>Scale from: 0 to 100 (higher score indicates better QoL).</p> <p>No difference between groups.</p> <p>2 other studies assessed respiratory symptoms at this time point (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). These 2 studies also found no difference between groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lung function</b> </p> <p>FEV<sub>1</sub> % predicted </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The adjusted mean FEV<sub>1</sub> score was 1.40% predicted higher in the intervention group compared to usual care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.40 (‐0.20 to 3.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>556 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We report an adjusted MD; adjusted data<sup>c</sup> taken directly from the study (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>A higher score indicates better lung function.</p> <p>No difference between groups.</p> <p>2 other studies assessed FEV<sub>1</sub>% predicted at this time point (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>; <a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). Post‐intervention data were not available in 1 study, so results have been reported narratively (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>); no intervention effects were found for any of the secondary outcomes compared to usual care (and FEV<sub>1</sub>% predicted was a secondary outcome). The other study also found no difference between groups (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>In one trial, there were 526 exacerbations in the control arm (adjusted rate 1.77/year, n = 303) compared with 482 in the intervention arm (1.63/year, n = 304). There was no difference between groups in exacerbation incidence rates (adjusted<sup>e</sup> RR 0.96, 95% CI 0.83 to 1.11; unadjusted RR 0.92, 95% CI 0.77 to 1.10) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>607 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this study, pulmonary exacerbations were defined as "Number of exacerbations treated with IV antibiotics with at least 1 modified Fuchs’ criteria (e.g. change in sputum, increased cough) (<a href="./references#CD013766-bbs2-0168" title="RatjenF , DurhamT , NavratilT , SchabergA , AccursoFJ , Wainwright C et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis2012;11(6):539-49. [DOI: 10.1016/j.jcf.2012.05.003]">Ratjen 2012</a>)." The authors reported that incidence RRs indicated no between‐group difference in exacerbations (MD 0.96 (95% CI 0.83 to 1.12); P = 0.64) (<a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a>). </p> <p>One other study assessed pulmonary exacerbations at this time point (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). Post‐intervention data were not available in this study and results have been reported narratively. It was also unclear how this study defined exacerbations. The authors did however report that no intervention effect was found for pulmonary exacerbations (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CF: cystic fibrosis; CFQ‐R: Cystic Fibrosis Questionnaire‐Revised (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>); CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume at 1 second; GAD‐7: Generalized Anxiety Disorder‐7 (<a href="./references#CD013766-bbs2-0183" title="SpitzerRL , KroenkeK , WilliamsJBW , LöweB . A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine2006;166(10):1092-7. [DOI: 10.1001/archinte.166.10.1092]">Spitzer 2006</a>); IV: intravenous; MD: mean difference; PHQ‐8: Patient Health Questionnaire‐8 (<a href="./references#CD013766-bbs2-0143" title="KroenkeK , StrineTW , SpritzerRL , WilliamsJB , BerryJT , MokdadAH . The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders2009;114(1-3):163-73. [DOI: 10.1016/j.jad.2008.06.026]">Kroenke 2009</a>); QoL: quality of life; RR: rate ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Non‐blinding of outcome assessors would not affect the results as it is an objective measure, so no need to downgrade.<br/><sup>b</sup>Downgraded once due to indirectness. The evidence includes only adults with CF aged 16 years and older, and was not designed to answer the specific question posed in this review.<br/><sup>c</sup>The post‐intervention MDs are adjusted for past year IV antibiotic days, CF centre, and outcome measure at baseline.<br/><sup>d</sup>Downgraded once due to unclear risk of detection bias, as outcome assessors were not blinded.<br/><sup>e</sup>The post‐intervention MDs are adjusted for CF centre and past year IV antibiotic days. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: psychological interventions compared with usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013766-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: psychological interventions compared with an active comparator</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychological interventions compared with an active comparator intervention (e.g. education plus problem‐solving; EPS) for improving adherence to inhaled therapies in people with cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults (aged 16 years and over) with CF </p> <p><b>Settings</b>: single CF centre in the USA </p> <p><b>Intervention</b>: psychological intervention (MI) </p> <p><b>Comparison</b>: active comparator (EPS) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Active comparator (EPS)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Psychological intervention (MI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adherence to inhaled therapies cMPR</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Please see comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An objective‐count measure (cMPR), which included inhaled therapies (dornase alfa, hypertonic saline, inhaled tobramycin, and aztreonam), as well as one non‐inhaled treatment (azithromycin). </p> <p>This study reported only medians and IQRs (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). At 12 months, median (IQR) cMPR was 54 (37 to 73) in the MI group, compared with 51 (17 to 71) in the EPS group. The study authors also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that no intervention effects were found for the cMPR (P = 0.763; no effect size reported or calculable) or any of the individual drugs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐related adverse events</b> </p> <p><b>Anxiety</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐related adverse events</b> </p> <p><b>Depression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>CFQ‐R (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Please see comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scale from: 0 to 100 (higher score indicates better QoL)</p> <p>This study reported only medians and IQRs for QoL, measured using 3 domains of the CFQ‐R (respiratory, physical functioning, and treatment burden) (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). At 12 months, median (IQR) score was 67 (50 to 83) in the MI group and 67 (50 to 72) in the EPS group (respiratory); 79 (60 to 96) in the MI group and 79 (54 to 96) in the EPS group (physical functioning); and 56 (44 to 67) in the MI group and 56 (44 to 78) in the EPS group (treatment burden). The investigators also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that no intervention effects were found for QoL at this time point. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lung function</b> FEV<sub>1</sub> % predicted </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Please see comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A higher score indicates better lung function.</p> <p>This study reported only medians and IQRs (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). At 12 months, median (IQR) FEV<sub>1</sub>% predicted was 66% (48 to 85%) in the MI group and 64% (49 to 84%) in the EPS group. The authors also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that the intervention had no effect on lung function (P = 0.773; no effect size reported or calculable). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Please see comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study reported the percentage of people in each group with at least 1 exacerbation in the past year (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>). Method of assessing exacerbations not reported. We calculated the number of participants in each group who had experienced an exacerbation over the 12‐month study period. In the MI group, 12 out of 63 participants (19%) experienced an exacerbation compared with 12 out of 65 (18%) in the EPS group. The study authors also assessed whether there was an effect of the intervention between groups (MI and EPS) over time (baseline and 12 months); they reported that the intervention had no effect on pulmonary exacerbations (P = 0.929; no effect size reported or calculable). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CF: cystic fibrosis; CFQ‐R: Cystic Fibrosis Questionnaire‐Revised (<a href="./references#CD013766-bbs2-0165" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>); cMPR: composite medication possession ratio; EPS: education plus problem‐solving; FEV<sub>1</sub>: forced expiratory volume at 1 second; IQR: interquartile range; MI: motivational interviewing; QoL: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for imprecision; relatively small participant numbers which do not meet the optimal information size.<br/><sup>b</sup>Downgraded once due to indirectness. The evidence includes only adults with CF aged 16 years and older, and was not designed to answer the specific question posed in this review.<br/><sup>c</sup>Downgraded once due to unclear risk of selection bias and attrition bias.<br/><sup>d</sup>Downgraded once due to unclear risk of selection bias (not reported), attrition bias (withdrawals not described), and detection bias (outcome assessors not blinded). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: psychological interventions compared with an active comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013766-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Behaviour change techniques present in included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention arm</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control arm</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0001" title="CottrellCK , YoungGA , CreerTL , HolroydKA , KotsesH . The development and evaluation of a self-management program for cystic fibrosis. Pediatric Asthma, Allergy &amp; Immunology1996;10(3):109-18. [CENTRAL: CN-01412414] [CFGD REGISTER: MH31a] [DOI: 10.1089/pai.1996.10.109]CottrellCK . The effects of self-management training in children/adolescents with cystic fibrosis. Unpublished doctoral dissertation, Ohio University, Ohio, USA (first received 1994). [CENTRAL: CN-01412369] [CFGD REGISTER: MH31b] ">Cottrell 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0011"> <li> <p>1.2 Problem solving</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> <li> <p>9.1 Credible source</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0012"> <li> <p>1.1 Goal setting (behaviour)</p> </li> <li> <p>1.2 Problem solving</p> </li> <li> <p>1.3 Goal setting (outcome)</p> </li> <li> <p>1.4 Action planning</p> </li> <li> <p>1.6 Discrepancy between current behaviour and goal</p> </li> <li> <p>1.9 Commitment</p> </li> <li> <p>2.3 Self‐monitoring of behaviour</p> </li> <li> <p>3.1 Social support (unspecified)</p> </li> <li> <p>3.2 Social support (practical)</p> </li> <li> <p>3.3 Social support (emotional)</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> <li> <p>5.1 Information about health consequences</p> </li> <li> <p>5.2 Salience of consequences</p> </li> <li> <p>6.1 Demonstration of the behaviour</p> </li> <li> <p>6.3 Information about others' approval</p> </li> <li> <p>7.1 Prompts/cues</p> </li> <li> <p>8.1 Behavioural practice/rehearsal</p> </li> <li> <p>8.3 Habit formation</p> </li> <li> <p>9.1 Credible source</p> </li> <li> <p>9.2 Pros and cons</p> </li> <li> <p>10.3 Non‐specific reward</p> </li> <li> <p>10.4 Social reward</p> </li> <li> <p>10.7 Self‐incentive</p> </li> <li> <p>10.9 Self‐reward</p> </li> <li> <p>11.2 Reduce negative emotions</p> </li> <li> <p>12.5 Adding objects to the environment</p> </li> <li> <p>13.2 Framing/ reframing</p> </li> <li> <p>15.1 Verbal persuasion about capability</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0013"> <li> <p>1.2 Problem‐solving</p> </li> <li> <p>2.1 Monitoring of behaviour by others without feedback</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0014"> <li> <p>1.1 Goal setting (behaviour)</p> </li> <li> <p>1.2 Problem solving</p> </li> <li> <p>1.4 Action planning</p> </li> <li> <p>1.5 Review behavioural goal(s)</p> </li> <li> <p>1.6 Discrepancy between current behaviour and goal</p> </li> <li> <p>2.2 Feedback on behaviour</p> </li> <li> <p>2.3 Self‐monitoring of behaviour</p> </li> <li> <p>3.2 Social support (practical)</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> <li> <p>5.1 Information about health consequences</p> </li> <li> <p>5.2 Salience of consequences</p> </li> <li> <p>6.1 Demonstration of the behaviour</p> </li> <li> <p>7.1 Prompts/cues</p> </li> <li> <p>8.1 Behavioural practice/rehearsal</p> </li> <li> <p>8.3 Habit formation</p> </li> <li> <p>8.7 Graded tasks</p> </li> <li> <p>9.1 Credible source</p> </li> <li> <p>10.4 Social reward</p> </li> <li> <p>12.1 Restructure the physical environment</p> </li> <li> <p>12.5 Adding objects to the environment</p> </li> <li> <p>15.3 Focus on past success</p> </li> <li> <p>15.4 Self‐talk</p> </li> <li> <p>16.3 Vicarious consequences</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0015"> <li> <p>3.1 Social support (unspecified)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0016"> <li> <p>1.2 Problem solving</p> </li> <li> <p>3.1 Social support (unspecified)</p> </li> <li> <p>9.2 Pros and cons</p> </li> <li> <p>13.3 Incompatible beliefs</p> </li> <li> <p>12.1 Restructuring the physical environment</p> </li> <li> <p>12.2 Restructuring the social environment</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0017"> <li> <p>1.2 Problem solving;</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0018"> <li> <p>2.2 Feedback on behaviour</p> </li> <li> <p>2.7 Feedback on outcome(s) of behaviour</p> </li> <li> <p>3.1 Social support (unspecified)</p> </li> <li> <p>5.1 Information about health consequences</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0019"> <li> <p>1.2 Problem solving</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> <li> <p>10.4 Social reward</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0020"> <li> <p>2.4 Self‐monitoring of outcome(s) of behaviour</p> </li> <li> <p>2.6 Biofeedback</p> </li> <li> <p>7.1 Prompts/cues</p> </li> <li> <p>12.5 Adding objects to the environment</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013766-list-0021"> <li> <p>1.1 Goal setting (behaviour)</p> </li> <li> <p>1.2 Problem solving</p> </li> <li> <p>1.4 Action planning</p> </li> <li> <p>1.5 Review behavioural goal(s)</p> </li> <li> <p>1.6 Discrepancy between current behaviour and goal</p> </li> <li> <p>2.2 Feedback on behaviour</p> </li> <li> <p>2.3 Self‐monitoring of behaviour</p> </li> <li> <p>3.2 Social support (practical)</p> </li> <li> <p>4.1 Instruction on how to perform the behaviour</p> </li> <li> <p>5.1 Information about health consequences</p> </li> <li> <p>5.2 Salience of consequences</p> </li> <li> <p>6.1 Demonstration of the behaviour</p> </li> <li> <p>7.1 Prompts/cues</p> </li> <li> <p>8.1 Behavioural practice/rehearsal</p> </li> <li> <p>8.3 Habit formation</p> </li> <li> <p>8.7 Graded tasks</p> </li> <li> <p>9.1 Credible source</p> </li> <li> <p>10.4 Social reward</p> </li> <li> <p>12.1 Restructure the physical environment</p> </li> <li> <p>12.5 Adding objects to the environment</p> </li> <li> <p>15.3 Focus on past success</p> </li> <li> <p>15.4 Self‐talk</p> </li> <li> <p>16.3 Vicarious consequences</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (usual care)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Used TIDiER description supplied by authors in study protocol ‐ note these behaviour change techniques were assigned by the authors and we have made no amendments. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Behaviour change techniques present in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013766-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Definitions and illustrative quotations of behaviour change techniques present in one or more of the included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BCT present</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BCT category</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BCT definition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of studies present in</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative quotations</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1. Goal setting (behavior)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Set or agree on a goal defined in terms of the behavior to be achieved</p> <p><i>Note: only code goal‐setting if there is sufficient evidence that goal set as part of intervention; if goal unspecified or a behavioral outcome, code 1.3, Goal setting (outcome); if the goal defines a specific context, frequency, duration or intensity for the behavior, also code 1.4, Action planning</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0022"> <li> <p>Indication of goal line on charts of adherence</p> </li> <li> <p>Visual indication of goal met on CFHealthHub</p> </li> <li> <p>(Optional) weekly push notifications indicating whether goal was met</p> </li> <li> <p>(Optional) reward messages sent when goal met</p> </li> </ul> </p> <p>Interventionist:</p> <p> <ul id="CD013766-list-0023"> <li> <p>Discussion and agreement of goals with interventionist." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2. Problem solving</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analyse, or prompt the person to analyse, factors influencing the behavior and generate or select strategies that include overcoming barriers and/or increasing facilitators (includes Relapse Prevention and Coping Planning) </p> <p><i>Note: barrier identification without solutions is not sufficient. If the BCT does not include analysing the behavioral problem, consider 12.3, Avoidance/changing exposure to cues for the behavior, 12.1, Restructuring the physical environment, 12.2, Restructuring the social environment, or 11.2, Reduce negative emotions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This intervention involves a member of the multidisciplinary team working with the adolescent to identify barriers to daily treatments and brainstorm solutions to those barriers with their parent." (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3. Goal setting (outcome)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Set or agree on a goal defined in terms of a positive outcome of wanted behavior</p> <p><i>Note: only code guidelines if set as a goal in an intervention context; if goal is a behavior, code 1.1, Goal setting (behavior); if goal unspecified code 1.3, Goal setting (outcome)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Plan</p> <p>What you want to get out of something is called a goal.</p> <p>What would you like to get out of doing this program?</p> <p>Set goals about doing chest treatments and doing this program.</p> <p>Some goals are already written into the boxes below. Highlight the goals you would like and write any others you’d like in the empty boxes." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4. Action planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt detailed planning of performance of the behavior (must include at least one of context, frequency, duration and intensity). Context may be environmental (physical or social) or internal (physical, emotional or cognitive) (includes Implementation Intentions) </p> <p><i>Note: evidence of action planning does not necessarily imply goal setting, only code latter if sufficient evidence</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:<br/>• Action planning tool and storage within<br/>CFHealthHub." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5. Review behavior goal(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review behavior goal(s) jointly with the person and consider modifying goal(s) or behavior change strategy in light of achievement. This may lead to re‐setting the same goal, a small change in that goal or setting a new goal instead of (or in addition to) the first, or no change </p> <p><i>Note: if goal specified in terms of behavior, code 1.5, Review behavior goal(s), if goal unspecified, code 1.7, Review outcome goal(s); if discrepancy created consider also 1.6, Discrepancy between current behavior and goal</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Interventionist:<br/>• Discussion and agreement of goals with<br/>interventionist<br/>• Review of goals<br/>• Suggested steady increase in goal as improvements are made<br/>• Feedback and social reward on progress." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6. Discrepancy between current behavior and goal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Draw attention to discrepancies between a person's current behavior (in terms of the form, frequency, duration, or intensity of that behavior) and the person's previously set outcome goals, behavioral goals or action plans (goes beyond self‐monitoring of behavior) </p> <p><i>Note: if discomfort is created, only code:</i> <br/><i>13.3, Incompatible beliefs and not 1.6, Discrepancy between current behavior and goal; if goals are modified, also code</i> <br/><i>1.5, Review behavior goal(s) and/or 1.7, Review outcome goal(s); if feedback is provided, also code 2.2, Feedback on behaviour</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0024"> <li> <p>Indication of goal line on charts of adherence</p> </li> <li> <p>Visual indication of goal met on CFHealthHub</p> </li> <li> <p>(Optional) Weekly push notifications indicating whether goal was met</p> </li> <li> <p>(Optional) Reward messages sent when goal met</p> </li> </ul> </p> <p>Interventionist:</p> <p> <ul id="CD013766-list-0025"> <li> <p>Discussion and agreement of goals with interventionist</p> </li> <li> <p>Review of goals</p> </li> <li> <p>Suggested steady increase in goal as improvements are made." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9. Commitment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Goals and planning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ask the person to affirm or reaffirm statements indicating commitment to change the behavior </p> <p><i>Note: if defined in terms of the behavior to be achieved also code 1.1, Goal setting (behavior)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Practise remembering, fitting in and doing your puffer, nebuliser and ACT treatments.</p> <p>The chest treatments that I need to remember, fit in and do are: ___________________, ____times/day." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1 Monitoring of behaviour by others without feedback</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observe or record behaviour with the person's knowledge as part of a behaviour change strategy. </p> <p><i>Note: if monitoring is part of a data collection procedure rather than a strategy aimed at changing behaviour, do not code; if feedback given, code only 2.2, Feedback on behaviour, and not 2.1, Monitoring of behaviour by others without feedback; if monitoring outcome(s) code 2.5, Monitoring outcome(s) of behaviour by others without feedback; if self‐monitoring behaviour, code 2.3, Self‐monitoring of behaviour.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The interviewer will assess adherence over the week prior to the chat..." (<a href="./references#CD013766-bbs2-0003" title="GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (WhatsApp and Skype based communication) in patients with cystic fibrosis. Journal of Cystic Fibrosis2016;15 Suppl 1:S109. [CENTRAL: CN-01334187] [CFGD REGISTER: MH46b] [EMBASE: 614323572]GurM , NirV , TeleshovA , Bar-YosephR , ManorE , DiabG , et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare2017;23(4):489-93. [CENTRAL: CN-01412392] [CFGD REGISTER: MH46a] [PMID: 27177869]">Gur 2016</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2. Feedback on behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monitor and provide informative or evaluative feedback on performance of the behavior <i>(e.g. form, frequency, duration, intensity)</i> </p> <p><i>Note: if Biofeedback, code only 2.6, Biofeedback and not 2.2, Feedback on behavior; if feedback is on outcome(s) of behavior, code 2.7, Feedback on outcome(s) of behavior; if there is no clear evidence that feedback was given, code 2.1, Monitoring of behavior by others without feedback; if feedback on behaviour is evaluative e.g. praise, also code 10.4, Social reward</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic‐level figures showing the association between adherence and health outcomes." (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3. Self‐monitoring of behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Establish a method for the person to monitor and record their behavior(s) as part of a behavior change strategy </p> <p><i>Note: if monitoring is part of a data collection procedure rather than a strategy aimed at changing behavior, do not code; if monitoring of outcome of behavior, code 2.4, Self‐monitoring of outcome(s) of behavior; if monitoring is by someone else (without feedback), code 2.1, Monitoring of behavior by others without feedback</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0026"> <li> <p>Charts and tables of objective adherence data presented within CFHealthHub</p> </li> </ul> </p> <p>Interventionist:</p> <p> <ul id="CD013766-list-0027"> <li> <p>Introducing and explaining charts and tables to participants." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4. Self‐monitoring of outcome(s) of behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Establish a method for the person to monitor and record the outcome(s) of their behavior as part of a behavior change strategy </p> <p><i>Note: if monitoring is part of a data collection procedure rather than a strategy aimed at changing behavior, do not code ; if monitoring behavior, code 2.3, Self‐monitoring of behavior; if monitoring is by someone else (without feedback), code 2.5, Monitoring outcome(s) of behavior by others without feedback</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Subjects in this group were asked to use the Spiro PD personal spirometer to check their lung function once a week for 3 months." (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6. Biofeedback</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provide feedback about the body (e.g. physiological or biochemical state) using an external monitoring device as part of a behavior change strategy </p> <p><i>Note: if Biofeedback, code only 2.6, Biofeedback and not 2.2, Feedback on behavior or 2.7, Feedback on outcome(s) of behaviour</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Participants were trained on the appropriate use of their device at the time of enrollment. They also <b>r</b>eceived weekly telephone calls from a respiratory therapist to review that week's lung function results." (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7. Feedback on outcome(s) of behavior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Feedback and monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monitor and provide feedback on the outcome of performance of the behavior</p> <p><i>Note: if Biofeedback, code only 2.6, Biofeedback and not 2.7, Feedback on outcome(s) of behavior; if feedback is on behavior code 2.2, Feedback on behavior; if there is no clear evidence that feedback was given code 2.5, Monitoring outcome(s) of behavior by others without feedback; if feedback on behaviour is evaluative e.g. praise, also code 10.4, Social reward</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g. trajectory of lung function values, frequency of exacerbations) as well as clinic‐level figures showing the association between adherence and health outcomes." (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1. Social support (unspecified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Social support</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise on, arrange or provide social support (e.g. from friends, relatives, colleagues, 'buddies' or staff) or noncontingent praise or reward for performance of the behavior. It includes encouragement and counselling, but only when it is directed at the behavior </p> <p><i>Note: attending a group class and/or mention of 'follow‐up' does not necessarily apply this BCT, support must be explicitly mentioned; if practical, code 3.2, Social support (practical); if emotional, code 3.3, Social support (emotional) (includes 'Motivational interviewing' and 'Cognitive Behavioral Therapy')</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The coaching intervention included the following elements: client‐centeredness, empathy and collaboration, focus on preferences, reflective dialogue, use of positive language, and promotion of capacity and self‐determination. Sessions included different tools; for example, “the wheel of life” on which coachees could rate their level of satisfaction in different life areas." (<a href="./references#CD013766-bbs2-0005" title="KnudsenKB , BoisenKA , KatzensteinTL , MortensenLH , PresslerT , SkovM , et al. Living with cystic fibrosis - a qualitative study of a life coaching intervention. Patient Preference and Adherence2018;12:585-94. [CFGD REGISTER: MH48c] [DOI: 10.2147/PPA.S159306]KnudsenKB , PresslerT , MortensenLH , BoisenKA , SkovM , QuittnerAL , et al. Coach to cope: feasibility of a coaching intervention for young adults with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:464-5. [CENTRAL: CN-01212563] [CFGD REGISTER: MH48a] [EMBASE: 612359035]KnudsenKB , PresslerT , MortensenLH , JardenM , BoisenKA , SkovM , et al. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis. Patient Preference and Adherence2017;11:1613-23. [CENTRAL: CN-01422904] [CFGD REGISTER: MH48b] [EMBASE: 618493577]NCT02110914. A coaching intervention to young adults with cystic fibrosis [Coach to Cope. Coaching young adults with cystic fibrosis - a feasibility study]. clinicaltrials.gov/ct2/show/NCT02110914 (first posted 10 April 2014). ">Knudsen 2016</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2. Social support (practical)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Social support</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise on, arrange, or provide practical help (e.g. from friends, relatives, colleagues, 'buddies' or staff) for performance of the behavior </p> <p><i>Note: if emotional, code 3.3, Social support (emotional); if general or unspecified, code 3.1, Social support (unspecified) If only restructuring the physical environment or adding objects to the environment, code 12.1, Restructuring the physical environment or 12.5, Adding objects to the environment; attending a group or class and/or mention of 'follow‐up' does not necessarily apply this BCT, support must be explicitly mentioned.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Find Solutions</p> <p>Remembering: Tick the boxes for the different ways that you could use to remember to do your treatment. Write down more ways that you think of. </p> <p>Put a timetable on fridge;</p> <p>Ask a family member to remind me;</p> <p>Put a sign up in my parent’s bedroom;</p> <p>Put a sign up in my bedroom;</p> <p>I just remember;</p> <p>Other ____________." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3. Social support (emotional)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Social support</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise on, arrange, or provide emotional social support (e.g. from friends, relatives, colleagues, 'buddies' or staff) for performance of the behavior </p> <p><i>Note: if practical, code 3.2, Social support (practical); if unspecified, code 3.1, Social support (unspecified)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Team partners have a big responsibility for chest treatments. Your role includes: doing and helping your child to do regular chest assessment and treatment; teaching your child about treatment and encouraging them to stick with it; being an important role model of a healthy lifestyle; being able to talk and deal with problems when they arise. It is a big job and not always easy." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1. Instruction on how to perform the behavior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Shaping knowledge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise or agree on how to perform the behavior (includes 'Skills training')</p> <p><i>Note: when the person attends classes such as exercise or cookery, code 4.1, Instruction on how to perform the behavior, 8.1, Behavioral practice/rehearsal and 6.1, Demonstration of the behavior</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The intervention also includes provision of a written, Prescribed Treatment Plan, assessment and remediation of gaps in Knowledge of Disease Management, and evaluation and re‐instruction/ re‐training of skills needed to perform daily treatments." (<a href="./references#CD013766-bbs2-0007" title="AlpernAN , McLeanKA , BeckerEM , RiekertKA , QuittnerAL . Predictors of providers' competence delivering a problem-solving adherence intervention. Pediatric Pulmonology2016;51 Suppl 45:458. [CENTRAL: CN-01212594] [CFGD REGISTER: MH29p] [EMBASE: 612358752]AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA , QuittnerAL . Effects of clinical supervision on treatment fidelity in ICare. Pediatric Pulmonology2012;47 Suppl 35:433. [ABSTRACT NO.: 572] [CFGD REGISTER: MH29g] BarkerD , QuittnerAL , RiekertKA . Relating patterns of social support from friends and family to health-related quality of life. Pediatric Pulmonology2013;48 Suppl 36:433. [ABSTRACT NO.: 615] [CENTRAL: CN-00875656] [CFGD REGISTER: MH29k] BlackwellLS , MarcielKK , RomeroCV , QuittnerAL . Pain assessment in children and adolescents with cystic fibrosis: utilizing an online pain diary. Pediatric Pulmonology2011;46 Suppl 34:411. [CENTRAL: CN-01003735] [CFGD REGISTER: MH29d] [EMBASE: 70555418]BlackwellLS , QuittnerAL . Daily pain in adolescents with CF: effects on adherence, psychological symptoms, and health-related quality of life. Pediatric Pulmonology2015;50(3):244-51. [CENTRAL: CN-01046754] [CFGD REGISTER: MH29l] [PMID: 25187182]BlackwellLS , RomeroSL , MarcielKK , RomeroCV , QuittnerAL . Pain in adolescents and young adults with CF: location, severity, and predictors. Pediatric Pulmonology2012;47 Suppl 35:430. [ABSTRACT NO.: 561] [CFGD REGISTER: MH29j] EakinMN , BilderbackA , RidgeA , KimburgC , MarcielK , SwensonA , et al. Disparities by socioeconomic status in health outcomes in pediatric CF patients. Pediatric Pulmonology2010;45 Suppl 33:449. [ABSTRACT NO.: 449] [CFGD REGISTER: MH29r] EakinMN , BilderbackA , RidgeA , QuittnerAL , ZhangJ , RiekertKA . Out-of-pocket costs for medication in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:420. [ABSTRACT NO.: 568] [CFGD REGISTER: MH29c] KimbergCI , MarcielKK , RiekertKA , ZhangJ , QuittnerAL . Knowledge of disease management in adolescents with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:447. [ABSTRACT NO.: 625] [CFGD REGISTER: MH29v] MarcielKK , HernandezC , KimbergCI , ZhangJ , RiekertKA , QuittnerAL . Developmental differences in health-related quality of life and associations between treatments and patient burden in the I change adherence and raise expectations (ICARE) study. Pediatric Pulmonology2011;46 Suppl 34:419. [CFGD REGISTER: MH29b] MarcielKK , KimbergCI , RiekertKA , SwensonA , QuittnerAL . Participation of multidisciplinary team members in a behavioural intervention to improve adherence in adolescents with CF. Pediatric Pulmonology2010;45 Suppl 33:437. [ABSTRACT NO.: 599] [CFGD REGISTER: MH29a] McLeanKA , QuittnerAL , AlpernAN , MarcielKK , RiekertKA . Healthcare provider acceptability of problem-solving in the I change adherence and raise expectations (iCARE) study. Pediatric Pulmonology2013;48 Suppl 36:437. [CFGD REGISTER: MH29i] NCT01232478. I Change Adherence &amp; Raise Expectations iCARE [I Change Adherence &amp; Raise Expectations]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01232478 (date of registration 28 October 2010). NCT01232478. I change adherence &amp; raise expectations. clinicaltrials.gov/ct2/show/NCT01232478 (first posted 02 November 2010). [CFGD REGISTER: MH29t] NicolaisCJ , BernsteinR , RiekertKA , QuittnerAL . Parent knowledge of disease management in cystic fibrosis: assessing behavioral treatment management. Pediatric Pulmonology2018;53(2):162-73. [CFGD REGISTER: MH29q] NicolaisCJ , Saez-FloresE , BernsteinR , RiekertKA , EakinMN , BilderbackA , et al. Frequency of self-reported barriers in relation to medication adherence in adolescents with cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:365. [CENTRAL: CN-01126910] [CFGD REGISTER: MH29n] [EMBASE: 72081740]QuittnerA , KimbergC , MarcielK , ZhangJ , RiekertK . Randomized, controlled trial of a behavioral adherence intervention for adolescents with cystic fibrosis: I change adherence and raise expectations (iCARE). Chest2011;140(4 Suppl):908a. [CFGD REGISTER: MH29e] QuittnerAL , AlpernAN , McLeanKA , MarcielKK , ZhangJ , RiekertKA . Clinical supervision improves treatment fidelity to an adherence intervention. Journal of Cystic Fibrosis2012;11 Suppl 1:S9. [ABSTRACT NO.: WS4.1] [CENTRAL: CN-00867601] [CFGD REGISTER: MH29f] QuittnerAL , BiesenJ , MarcielK , RidgeA , ZhangJ , RiekertKA . Health-related quality of life in adolescents with cystic fibrosis: associations with age, gender, nutrition and pulmonary function. American Journal of Respiratory and Critical Care Medicine2013;187:A26. [CENTRAL: CN-01107745] [CFGD REGISTER: MH29o] [EMBASE: 71980545]QuittnerAL , EakinMN , AlpernAN , RidgeAK , McLeanKA , BilderbackA , et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. Journal of Cystic Fibrosis2019;18(6):879-85. [CFGD REGISTER: MH29w] [DOI: 10.1016/j.jcf.2019.05.004]QuittnerAL , RiekertKA , MarcielKK , KimbergCI , EakinMN , ZhangJ . Adolescent management of CF: GAPS in knowledge and treatment skills in the icare study. Pediatric Pulmonology2010;45:199-200. [CFGD REGISTER: MH29s] QuittnerAL , RiekertKA . I Change adherence and raise expectations: the iCARE study. Pediatric Pulmonology2013;48 Suppl 36:136. [CFGD REGISTER: MH29h] [SYMPOSIUM SUMMARY NO.: S7.3]QuittnerALQ . Practical tools to improve adherence. Journal of Aerosol Medicine and Pulmonary Drug Delivery2011;24(3):5. [CFGD REGISTER: MH29u] Saez-FloresE , ThomasK , RiekertKA , EakinMN , BilderbackA , QuittnerAL . Associations between treatment complexity, CFQ-R treatment burden, and adherence in adolescents with CF. Pediatric Pulmonology2015;50 Suppl 41:439. [CENTRAL: CN-01126909] [CFGD REGISTER: MH29m] [EMBASE: 72081927]">Quittner 2019</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1. Information about health consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Natural consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provide information (e.g. written, verbal, visual) about health consequences of performing the behavior </p> <p><i>Note: consequences can be for any target, not just the recipient(s) of the intervention; emphasising importance of consequences is not sufficient; if information about emotional consequences, code 5.6, Information about emotional consequences; if about social, environmental or unspecified consequences code 5.3, Information about social and environmental consequences</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic‐level figures showing the association between adherence and health outcomes." (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2. Salience of consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Natural consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use methods specifically designed to emphasise the consequences of performing the behaviour with the aim of making them more memorable (goes beyond informing about consequences) </p> <p><i>Note: if information about consequences, also code 5.1, Information about health consequences, 5.6, Information about emotional consequences or 5.3, Information about social and environmental consequences</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Some children also need to use nebulisers and puffers. Don’t wait until you get sick before you do your treatments. BE A GERM BUSTER and BUST GERMS TODAY! Draw some more germs in the box below." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1. Demonstration of the behavior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Comparison of behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provide an observable sample of the performance of the behaviour, directly in person or indirectly e.g. via film, pictures, for the person to aspire to or imitate (includes 'Modelling'. </p> <p><i>Note: if advised to practice, also code, 8.1, Behavioural practice and rehearsal; If provided with instructions on how to perform, also code 4.1, Instruction on how to perform the behaviour</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0028"> <li> <p>Solution bank within CFHealthHub (including advice to problem solve, restructure the physical environment, engage social support) </p> </li> <li> <p>Coping planning, Day planner and Party planner tools and storage within CFHealthHub</p> </li> <li> <p>Videos demonstrating correct use of nebulisers within CFHealthHub." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3. Information about others' approval</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Comparison of behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Provide information about what other people think about the behavior. The information clarifies whether others will like, approve or disapprove of what the person is doing or will do </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This is what one child said. “Don’t say “It will be OK, I’ll sort it out tomorrow”, because infections can happen slowly. Once I feel tired and have less energy, then I don’t want to do my chest treatments at all.” (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1. Prompts/cues</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Associations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance </p> <p><i>Note: when a stimulus is linked to a specific action in an if‐then plan including one or more of frequency, duration or intensity also code 1.4, Action planning.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Devices were programmed to provide daily medication reminders for inhaled hypertonic saline, dornase alfa, and CF multivitamins." (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1. Behavioral practice/rehearsal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Repetition and substitution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt practice or rehearsal of the performance of the behavior one or more times in a context or at a time when the performance may not be necessary, in order to increase habit and skill </p> <p><i>Note: if aiming to associate performance with the context, also code 8.3, Habit formation</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0029"> <li> <p>Solution bank within CFHealthHub (including advice to problem solve, restructure the physical environment, engage social support) </p> </li> <li> <p>Coping planning, day planner and party planner tools and storage within CFHealthHub</p> </li> <li> <p>Videos demonstrating correct use of nebulisers within CFHealthHub</p> </li> </ul> </p> <p>Interventionist:</p> <p> <ul id="CD013766-list-0030"> <li> <p>Tailored problem‐solving guided by interventionist</p> </li> <li> <p>Support to create day plans/party plans where appropriate</p> </li> <li> <p>Support to construct if‐then coping plans including identifying self‐talk where appropriate." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3. Habit formation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Repetition and substitution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt rehearsal and repetition of the behavior in the same context repeatedly so that the context elicits the behavior </p> <p><i>Note: also code 8.1, Behavioral practice/rehearsal</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Interventionist:</p> <p> <ul id="CD013766-list-0031"> <li> <p>Help to focus on identifying consistent cues and linking to behaviour (habit formation)</p> </li> <li> <p>Discussion and identification of appropriate cues ‐ and how to add to the environment (if necessary)." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7. Graded tasks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Repetition and substitution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Set easy‐to‐perform tasks, making them increasingly difficult, but achievable, until behavior is performed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Interventionist:</p> <p> <ul id="CD013766-list-0032"> <li> <p>Discussion and agreement of goals with interventionist</p> </li> <li> <p>Review of goals</p> </li> <li> <p>Suggested steady increase in goal as improvements are made." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1. Credible source</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Comparison of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Present verbal or visual communication from a credible source in favour of or against the behavior </p> <p><i>Note: code this BCT if source generally agreed on as credible e.g., health professionals, celebrities or words used to indicate expertise or leader in field and if the communication has the aim of persuading; if information about health consequences, also code 5.1, Information about health consequences, if about emotional consequences, also code 5.6, Information about emotional consequences; if about social, environmental or unspecified consequences also code 5.3, Information about social and environmental consequences</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0033"> <li> <p>Information about CF, the need for treatment, how each treatment works and the importance of adherence </p> </li> <li> <p>Information presented in a variety of ways though written text, patient stories, 'talking heads' and animation videos, with links to external content including Cochrane reviews </p> </li> <li> <p>Range of different credible information sources including people CF, clinicians, links to scientific papers." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2. Pros and cons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Comparison of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise the person to identify and compare reasons for wanting (pros) and not wanting to (cons) change the behavior (includes 'Decisional balance') </p> <p><i>Note: if providing information about health consequences, also code 5.1, Information about health consequences; if providing information about emotional consequences, also code 5.6, Information about emotional consequences; if providing information about social, environmental or unspecified consequences also code 5.3, Information about social and environmental consequences</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"An important aspect of this work is the weighing up of the pros and cons of the problem and the solution, for example, helping them to make positive evaluations of increasing their nebuliser use (looking for the benefits) and weighing them as more important than the ‘costs’ of increasing their nebuliser use (time consumption, inconvenience etc.)." (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.3. Non‐specific reward</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Reward and threat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arrange delivery of a reward if and only if there has been effort and/or progress in performing the behavior (includes 'Positive reinforcement') </p> <p><i>Note: if reward is material, code 10.2, Material reward (behavior), if social, code 10.4, Social reward, and not 10.3, Nonspecific reward; if reward is for outcome code 10.10, Reward (outcome). If informed of reward in advance of rewarded behaviour, also code one of: 10.1, Material incentive (behaviour); 10.5, Social incentive; 10.6, Non‐specific incentive; 10.7, Self‐incentive; 10.8, Incentive (outcome)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This week’s activity is to fill the waves with sea creatures for doing all your chest treatments... Did you complete 5 or more waves last week? If you didn’t, do the activity again this week. If you did, enjoy your reward for learning about chest treatments. My reward for learning more about chest treatments is ___<b>_</b>". (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4. Social reward</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Reward and threat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arrange verbal or non‐verbal reward if and only if there has been effort and/or progress in performing the behavior (includes 'Positive reinforcement') </p> <p><i>Note: if reward is material, code 10.2, Material reward (behavior), if unspecified code 10.3, Non‐specific reward, and not 10.4, Social reward; if reward is for outcome code 10.10, Reward (outcome). If informed of reward in advance of rewarded behaviour, also code one of: 10.1, Material incentive (behaviour); 10.5, Social incentive; 10.6, Non‐specific incentive; 10.7, Self‐incentive; 10.8, Incentive (outcome)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This intervention is designed to increase knowledge and enhance the skills needed to optimize CF‐management. The strategies used to achieve improved adherence include providing didactic education and skills training, and proscriptively using behavioral modification strategies, such as positive reinforcement for desired behaviors, and problem‐solving training to overcome barriers." (<a href="./references#CD013766-bbs2-0008" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CENTRAL: CN-01126911] [CFGD REGISTER: MH51c] [EMBASE: 72081278] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CENTRAL: CN-01305603] [CFGD REGISTER: MH51b] [EMBASE: 609133639] [PMID: 26996270]HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CENTRAL: CN-01069919] [CFGD REGISTER: MH51a] [EMBASE: 2014705719] [PMID: 25110847]NCT01013896. Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience BALANCE [Building Adherence to Live With And Navigate my CF Experience]. trialsearch.who.int/Trial2.aspx?TrialID=NCT01013896 (Date of registration 13 November 2009). NCT01013896. Building Adherence to Live with And Navigate my Cystic fibrosis (CF) Experience (BALANCE) [Building Adherence to Live with And Navigate my CF Experience]. clinicaltrials.gov/ct2/show/NCT01013896 (first posted 16 November 2009). RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CENTRAL: CN-01063277] [CFGD REGISTER: MH51d] [EMBASE: 71321286] [SUMMARY NO.: S7.1]">Riekert 2013</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7. Self‐incentive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Reward and threat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plan to reward self in future if and only if there has been effort and/or progress in performing the behavior </p> <p><i>Note: if self‐reward is material, also code 10.1, Material incentive (behavior), if social, also code 10.5, Social incentive, if unspecified, also code 10.6, Non‐specific incentive; if incentive is for outcome code 10.8, Incentive (outcome). If reward is delivered also code one of: 10.2, Material reward (behavior); 10.3, Non‐specific reward; 10.4, Social reward, 10.9, Selfreward; 10.10, Reward (outcome)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This week’s activity is to fill the waves with sea creatures for doing all your chest treatments. Find the activity sheet with the picture of the sea. Draw and colour a sea creature in each day’s wave when you have remembered, fitted in and done all your treatments. Enjoy watching it fill up." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9. Self‐reward</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Reward and threat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt self‐praise or self‐reward if and only if there has been effort and/or progress in performing the behavior </p> <p><i>Note: if self‐reward is material, also code 10.2, Material reward (behavior), if social, also code 10.4, Social reward, if unspecified, also code 10.3, Non‐specific reward; if reward is for outcome code 10.10, Reward (outcome). If informed of reward in advance of rewarded behaviour, also code one of: 10.1, Material incentive (behaviour); 10.5, Social incentive; 10.6, Non‐specific incentive; 10.7, Selfincentive; 10.8, Incentive (outcome)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"This week’s activity is to fill the waves with sea creatures for doing all your chest treatments. Find the activity sheet with the picture of the sea. Draw and colour a sea creature in each day’s wave when you have remembered, fitted in and done all your treatments. Enjoy watching it fill up." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2. Reduce negative emotions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Regulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise on ways of reducing negative emotions to facilitate performance of the behavior (includes 'Stress management') </p> <p><i>Note: if includes analysing the behavioural problem, also code 1.2, Problem solving</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The chapters contain information and exercises to explore the clinical nature of the respiratory aspect of CF; the promotion of co‐operative behaviour and teamwork; the use of cognitive theories that promote optimism and help the child cope with negative feelings about long‐term treatments; and issues pertaining to recommended aerosol and ACT treatments." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.1. Restructuring the physical environment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Antecedents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change, or advise to change the physical environment in order to facilitate performance of the wanted behavior or create barriers to the unwanted behavior (other than prompts/cues, rewards and punishments) </p> <p><i>Note: this may also involve 12.3, Avoidance/reducing exposure to cues for the behavior; if restructuring of the social environment code 12.2, Restructuring the social environment; if only adding objects to the environment, code 12.5, Adding objects to the environment</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"In the Action stage, the person actively modifies their behaviour, experience or environment in order to improve their nebuliser use." (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2. Restructuring the social environment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Antecedents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change, or advise to change the social environment in order to facilitate performance of the wanted behavior or create barriers to the unwanted behavior (other than prompts/cues, rewards and punishments) </p> <p><i>Note: this may also involve 12.3, Avoidance/reducing exposure to cues for the behavior; if also restructuring of the physical environment also code 12.1, Restructuring the physical environment</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"In the Action stage, the person actively modifies their behaviour, experience or environment in order to improve their nebuliser use." (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5. Adding objects to the environment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Antecedents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Add objects to the environment in order to facilitate performance of the behavior</p> <p><i>Note: Provision of information (e.g. written, verbal, visual) in a booklet or leaflet is insufficient. If this is accompanied by social support, also code 3.2, Social support (practical); if the environment is changed beyond the addition of objects, also code 12.1, Restructuring the physical environment</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"...we also conducted a pilot study to assess the feasibility of a portable personal spirometer device that also provided medication reminders among pediatric CF patients." (<a href="./references#CD013766-bbs2-0009" title="NCT02301377. Exploring novel interventions to improve adherence in children with cystic fibrosis. clinicaltrials.gov/ct2/show/study/NCT02301377 (first posted 25 November 2014). ShakkottaiA , NasrSZ . The use of home spirometry in pediatric cystic fibrosis patients: results of a feasibility study. Global Pediatric Health2017;4:1-6. [DOI: 10.1177/2333794X17690315]">Shakkottai 2017</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2. Framing/reframing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Identity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suggest the deliberate adoption of a perspective or new perspective on behavior (e.g. its purpose) in order to change cognitions or emotions about performing the behavior (includes 'Cognitive structuring'); <i>If information about consequences then code 5.1, Information about health consequences, 5.6, Information about emotional consequences or 5.3, Information about social and environmental consequences instead of 13.2, Framing/reframing</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Write 1 of your negative thoughts about chest treatments in the top thought bubble. Draw a face to show how this makes you feel. Then, think of a positive thought that will help you to feel better about treatment and write this in the bottom thought bubble. Draw a face to show how this might make you feel." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3. Incompatible beliefs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Identity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Draw attention to discrepancies between current or past behavior and self‐image, in order to create discomfort (includes 'Cognitive dissonance') </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The intervention uses dialogue from the patient to create dissonance when ambivalent about behaviour change by weighing the importance of change against the costs of not changing." (<a href="./references#CD013766-bbs2-0006" title="ISRCTN86935165. Measurement of, and psychological intervention with, partial adherence to inhaled antibiotic therapies in adults with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN86935165 (date of registration 30 September 2004). QuinnJ , LatchfordG , DuffA , ConnerM , PollardK , MorrisonL , et al. Measuring, predicting and improving adherence to inhalation therapy in patients with CF: a randomised controlled study of motivational interviewing. Pediatric Pulmonology2004;38 Suppl 27:360. [CENTRAL: CN-00507915] [CFGD REGISTER: MH15] QuinnJE . A study to measure adherence with inhaled therapies in patients with cystic fibrosis and to assess the potential value of psychological interventions aimed at addressing barriers to good compliance. Doctorate in Clinical Psychology Thesis2004. ">Quinn 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.1. Verbal persuasion about capability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Self‐belief</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tell the person that they can successfully perform the wanted behavior, arguing against self‐doubts and asserting that they can and will succeed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Getting mucus out of your lungs helps you to stay healthy. You CAN learn how to do your chest treatments well." (<a href="./references#CD013766-bbs2-0002" title="DownsJA , RobertsCM , BlackmoreAM , Le SouefPN , JenkinsSC . Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chronic Respiratory Disease2006;3(1):19-27. [CENTRAL: CN-00563017] [CFGD REGISTER: MH18] [DOI: 10.1191/1479972306cd100oa] [EMBASE: 2006077516] [PMID: 16509174]">Downs 2006</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.3. Focus on past success</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Self‐belief</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advise to think about or list previous successes in performing the behavior (or parts of it) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Interventionist:</p> <p> <ul id="CD013766-list-0034"> <li> <p>Interventionist encouraging focus on periods of higher adherence on charts." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.4. Self‐talk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Self‐belief</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt positive self‐talk (aloud or silently) before and during the behavior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Interventionist:</p> <p> <ul id="CD013766-list-0035"> <li> <p>Interventionist introducing and highlighting relevant content on CFHealthHub</p> </li> <li> <p>Interventionist eliciting self‐talk through discussion of motivation." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3. Vicarious consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3. Vicarious consequences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prompt observation of the consequences (including rewards and punishments) for others when they perform the behavior </p> <p><i>Note: if observation of health consequences, also code 5.1, Information about health consequences; if of emotional consequences, also code 5.6, Information about emotional consequences, if of social, environmental or unspecified consequences, also code 5.3, Information about social and environmental consequences</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"CFHealthHub:</p> <p> <ul id="CD013766-list-0036"> <li> <p>Demonstration of techniques for nebuliser use, cleaning and treatment mixing</p> </li> <li> <p>Information about CF, the need for treatment, how each treatment works, and the importance of adherence </p> </li> <li> <p>Information presented in a variety of ways though written text, patient stories, ‘talking heads’, and animation videos, with links to external content including Cochrane Reviews </p> </li> <li> <p>Range of different credible information sources including PWCF, Clinicians, links to scientific papers </p> </li> </ul> </p> <p>Interventionist:</p> <p> <ul id="CD013766-list-0037"> <li> <p><b>I</b>nterventionist introducing and highlighting relevant content on CFHealthHub." (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a>; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a><sup>a</sup>) </p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>BCT: behaviour change technique</p> <p>BCT definitions taken from the BCT Taxonomy (v1) (<a href="./references#CD013766-bbs2-0151" title="MichieS , RichardsonM , JohnstonM , AbrahamC , FrancisJ , HardemanW , et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Annals of Behavioral Medicine2013;46(1):81-95. [DOI: 10.1007/s12160-013-9486-6]">Michie 2013</a>). </p> <p><sup>a</sup>The same intervention was used in two included studies but with different populations (<a href="./references#CD013766-bbs2-0004" title="ArdenMA , DrabbleS , O'CathainA , HutchingsM , WildmanM . Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework. British Journal of Health Psychology2019;24(2):357–80. [CFGD REGISTER: MH53p] [DOI: 10.1111/bjhp.12357]ArdenMA , DrabbleSJ , O’CathainA , HutchingsM , WildmanM . ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. In: Journal of Cystic Fibrosis. Vol. 15. 2016:S26. [CFGD REGISTER: MH53c] [DOI: 10.1016/S1569-1993(16)30151-5]ArdenMA , HutchingsM , NightingaleJA , AllenbyM , DewarJ , OliverC , et al. CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S60. [CENTRAL: CN-01461910] [CFGD REGISTER: MH53d] [EMBASE: 620749167]ArdenMA , HutchingsM , WhelanP , DrabbleSJ , BeeverD , BradleyJ , et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot and Feasibility Studies2021;7(1):1. [CFGD REGISTER: MH53m] [DOI: 10.1186/s40814-020-00739-2]DrabbleSJ , O'CathainA , ArdenMA , HutchingsM , BeeverD , WildmanM . When Is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qualitative Health Research2019;29(14):2119–31. [CFGD REGISTER: MH53q] [DOI: 10.1177/1049732319856580]DrabbleSJ , O'CathainA , ScottAJ , ArdenMA , KeatingS , HutchingsM , et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. Journal of Medical Internet Research2020;22(10):e16782. [CENTRAL: CN-02139984] [CFGD REGISTER: MH53e] [EMBASE: 632427980] [PMID: 32697197]GaoJ , ArdenM , HooZH , WildmanM . Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study. BMC Health Services Research2019;19:420. [CFGD REGISTER: MH53r] [DOI: 10.1186/s12913-019-4260-5]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open2020;10(10):e039089. [CFGD REGISTER: MH53s] [DOI: 10.1136/bmjopen-2020-039089]HindD , DrabbleSJ , ArdenMA , MandefieldL , WaterhouseS , MaguireC , et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulmonary Medicine2019;19(1):77. [CENTRAL: CN-01938950] [CFGD REGISTER: MH53g] [DOI: 10.1186/s12890-019-0834-6] [EMBASE: 627140721] [PMID: 30975206]HindD , MaguireC , CantrillH , O'CathainA , WildmanM . CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. Journal of Cystic Fibrosis2017;16 Suppl 1:S40. [ABSTRACT NO.: EPS2.8] [CENTRAL: CN-01461879] [CFGD REGISTER: MH53a] [EMBASE: 620749594]HooZH , EdenboroughFP , CurleyR , PrtakL , DewarJ , AllenbyMI , et al. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision. European Journal of Clinical Microbiology &amp; Infectious Diseases2018;37(4):735-43. [CFGD REGISTER: MH53j] [DOI: 10.1007/s10096-017-3168-4]HooZH , GardnerB , ArdenMA , WaterhouseS , WaltersSJ , CampbellMJ , et al. Role of habit in treatment adherence among adults with cystic fibrosis. Thorax2019;74(2):197-9. [CENTRAL: CN-01930335] [CFGD REGISTER: MH53f] [PMID: 29886416]HooZH , WaterhouseS , NightingaleJA , DewarJ , AllenbyM , HaynesF , et al. CFHealthHub: using Leeds criteria and clinicians’ decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study. In: Journal of Cystic Fibrosis. Vol. 16 Suppl 1. 2017:S105. [CFGD REGISTER: MH53i] [DOI: 10.1016/S1569-1993(17)30519-2]HutchingsM , KirkpatrickS , ArdenMA , DrabbleSJ , MaguireC , CantrillH , et al. Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'people like me'. Cureus2022;14(7):e26511. [CFGD REGISTER: MH53t] [DOI: 10.7759/cureus.26511]ISRCTN13076797. Adherence to treatment in adults with cystic fibrosis [Development and evaluation of an intervention to support Adherence to treatment in adults with cystic fibrosis: A feasibility study comprised of an external pilot randomised controlled trial and process evaluation (WP 3.1)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13076797 (date of registration 7 June 2016). [CFGD REGISTER: MH53k] SadlerS , WildmanM , TappendenP . Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis2016;15 Suppl:S119. [CFGD REGISTER: MH53h] [DOI: 10.1016/S1569-1993(16)30505-7]TappendenP , SadlerS , WildmanM . An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics2017;35(6):647-59. [CENTRAL: CN-01336764] [CFGD REGISTER: MH53b] [EMBASE: 614979129] [PMID: 28337719]">Hind 2017</a> was a feasibility trial conducted in two CF centres; <a href="./references#CD013766-bbs2-0010" title="ISRCTN55504164. A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN55504164 (date of registration 12 Oct 2017). [CFGD REGISTER: MH205c] LumleyE , DrabbleSJ , ScottA , WildmanMJ , O'CathainA . Objective nebuliser adherence data as &quot;proof&quot; of adherence in the management of cystic fibrosis: a qualitative interview study. Patient Preference and Adherence2022;16:771-80. [CFGD REGISTER: MH205g] [DOI: 10.2147/PPA.S353434]WarnockL , FaulknerJ , FlightWG . Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals. Journal of Cystic Fibrosis2020;19 Suppl 2:S147. [CFGD REGISTER: MH205b] WildmanM , O'CathainA . Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis: a randomised controlled trial and parallel process evaluation. https://www.sheffield.ac.uk/media/10446/download?attachment (first received 2017):1-58. [CENTRAL: CN-01402855] [CFGD REGISTER: MH205a] WildmanM , for the CFHealthHub Study Team. Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2020;55 Suppl 2:265-6. [CFGD REGISTER: MH205d] WildmanM . UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care. Pediatric Pulmonology2019;54(Suppl 2):92-3. [CFGD REGISTER: MH53l] WildmanMJ , O'CathainA , HindD , MaguireC , ArdenMA , HutchingsM , et al. An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research2021;9(11). [CFGD REGISTER: MH205e] [DOI: 10.3310/pgfar09110]WildmanMJ , O’CathainA , MaguireC , ArdenMA , HutchingsM , BradleyJ , et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax2022;77(5):461-9. [CFGD REGISTER: MH205f] [DOI: 10.1136/thoraxjnl-2021-217594]">Wildman 2022</a> was a larger RCT conducted in 19 different CF centres). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Definitions and illustrative quotations of behaviour change techniques present in one or more of the included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/full#CD013766-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013766-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Psychological interventions versus usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Adherence ‐ percentage of prescribed inhaled therapies taken (objective recorded measures) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Adherence ‐ percentage of prescribed inhaled therapies taken (objective recorded measures ‐ adjusted mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Adherence ‐ percentage of prescribed inhaled therapies taken (subjective measures) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Adherence to dornase alfa <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.62, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [‐0.41, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [‐0.00, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adherence to inhaled antibiotics (mean score on MMAS‐8) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [‐1.01, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.99, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.91, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adherence to inhaled steroids (subjective measure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adherence to hypertonic saline (subjective measure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adherence to bronchodilators (subjective measure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Anxiety (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Anxiety (adjusted mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Depression (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Depression (adjusted mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 QoL: Quality of Well‐being scale (mean score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 QoL: Physical functioning (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.57, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.57, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.04, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.4 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐1.10, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 QoL: Physical functioning (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 QoL: Emotional functioning (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [‐0.14, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.58, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.11, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.4 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐1.23, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 QoL: Emotional functioning (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 QoL: Social functioning (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [‐0.22, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.43, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.12, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.4 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.95, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 QoL: Social functioning (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 QoL: Treatment burden (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐1.50, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.44, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.01, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.4 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐1.05, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 QoL: Treatment burden (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 QoL: Role limitations (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.54, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.21, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.3 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐1.31, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 QoL: Role limitations (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 QoL: Body image (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.00, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.56, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.03, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.4 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐1.59, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 QoL: Body image (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 QoL: Vitality (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.77, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.99, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.3 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐1.28, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 QoL: Vitality (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 QoL: Eating disturbance (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.38, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.01, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.3 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [‐0.35, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 QoL: Eating disturbance (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 QoL: Weight problems (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.45, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.03, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.3 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.80, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 QoL: Weight problems (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.31.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 QoL: Respiratory symptoms (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.42, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.78, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.10, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.4 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.27, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 QoL: Respiratory symptoms (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 QoL: Digestive symptoms (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐1.10, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.08, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.3 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.33, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 QoL: Digestive symptoms (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.36 QoL: Health perceptions (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.36.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.69, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.36.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.20, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.36.3 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐1.16, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.37 QoL: Health perceptions (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.37.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.38 QoL: Treatment issues (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.38.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.39 QoL: Career concerns (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.40 QoL: Interpersonal relationships (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.41 QoL: Concerns for the future (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.42 FEV1 % predicted (endpoint data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.25 [‐18.13, 11.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.2 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.98 [‐12.50, 6.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.3 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.20 [‐0.59, 6.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.4 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.20 [‐19.31, 10.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.43 FEV1 % predicted (adjusted mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.43.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.43.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.44 Number of pulmonary exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.44.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.45 Pulmonary exacerbations incidence rate (unadjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.45.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.45.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.46 Pulmonary exacerbations incidence rate (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.1 Over 3 months and up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.2 Over 6 months and up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Psychological interventions versus usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013766.pub2/references#CD013766-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013766.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013766-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013766-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013766-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013766-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013766-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013766-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013766-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD013766-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013766-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013766\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013766\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013766\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013766\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013766\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013766.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013766.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013766.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013766.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013766.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717959982"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013766.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717959986"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013766.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc4a26e379377',t:'MTc0MDcxNzk2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 